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Despite considerable advances in treatment modalities during the last decades, cancer is 
still the second cause of death in the Western world. Improvements in the traditional 
approaches to cancer therapy, surgical removal of the tumor, radiotherapy and 
chemotherapy, have generally led to some improved prognosis of cancer patients. 
However, the majority of cancer related deaths are due to the occurrence of metastases, 
which may be too numerous to be treated by surgery, or recurrent tumors which may 
eventually become resistant to chemotherapeutic or radiotherapeutic treatment. In 
addition, conventional anti-tumor drugs and radiotherapy often non-selectively interfere 
with the basic proliferation machinery of cells, resulting in toxicity to non-malignant cells. 
This along with therapy resistance are major therapy-limiting factors.  
 
Targeted therapy of solid tumors 
With the increasing knowledge about the molecular pathways that lead to deranged 
growth in cancer, targeting of these pathways has also become possible, resulting in a 
burst of research in the field of targeted tumor therapies (Table 1). Since targeted 
therapies are directed against particular tumor-specific molecular targets, these are 
supposed to result in less toxicity compared to conventional anti-tumor therapies.  
 
Tyrosine kinase inhibitors 
The discovery that tyrosine kinase (TK) membrane receptors are often dysregulated in 
tumor cells in several ways has led to inhibitors of TKs as a novel class of therapeutic 
compounds in oncology.
1
 Activation of TKs affects many cellular events involved in tumor 
progression including cell growth, proliferation, survival, adhesion, and migration. TK 
receptor signaling can be interrupted by antibodies against these receptors or their 
ligands. As an example, the humanized anti-EGFR antibody cetuximab inactivates EGFR by 
preventing the binding of its ligands EGF and TNFα, and  promoting its internalization and 
lysosomal degradation. Another class of TK inhibitors includes small molecules that 
directly inhibit the catalytic activity of kinases via interference with binding of ATP. 
 
c-KIT  
Approximately 85% of the patients with gastrointestinal stromal tumors (GISTs) have 
activating mutations of the c-KIT TK, the receptor for the cytokine stem cell factor. 
Imatinib, a small-molecule inhibitor of the TK activities of c-KIT, is approved by the USA 
Food and Drug Administration (FDA) for treatment of advanced GIST. In a multicenter trial 
of imatinib in GIST patients that failed conventional therapy more than 80% of these 
patients showed response to imatinib treatment, although none of them showed 
complete response.
2
 In addition, in 5% of these patients the tumor exhibited primary 
resistance to imatinib within the first two months. 
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Platelet-Derived Growth Factor Receptor (PDGFR)  
Tumor cells in different malignancies are associated with (mutational) activation of PDGF 
or its receptors (PDGFR).
3,4
 The PDGFRs (α and β) are activated by PDGFs (PDGF-A, -B, -C 
and -D). Because imatinib is also an inhibitor of PDFGRs, this agent has been evaluated in a 
number of malignancies in which PDGFR signaling has been implicated. 
Due to a translocation that places the PDGF-B gene under control of the collagen 1A1 
promoter, which is observed in more than 90% of dermatofibrosarcomas protuberans 
(DFSP), PDGF-B is up-regulated in these tumors resulting in overactivation of PDGFR-β. In a 
phase II study of eight patients with locally advanced DFSP treated with imatinib all 
patients achieved a clinical response, with four complete responses.
5
  
Although overexpression of PDGFR-α has been documented in all grades of malignancy in 
glioma,
6
 phase II trials revealed that imatinib had minimal single-agent activity in recurrent 
gliomas, since a partial response was observed in approximately 5% of the patients.
7,8
 
Currently, the therapeutic efficacy of imatinib in combination with chemotherapy in 
glioma patients is evaluated in several clinical trials. A phase II study of patients with 
recurrent high grade glioma already demonstrated that imatinib plus hydroxyurea had 
modest activity with a partial radiographic response in only 9% of the patients.
9
 
High levels of PDGFR-α and PDGF have been reported in a subset of ovarian 
carcinomas.
10,11
  A phase II trial of patients with recurrent epithelial ovarian or primary 
peritoneal carcinoma revealed that imatinib had minimal activity as single agent in these 
patients, although the majority of them had tumors co-expressing imatinib-sensitive 
receptors c-KIT and PDGFR-β.
12
 
 
Human Epidermal Growth Factor Receptor family 
Members of the human Epidermal Growth Factor Receptor (EGFR and HER2) family are 
overexpressed or mutated in many solid tumors.
13,14
 Trastuzumab, a humanized 
monoclonal antibody which is FDA-approved for treatment of breast cancer, targets the 
receptor TK HER2, which is overexpressed in approximately 25% percent of invasive breast 
tumors. In patients with HER2-positive breast tumors addition of trastuzumab to 
chemotherapy significantly improved median time to progression (7.4 vs. 4.6 months) and 
median survival (25.1 vs. 20.3 months).
15
 However, disease recurrence and trastuzumab 
resistance are observed in a subset of patients.
15,16
 
Targeting EGFR TK signaling has demonstrated  clinical activity in many solid tumor 
types.
13
 Promising results in patients with advanced head and neck squamous cell 
carcinoma
17
 and refractory metastatic colorectal cancer
18
 led to the approval by the FDA 
of cetuximab, a chimeric monoclonal antibody to the extracellular domain of EGFR, for 
these patient populations. In contrast, recent data from a phase III trial of previously 
untreated metastatic colorectal cancer patients revealed that the addition of cetuximab to 
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capecitabine, oxaliplatin and bevacizumab resulted in a significantly decreased 
progression-free survival and inferior quality of life.
19
 Of importance, a mutated, 
constitutively active K-ras bypasses the need for EGFR-mediated K-ras phosphorylation 
and renders tumors resistant to cetuximab therapy.  
Erlotinib, a specific small molecule inhibitor of ATP binding by EGFR, displayed anti-tumor 
activity in refractory advanced non-small cell lung cancer
20
 and advanced pancreatic 
cancer
21
 and is approved by the FDA for treatment of these tumors. Recently, 
panitumumab, a human monoclonal antibody  against EGFR, was approved by the FDA for 
metastastic colorectal cancer.
22
 Although the EGFR gene is amplified in approximately 50% 
of high grade gliomas
23
 only a small percentage of patients showed response to EGFR 
kinase inhibitors erlotinib or gefitinib, in particular those patients in whom glioma cells co-
expressed EGFRvIII, a constitutively active mutant variant of EGFR, and wild-type PTEN.
24
 A 
recent study confirmed the relatively poor therapeutic efficacy of erlotininb and gefitinib 
in patients with recurrent or progressive high grade glioma. Furthermore,  in the 
responding subpopulation there was no consistent association with EGFRvIII/PTEN co-
expression.
25
 Very recently, the addition of erlotinib to standard treatment with 
radiotherapy and temozolomide did not demonstrate additive or synergistic effects in a 
phase I/II trial of newly diagnosed high grade glioma patients.
26
 
 
Insulin-like Growth Factor Receptor type 1 (IGF-1R)  
IGF-1R is frequently overexpressed in a variety of tumor types.
27
 Different preclinical 
studies indicated that IGF-1R signaling, induced by binding of its principal ligand IGF-1,  
promotes tumor growth and metastasis which can be reduced by interference with IGF-
1R-mediated signaling.
28-30
 Preclinical testing also revealed that antibodies raised against 
IGF-1R have, in addition to directly blocking its ability to bind IGF-1, the potential to 
improve sensitivity and block resistance to other antitumor therapies.
29,30
 Currently, 
various IGF-1R antibodies are evaluated in phase I and II trials. Results from a recent phase 
I trial of CP-751,871, a human monoclonal antibody against IGF-1R,  in different advanced 
solid tumors suggest that a subset of patients treated with this antibody experience 
clinical benefit as evidenced by disease stabilization.
31
 In addition, early data from 
different clinical trials support the observation from preclinical studies that targeting IGR-
1R enhances the efficacy of cytotoxic cancer therapies.
32
 However, due to the body-wide 
expression of IGF-1R targeting of this receptor might result in serious adverse effects. In 
addition, as IGF-1R and Insulin Receptor (IR) are nearly identical, compounds with 
crossreactivity to IR  could induce toxicity. Interestingly, specific targeting of IGF-1R/IR 
hybrid receptors in addition to IGF-1R resulted in increased anti-tumor activity in vivo.
33
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Mammalian target of rapamycin (mTOR) inhibitors  
mTOR is a cytoplasmic serine-threonine kinase of the phosphatidylinositol 3-kinase 
(PI3K)/Akt signalling pathway and as such involved in the regulation of cellular 
metabolism, growth, proliferation, and angiogenesis. Upon stimulation growth factor 
receptor TKs recruit PI3K leading to activation of Akt, which subsequently phosphorylates 
mTOR resulting in increased translation rates, enhanced phosphorylation of Akt and 
effects on actin skeleton.
34,35
  In a phase III study patients with newly diagnosed advanced 
renal cell carcinoma treated with temsirolimus, a specific inhibitor of mTOR kinase, 
exhibited improved median progression-free and median survival compared with those 
receiving interferon (3.8 vs. 1.9 months and 10.9 vs. 7.3 months respectively).
36
 Despite an 
objective response rate of 8.6%, these trial results led to the recent approval of 
temsirolimus by the FDA for treatment of this patient population. 
 
Table 1. Targeted therapies of solid tumors 
Compound 
 
Target(s) in 
solid tumors 
 
FDA approved for Adverse effects  
Imatinib 
c-KIT 
PDGFR 
Gastrointestinal stromal tumors 
Hemorrhages  
Diarrhea 
Edema 
Fatigue 
Trastuzumab HER2 Breast cancer Cardiac dysfunction 
Cetuximab EGFR 
Advanced head and neck squamous cell carcinoma 
Metastatic colorectal tumors 
Acneiform rash 
Erlotinib EGFR 
Refractory advanced non-small cell lung cancer 
Advanced pancreatic cancer 
Rash 
Diarrhea 
Stomatitis 
Infection 
Panitumumab EGFR Metastastic colorectal cancer 
Skin toxicities 
Diarrhea 
Temsirolimus mTOR Advanced renal cell carcinoma 
Rash 
Peripheral edema 
Stomatitis 
 
 
Antibody-Dependent Cell-Mediated Cytotoxicity  
Apart from selective and specific blockade of signaling pathways, clinical efficacy of 
monoclonal antibodies may also be a result of their ability to activate the immune system, 
called antibody-dependent cellular cytotoxicity (ADCC), which differentiates them from 
small molecule compounds.
37
 ADCC occurs when tumor cell-bound antibodies interact via 
their Fc domain with Fcγ receptors (FcγR) on the surface of effector cells, principally 
natural killer cells, resulting in the release of cytotoxic substances (perphorin) and 
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subsequent lysis of the target cell. In addition, macrophages also express FcγRs and can 
induce phagocytosis of antibody-bound tumor cells as well as enhance ADCC through 
release of proteases and reactive oxygen species.
38
 The ability of monoclonal antibodies to 
induce ADCC depends on their isotype. Whereas IgG1 and IgG3 antibodies bind very well 
to FcγRs, IgG2 and IgG4 isotypes bind weakly to these receptors.
37,38
 Because trastuzumab 
and cetuximab have a human IgG1 backbone they potentially can provoke immunologic 
anti-tumor effects. Indeed, ADCC activity was found to play a prominent role in the 
efficacy of trastuzumab in a mouse xenograft model of breast cancer.
39
 In addition, 
cetuximab is described to induce ADCC activity against different EGFR-expressing tumor 
cell lines.
40,41
 
 
Pitfalls of targeted tumor therapy 
Targeted cancer therapy has been proposed as a promising therapeutic approach in 
oncology. However, as described above, results from clinical trials demonstrate that most 
targeted therapies are likely beneficial for only a small subset of cancer patients. Due to 
the generally heterogeneous nature of cancer, different tumor cells may depend on 
different specific signaling pathways for progression and display specific antigens, which 
differ between, or even within various tumor types or within an individual tumor. This 
calls for tailor-made therapy approaches as pan-tumor cell targets which are present in 
the majority of cancer patients have not yet been identified.  
Another factor limiting efficient targeted therapy in solid tumors is the distribution of 
targeting agents to tumor cells, which may be inadequate due to elevated tumor 
interstitial pressure, poor or irregular tumor vascularisation and slow diffusion of large 
molecules, which all worsen with increasing tumor size. In case of astrocytomas in the 
brain, the blood brain barrier which is generally intact in large areas of these tumors, 
precludes efficient delivery of therapeutic compounds. Although specific targeting of 
malignant cells results in moderate toxicity compared to conventional anti-tumor 
therapies (Table 1), tumor cells also frequently adjust to targeted tumor therapy, resulting 
in therapy resistance, also to TK targeted treatments.
1
 
Alternatively, the beneficial effects of targeting stroma of solid tumors, including blood 
vessels, fibroblasts and macrophages, is now widely recognized. An efficient blood supply 
is crucial for tumor growth and metastasis and already in the early 1970s interference with 
the tumor blood supply was proposed as an attractive therapeutic option.
42
 Unlike tumor 
cells, tumor endothelial cells are well accessible to intravenously administered compounds 
and are genetically stable, reducing the risk of therapy resistance. Importantly, therapy 
directed against tumor vasculature may be effective against a range of tumor types.   
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Tumor angiogenesis 
To grow beyond a size of 1-2 mm
3
, solid tumors depend on the formation of new blood 
vessels from pre-existing ones to supply them with nutrients and oxygen.
43
 In addition, 
tumor angiogenesis propagates tumor progression by increasing the opportunity for 
tumor cells to enter the circulation and disseminate.  
Tumor angiogenesis (figure 1) is orchestrated by a variety of pro- and anti-angiogenic 
molecules which are secreted by tumor cells and supportive cells, such as tumor-
associated endothelial cells, pericytes, smooth muscle cells, fibroblasts, and macrophages. 
The relative balance of pro- and anti-angiogenic molecules in the tumor micro-
environment can switch angiogenesis on or off. When pro-angiogenic factors outbalance 
the action of anti-angiogenic molecules, the tumor acquires an angiogenic phenotype that 
leads to the formation of new blood vessels. Different situations, such as hypoxia and 
metabolic and mechanical stresses, and activation of oncogenes and inactivation of 
tumor-suppressor genes
44,45
 can provoke an unbalanced shift towards pro-angiogenic 
factors, including Vascular Endothelial Growth Factor (VEGF), Angiopoietins, PDGF and 
others. 
Angiogenesis is a complex, multistep process which starts with VEGF-A-induced 
vasodilatation and increased vascular permeability of pre-existing capillaries, or post-
capillary venules (Fig. 1B). The vascular permeability allows the extravasation of plasma 
proteins such as fibrinogen, which is subsequently converted to fibrin serving as a 
provisional matrix for migrating endothelial cells. This is accompanied by Angiopoietin-2 
mediated detachment of pericytes (Fig. 1B).
46
 To allow endothelial cells to migrate 
towards chemotactic angiogenic stimuli the vascular basement membrane and 
extracellular matrix surrounding pre-existing capillaries are degraded by proteases, in 
particular matrix metalloproteinases, secreted by tumor cells and supporting cells.
47
 
Subsequently, endothelial cells proliferate, invade the surrounding extracellular matrix 
and adhere to each other to form hollow tubes (Fig. 1C). This is accompanied by 
Angiopoietin 1- and PDGF-B-induced recruitment of perivascular cells and basement 
membrane formation around the newly formed vessels. Finally, blood vessel sprouts fuse 
with other sprouts to form vascular loops. During physiological angiogenesis, as occurs 
during embryonic development and the menstruation cycle, the tightly regulated balance 
of pro- and anti-angiogenic signals results in rapid maturation and stabilization of newly 
formed microvasculature. However this step is incomplete during tumor-associated 
angiogenesis leading to formation of tumor vessels that are architecturally different from 
their normal counterparts (Fig. 1D).
44
 They spread without any organization, are tortuous, 
irregularly shaped, dilated, leaky, and poorly differentiated.
48
 Tumor vessels may have thin 
walls, with only partial endothelial linings, loss of adherence between endothelial 
junctions, loosely attached or absent perivascular cells and a discontinuous basement 
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membrane.
49,50
 These structural abnormalities contribute to an inefficient and irregular 
blood flow, which is slow and may be stationary or even exhibit turbulence or a reversal in 
the direction of flow. In addition, the hyperpermeability of tumor vasculature leads to 
elevated hydrostatic pressure in the interstitium. Importantly, both the inefficient tumor 
blood flow and interstitial hypertension reduces efficient delivery of chemotherapy to the 
tumor.
51
 
 
 
 
Figure 1. Schematic overview of tumor angiogenesis  
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Inhibition of angiogenesis 
The knowledge that has been gathered in the last decade on the formation of 
neovasculature in tumors led to the development of compounds that interfere with 
different pathways of the angiogenic process. In particular, three pathways have received 
considerable attention, VEGF and its receptor VEGFR2,  the angiopoietins and their Tie2 
receptor, and PDGF-B and its receptor PDGFR-β. 
 
VEGF-A/VEGFR2 pathway  
VEGF-A-mediated signal transduction via its TK receptor VEGFR2 and possibly VEGFR1 and 
the neuropilin class of receptors leads to a cascade of different signaling pathways, 
resulting in proliferation and migration of endothelial cells, production of tissue factor and 
proteases, vascular permeability and deposition of extravascular fibrin which serves as 
provisional matrix for newly formed endothelial cells.
50,52-54
  Alternative splicing yields at 
least six VEGF-A isoforms, existing of 121, 145, 165, 183, 189 and 206 amino acid 
residues,
55-57
 which differ in their incorporation of exons that determine the degree of cell 
surface and extracellular matrix association. While VEGF-A121 lacks these exons and is able 
to act at more distal sites because it is freely released from producing cells, the larger 
isoforms remain more cell and extracellular matrix associated resulting in effects on 
nearby vessels. Hypoxia, often relevant in the centers of rapidly growing tumors, is an 
important inducer of VEGF-A expression. In addition, expression of VEGF-A may also be 
induced by genetic mutations and several cytokines and growth factors.
52,58
   
The search for anti-angiogenic strategies for cancer treatment mainly focused on 
compounds that target the VEGF-A signaling pathway. Many of such agents have been 
developed and preclinical testing indicated that targeting of the VEGF-A/VEGFR2 pathway 
resulted in significant inhibition of neovascularization and tumor growth in various mouse 
xenograft models.
59-63
 
 
Angiopoietin/Tie2 pathway 
Despite its requisite role in vascular formation, VEGF-A must work in concert with other 
factors, among which the angiopoietins. Although angiopoietins are not able to induce 
tumor angiogenesis, they are involved in the angiogenic process at the level of vessel 
stabilization and maturation.
64,65
 The angiopoietins include angiopoietin-1 (Ang-1) through 
angiopoietin-4 (Ang-4). The best studied are Ang-1 and Ang-2 which have similar binding 
affinity for the endothelial cell specific TK receptor Tie2. Whereas binding of Ang-1 to its 
receptor induces autophosphorylation of Tie2, Ang-2 antagonizes the actions of Ang-1 by 
competitively binding to Tie2 without activating the receptor (in endothelial cells). Ang-
1/Tie2 signaling promotes recruitment of perivascular cells to immature angiogenic 
vessels and maintenance of the association of endothelial cells with surrounding support 
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cells and the matrix, resulting in vessel stabilization and maturation. Ang-2 is expressed 
primarily at sites of vascular remodeling, where it blocks the constitutive stabilizing action 
of Ang-1/Tie2 signaling, resulting in dissociation of perivascular cells and reduced contact 
of endothelial cells with the matrix, thereby preventing tumor vessel differentiation and 
maturation.
46,66
 This destabilizing action of Ang-2 facilitates the angiogenic action of VEGF, 
whereas such destabilization in the absence of VEGF leads to vessel regression.
46
 Although 
blockade of the angiopoietin/Tie2 pathway seems difficult due to the complexity of 
agonistic and antagonistic ligands for the same receptor, different mouse tumor models 
revealed that in vivo interference with the Tie2 pathway resulted in reduced tumor 
vascularization and tumor growth.
67-70
 In addition, antibodies against Ang-2 were also able 
to block tumor angiogenesis and tumor growth in preclinical models.
71
  
 
PDGF-B/PDGFR-β pathway  
Although above described anti-angiogenic approaches focus on receptor TKs that are 
selectively expressed within the vascular endothelium, recent data imply that targeting 
tumor associated pericytes may provide additional benefits. As is clear from the role of 
the Ang/Tie2 pathway, TK inhibitors reducing pericyte coverage of tumor vessels might 
have anti-tumor activity, in part by sensitizing them to inhibition of endothelial receptor 
TKs.
46
 
PDGF-B signaling via PDGFR-β, located on pericytes in the tumor stroma, plays a key role 
in angiogenesis and vessel maturation.
3
 PDGFR-β expression by pericytes is necessary for 
their recruitment to tumor vessels, whereas PDGF-B produced by tumor endothelium is 
required for the recruitment of adequate numbers of pericytes, as well as for proper 
integration of pericytes in the vascular wall.
72
 Adequate pericyte coverage functionally 
affects the tumor vasculature by promoting vessel stabilization and maturation thereby 
enhancing tumor perfusion. Blockade of signaling via PDGFRs in established tumors in 
transgenic RIP1Tag2 transgenic mice, which spontaneously develop pancreatic 
carcinomas, resulted in marked detachment of pericytes from tumor vessels and 
enlargement and distortion of these vessels leading to vascular dysfunction and reduced 
tumor growth.
73
 Treatment of early carcinomas with PDGFR inhibitors did not show an 
anti-tumor effect. Conversely, blockade of VEGF signaling was effective in the early stages 
of tumor formation, but not in advanced tumors. Simultaneous inhibition of early 
angiogenesis and vessel maturation by targeting VEGF and PDGF receptors indeed showed 
increased anti-tumor activity. Noteworthy, several multitargeted agents inhibit both VEGF 
and PDGF receptors, and thus inhibition of PDGFRs present on pericytes might contribute 
to the anti-angiogenic effects of these compounds.
59-61
 
Apart from targeting PDGF signaling via PDGFRs on pericytes, a recent study indicated that 
imatinib-induced blockade of PDGF signaling in carcimona-associated fibroblasts can 
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reduce tumor progression via down-regulation of fibroblast growth factors, thereby 
reducing tumor cell proliferation and angiogenesis.
74
   
 
Relevance of tumor micro-environment 
The angiogenic switch can occur at different stages of tumor progression, depending not 
only on the tumor type, but also on the specific tumor microenvironment. It is commonly 
accepted that most solid tumors originate as small avascular lesions, which initially thrive 
on pre-existent vessels in their surrounding micro-environment. In the next phase hypoxia 
arises because proliferating tumor cells outgrow the capacity of the existing vasculature, 
leading to the  localization of tumor cells beyond the maximum oxygen diffusion distance 
from supplying vessels. As a result, VEGF-A is overexpressed initiating tumor 
vascularization. However, it is now realized that when tumors arise in vessel dense tissues 
they do not progress in an angiogenic fashion, but rather associate with and grow 
preferentially along existing vessels, a  process called vessel co-option.
65,75
 We showed in a 
mouse brain metastasis model of human melanoma that in the well vascularized brain 
Mel57 cells grow to highly infiltrative tumors without the induction of angiogenesis.
76
 In 
this micro-environment tumor cells are able to thrive in the presence of pre-existing brain 
vasculature without becoming hypoxic by infiltrating the brain parenchyma in the 
perivascular space. In contrast, after subcutaneous injection these same cells grow to 
highly necrotic tumors with only a small viable tumor rim. In this point of view it is 
important to realize that many traditional tumor xenograft models generally involve the 
inoculation of tumor cells in the essentially avascular subcutaneous space. These 
experimental tumors are devoid of blood supply, forcing them to induce angiogenesis in 
order to grow. Interestingly, in the same mouse brain metastasis model of human 
melanoma we demonstrated that the most frequent VEGF-A isoforms, VEGF-A121, 165 and 
189, contribute differentially to the process of tumor vascularization. While stably 
transfected Mel57 cells overexpressing VEGF-A165 or VEGF-A189 develop to highly 
angiogenic brain lesions, VEGF-A121 overexpression results in profound peritumoral 
vasodilatation of mature pre-existent vessels thereby increasing the tumor’s blood supply, 
and thus tumor growth, without inducing a true angiogenic response.
77,78
  
Altogether these data demonstrate that tumors arising within or metastasizing to vessel-
rich tissues can grow along (modulated) pre-existent vessels to form a well vascularized 
lesion. Prototype clinical tumors which may progress almost exclusively without the 
induction of angiogenesis are diffuse infiltrative gliomas, the most frequent primary brain 
tumors, which are aggressive and highly invasive tumors considered to be among the 
deadliest of human cancers.
79
 Diffuse infiltrative gliomas are classified according to their 
suspected line of differentiation (astrocytic, oligodendroglial, oligoastrocytic) and graded 
on a scale of I to IV according to their degree of malignancy.
80,81
 Diffuse infiltrative gliomas 
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grow along pre-existing normal brain capillaries and may infiltrate throughout the whole 
brain parenchyma.
79
 In the most malignant manifestation of glioma, glioblastoma 
multiforme (GBM), rapidly proliferating tumor cells outgrow the capacity of the brain 
vasculature. In this situation, local hypoxia arises which results in induction of VEGF-A 
expression and angiogenesis and microvascular proliferations in these areas.
82,83
 Due the 
prominent diffuse infiltrative growth in the surrounding brain tissue, surgery or 
radiotherapy of gliomas is hardly ever curative. In addition, the intact blood-brain barrier 
in these diffuse infiltrative areas contributes to a poor response of these tumors to 
conventional tumor therapies
79,81,82
, whereas epigenetic alterations in gliomas result in 
intrinsic resistance to DNA-alkylating agents further deteriorating the efficacy of 
chemotherapy.
84
 GBM  is apart from the most aggressive form of glioma also the most 
frequent one, accounting for 40% of all primary brain tumors. Despite improvements in 
the treatment of GBM by surgery, radiotherapy and chemotherapy, the prognosis of 
patients affected by GBM remains relatively poor, with median overall survival times of 1-
2 year. Although angiogenesis inhibition does not affect diffuse infiltrative, co-optive 
growth, it is yet considered as a suitable anti-tumor approach for GBM patients, given the 
characteristic areas of prominent angiogenesis and microvascular proliferations in these 
tumors.
82,83
 
 
 
Translation to the clinic  
Results obtained from preclinical studies indicated that anti-angiogenic agents induced 
tumor stabilization or even regression in subcutaneous tumor models. As the suboptimal 
character of subcutaneous tumors for the purpose of studying anti-angiogenic therapy 
was not recognized at that time, these findings led to the assumption that also in the clinic 
anti-angiogenic therapy could turn cancer into a chronic disease. This resulted in 
numerous clinical trials evaluating the beneficial effects of different anti-angiogenic 
agents. To date three of them are approved by the FDA (Table 2).  
 
Bevacizumab  
Bevacizumab (a humanized antibody against all isoforms of VEGF-A
62
) has become part of 
first line treatment of patients with metastatic colorectal cancer, non-small-cell lung 
cancer and metastatic breast cancer. As monotherapy, bevacizumab prolonged the time 
to progression and improved response rates in patients with advanced renal cell 
carcinoma,
85
 epithelial ovarian cancer and peritoneal cancer.
86,87
 However, in combination 
with chemotherapy bevacizumab also increased overall survival in patients with 
metastatic colorectal cancer
88-90
 and non-small-cell lung cancer,
91
 while the benefit of 
bevacizumab therapy for patients with metastatic breast cancer was limited to increased 
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response rate and prolonged progression-free survival.
92,93
 Although GBMs are considered 
as good candidates for anti-angiogenic therapy, a phase II pilot study of bevacizumab in 
combination with temozolomide and radiation therapy in patients with newly diagnosed 
GBM revealed modest therapy efficacy as evidenced by the progression-free survival (>8.8 
months).
94
 In addition, one study evaluating treatment efficacy of the combination of 
bevacizumab and irinotecan in 13 patients with recurrent heavily pretreated GBM 
revealed that 10 patients had a partial response and 3 stable disease. However, after the 
initial response 8 patients had aggressive patterns of disease progression.
95
 It is now well 
accepted that the initial response which is seen in these patients on contrast-enhanced 
MRI, may be overestimated due to restoring effects of bevacizumab therapy on the blood 
brain barrier.
96
 
 
Sorafenib 
The small compound  multi-targeted receptor TK inhibitor sorafenib, which inhibits among 
others VEGFR2, and PDGFRβ,
61
 has been approved for treatment of metastatic renal cell 
cancer and advanced hepatocellular carcinoma. Single-agent sorafenib therapy had 
significant disease-stabilizing activity and prolongs progression-free survival in patients 
with advanced renal cell carcinoma
97,98
 from 2.8 months to 5.5 months
97
 and resulted in a 
3-month overall survival benefit in patients with advanced hepatocellular carcinoma.
99
 
Due to its activity against multiple kinases, sorafenib was brought into various trials in 
different malignancies. Recent results in patients with advanced melanoma and thyroid 
carcinoma showed promising response rates and progression-free survival improvements 
of  sorafenib therapy,
100-102
 while sorafenib had only modest anti-tumor activity in patients 
with advanced prostate cancer
103,104
 and patients with advanced head and neck cancer.
105
 
 
Sunitinib 
Sunitinib, like sorafenib a small compound multikinase inhibitor directed against among 
others VEGFR2, and PDGFRβ,
60
 is now approved for treatment of advanced renal cell 
cancer and gastrointestinal stromal tumors in patients who had been treated 
unsuccessfully with imatinib. Sunitinib monotherapy in patients with metastatic renal cell 
carcinoma resulted in improved response rates and a progression-free survival benefit.
106-
109
 Phase II trials demonstrated that sunitinib is associated with anti-tumor activity in 
advanced non-small-cell lung cancer,
110
 metastatic breast cancer 
111
 and advanced 
pancreatic neuroedocrine tumors,
112
 whereas its efficacy in advanced carcinoid patients 
could not be determined.
112
 Patients with advanced gastrointestinal stromal tumors 
withdrawn from imatinib treatment exhibited significantly longer time to tumor 
progression with sunitinib and improved overall survival.
113
 However, these effects may be 
also attributable to targeting c-KIT which is frequently expressed on tumor cells in GIST.  
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Table 2. Anti-angiogenic therapies 
Compound 
 
Target(s)  
 
FDA approved for Adverse effects  
Bevacizumab VEGF-A 
Metastatic colorectal cancer  
 
Non-small-cell lung cancer 
 
 Metastatic breast cancer 
Hypertension  
Hemorrhages  
Thrombosis 
Proteinuria 
Wound dehiscence  
Fatigue 
Headaches 
Sorafenib 
VEGFR2 and -3  
PDGFRβ  
Flt-3  
c-KIT 
Raf 
Metastatic renal cell cancer  
 
Advanced hepatocellular carcinoma 
Diarrhea 
Hand–foot syndrome 
Rash 
Fatigue  
Hypertension  
Sunitinib 
VEGFR2   
PDGFRβ 
Flt-3 
c-KIT 
 
Advanced renal cell cancer  
 
Gastrointestinal stromal tumors withdrawn 
from imatinib 
 
Diarrhea  
Hand-foot syndrome  
Fatigue 
Hypertension 
 
 
Although inhibition of angiogenesis has emerged as an important therapeutic strategy, 
clinical trials demonstrated that different tumor types respond differently to anti-
angiogenic therapy. Strikingly, as single agent therapy all three approved anti-angiogenic 
compounds have clinical activity in renal cell carcinoma patients. Since the von Hippel-
Lindau gene is mutated or silenced in approximately 80% of renal cell carcinomas, leading 
to constitutive overexpression of VEGF-A, these develop as truely angiogenic tumors. So, 
anti-angiogenic monotherapy significantly reduces progression of tumors with a truely 
angiogenic phenotype as also observed in ovarian cancer,
114
 whereas in most other, 
probably not entirely angiogenic tumors the beneficial effects of monotherapy with anti-
angiogenic agents are rather disappointing. The prolonged overall survival of patients with 
metastatic colorectal cancer or non-small-cell lung cancer, seen when bevacizumab is 
added to chemotherapy is hypothesized to be due to anti-angiogenic treatment-induced 
vessel normalization.
115
 As discussed above, the imbalanced expression of angiogenic 
factors during tumor-associated angiogenesis leads to a structurally abnormal vasculature 
which results in impaired blood supply and interstitial hypertension, both interfering with 
the delivery of therapeutics. Anti-angiogenic therapy inactivates the excess of pro-
angiogenic stimuli and is hypothesized to induce morphological changes leading to a more  
normal vasculature. These normalized vessels would be more regularly shaped, less 
tortuous and less permeable resulting in increased tumor blood supply and reduced 
interstitial pressure thereby improving the distribution of therapeutics.  
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Pitfalls of anti-angiogenic therapy in the clinic 
Because preclinical studies indicated that targeting of angiogenic pathways almost without 
exception resulted in tumor stabilization or even regression,
59-63,67-71,73,116
 there is a clear 
discrepancy with the efficacy of anti-angiogenic therapy in clinical settings. For this, there 
is a number of possible explanations. As already indicated, preclinical testing of anti-
angiogenic compounds is predominantly performed in experimental tumors which grow in 
the avascular subcutaneous space, forcing them to induce angiogenesis in order to grow. 
Consequently, this setting leads to the selection of tumors that have the ability to induce 
angiogenesis and thus will be susceptible to anti-angiogenic therapy. In contrast, clinical 
tumors frequently grow in tissues with intrinsically high vessel densities, which may, as 
discussed above, progress independently of angiogenesis via infiltration and incorporation 
of pre-existing blood vessels.
76,78
 Such tumors are less sensitive to anti-angiogenic therapy. 
Importantly, the aim of anti-angiogenic therapy is to halt progression of otherwise 
untreatable, mostly disseminated, cancers. However, most metastases are blood-borne 
and generally grow in vessel dense tissues (e.g. bone, liver, lung and brain). Consequently, 
metastatic lesions may progress by co-option of pre-existent vasculature, rendering them 
resistant to anti-angiogenic therapy. In addition, we demonstrated in a brain metastasis 
model of human melanoma that stably transfected tumor cells overexpressing VEGF-A165 
which develop to highly angiogenic tumors in the brain parenchyma,
77
 do not regress in 
response to treatment with the angiogenesis inhibitor vandetanib, but rather progress via 
increased reliance of tumor cells on vessel co-option.
117
 This provides tumors in a well 
vascularized environment with an escape mechanism which makes them partially 
insusceptible to anti-angiogenic compounds by shifting their phenotype to vessel co-
option. Similarly, we and others showed in different orthotopic mouse models of glioma 
that high grade gliomas do not adequately respond to anti-angiogenic therapy due to 
progression of tumor cells via co-option of pre-existing brain capillaries.
96,118-121
 
Importantly, a recent clinical study of bevacizumab in combination with irinotecan in GBM 
patients revealed that after an initial response the majority of patients indeed experience 
aggressive patterns of disease progression, including gliomatosis cerebri, which is 
characterized by its wide diffuse infiltration throughout the brain.
95
 In gliomas there is 
another factor complicating anti-angiogenic therapy. Whereas the beneficial effects of 
anti-angiogenic therapy in combination with chemotherapy are hypothesized to be 
attributable to anti-angiogenic treatment-induced vessels normalization in patients with 
metastatic colorectal cancer or non-small-cell lung cancer, in gliomas normalization of the 
vascular bed involves restoration of the blood-brain barrier, thereby possibly hampering, 
instead of enhancing, the delivery of therapeutic compounds to tumor cells.
120,122
 
However, the reduced vascular permeability also results in decreased interstitial pressure 
 Ch a p t e r  1  
 
General introduction 23 
 
and cerebral edema thereby improving quality of life of glioma patients treated with anti-
angiogenic therapy.
123
  
As discussed above, despite improvements in the standard treatment of GBM and several 
attempts to gain clinical benefit with the addition of therapies specifically targeting tumor 
cells, treatment efficacy of these tumors is still unsatisfactory. In addition, although high 
grade gliomas have long been considered as good candidates for anti-angiogenic therapy, 
preclinical results from orthotopic mouse models of glioma and recent data from clinical 
studies suggest otherwise. So, there is an urgent need for new approaches to improve 
treatment efficacy of these fatal tumors. Since gliomas, like other tumor types growing in 
well vascularized tissues, may progress via vessel co-option, targeting the existing vascular 
bed, instead of prevention of the formation thereof, seems an attractive approach.  
 
Vascular targeting 
Targeting the genetically stable tumor endothelium, which is well  accessible after 
intravenous injection of agents (without hindrance by the blood brain barrier in gliomas), 
may be a good alternative therapy to disrupt a tumor’s blood supply. This approach 
requires the availability of tumor-vessel specific targeting agents (TVTAs) with high enough 
specificity for existing tumor vasculature. Few candidate TVTAs have been identified so 
far. Effective tumor vessel targeting can be achieved with the L19 single chain antibody 
which is directed against the ED-B fragment of fibronectin, a splice variant which is 
deposited in the extracellular matrix of newly formed vessels only in actively growing 
tumors,
124
 whereas this single chain antibody was unable to detect quiescent endothelium 
in low grade malignancies.
125
 RGD peptides have been used to successfully target integrin 
αvβ3 in vivo.
126
 Receptor-targeted radiotherapy using radiolabeled RGD peptides has been 
shown to reduce tumor growth in xenograft mouse models.
127,128
 However, expression of 
αvβ3 is restricted to immature vessels. In addition, this integrin is also present on 
intestinal epithelium. Recombinant fusion proteins of a truncated form of the coagulation-
inducing protein tissue factor with vascular cell adhesion molecule 1 (VCAM-1), a luminal 
tumor endothelial antigen expressed in angiogenic vessels, induced tumor specific blood 
clotting, tumor necrosis and growth delay in different xenograft models.
129
 Since endoglin 
is strongly expressed in vasculature of different solid tumors it has been proposed as an 
attractive vascular molecule for targeted therapy, however, this protein is also observed in 
the vasculature of normal adult tissues, limiting its clinical usefulness.
130
   
 
 
Outline of this thesis 
Tumors obtain their blood supply by the formation of new vasculature or by the 
incorporation, and possibly subsequent modulation, of pre-existent vessels. Importantly, 
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vascular targeting, which is at the moment restricted to vessels in early maturation stages, 
requires that TVTAs with specificity for the entire existing vascular bed, including co-opted 
vessels, become available.  
The overall aim of this thesis was to map vascular heterogeneity between and within 
different clinical brain tumors and to identify novel vascular targets which may be of 
clinical use for treatment of these tumors. We set up a powerful platform for the 
identification of targetable tumor vessel associated markers.  
In chapter 2 vascular phenotypes of primary and metastatic clinical brain tumors are 
correlated with their VEGF-A expression profiles, resulting in a model where constitutively 
VEGF-A expressing tumors present with different vascular beds than tumors in which 
VEGF-A is expressed as a response to central hypoxia. Chapter 3 demonstrates the 
identification of a novel tumor vascular target: Plexin D1. Expression of this protein is 
examined during tumor angiogenesis in a brain metastasis model of human melanoma. In 
addition, this chapter describes the expression of Plexin D1 on both tumor vessels and 
tumor cells in a number of primary and metastatic clinical brain tumors. Furthermore, 
Plexin D1 recognizing antibodies are isolated and analyzed for their ability to target to 
melanoma brain metastases in a mouse model. Chapter 4 describes expression of Plexin 
D1 and one of its ligands, Semaphorin 3E, in a series of cutaneous melanocytic lesions 
representing different stages of melanoma progression. In addition, functional effects of 
Semaphorin 3E overexpression on tumor development are examined in a xenograft model 
of metastatic melanoma. In chapter 5, Plexin D1 expression is further evaluated in a large 
number of different clinical tumors and non-tumor related human tissues. Chapter 6 
describes the isolation of a tumor vessel targeting nanobody by in vivo biopanning of a 
phage display library in an orthotopic mouse model of glioma, the identification of its 
ligand and the expression of this ligand in different tumor xenograft models and a number 
of clinical gliomas. In addition, a platform for identification of novel targetable vessel 
associated markers is introduced. In chapter 7 we have extended our nanobody phage 
display technology by generating a novel nanobody library from an immunized Llama and 
subsequent isolation of additional TVTAs by in vivo biopanning of this library in orthotopic 
mouse models of glioma. Chapter 8 summarizes the results and discusses future 
perspectives.  
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Development of the tumor vascular bed                    
in response to hypoxia-induced VEGF-A              
differs from that in tumors with            
constitutive VEGF-A expression 
 
 
 
 
Ilse Roodink 
Jeroen van der Laak 
Benno Küsters 
Pieter Wesseling 
Kiek Verrijp 
Robert de Waal 
William Leenders  
 
Int J Cancer 2006, 119:2054-2062 
 
Ch a p t e r  2   
 
28 Vascular phenotypes in tumors with hypoxic vs genetic VEGF-A expression 
 
Abstract 
 
Tumors arise initially as avascular masses in which central hypoxia induces expression of 
Vascular Endothelial Growth Factor-A (VEGF-A) and subsequently tumor vascularization. 
However, VEGF-A can also be constitutively expressed as a result of genetic events. VEGF-
A is alternatively spliced to yield at least six different isoforms. Of these, VEGF-A121 is 
freely diffusible whereas basically charged domains in the larger isoforms confer affinity 
for cell surface or extracellular matrix components. We previously reported that in a 
mouse brain metastasis model of human melanoma, VEGF-A121 induced a qualitatively 
different tumor vascular phenotype than VEGF-A165 and 189: in contrast to the latter ones, 
VEGF-A121 did not induce a neovascular bed but rather led to leakage and dilatation of pre-
existent brain vessels.  
Here, we correlate vascular phenotypes with spatial VEGF-A expression profiles in clinical 
brain tumors (low grade gliomas; n=6, melanoma metastases; n=4, adenocarcinoma 
metastases; n=4, glioblastoma multiforme; n=3, sarcoma metastasis; n=1, renal cell 
carcinoma metastasis; n=1).  We show that tumors that constitutively express VEGF-A 
present with different vascular beds than tumors in which VEGF-A is expressed as a 
response to central hypoxia. This phenotypic difference is consistent with a model where 
in tumors with constitutive VEGF-A expression, all isoforms exert their effects on 
vasculature, resulting in a classical angiogenic phenotype. In tumors where only central 
parts express hypoxia-induced VEGF-A, the larger angiogenic isoforms are retained by 
extracellular matrix, leaving only freely diffusible VEGF-A121 to exert its dilatation effects 
on distant vessels. 
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Introduction 
 
Except for infiltrative tumors in organs where a high density of capillaries allows co-option 
of pre-existent vessels,
75,131
 tumors cannot grow beyond a minimum size of 3 mm
3
 unless 
they have the capacity to generate a new vasculature via angiogenesis.
132-134
 Angiogenesis 
not only enhances tumor growth by supplying tumor cells with oxygen and nutrients, but 
also increases the chance of tumor cell intravasation, an obligatory and rate-limiting step 
in the metastatic process. Indeed, in a number of tumor types positive correlations 
between vessel density and poor prognosis have been established.
135,136
  
Most research on tumor angiogenesis has focused on Vascular Endothelial Growth Factor-
A (VEGF-A). VEGF-A is a target gene for the transcription factor hypoxia-inducible factor-1 
(HIF-1), a dimeric complex of HIF-1α and HIF-1β.
137
 Hypoxia, often relevant in the centers 
of rapidly growing tumors, results in diminished proteasomal degradation of HIF-1α. 
Consequently, HIF-1 accumulates in the cell which results in enhanced transcription of the 
VEGF-A gene.
137-140
 In tumors, expression of VEGF-A is not always hypoxia-related as it 
may also be a consequence of genetic events, such as overactivation of proto-oncogenes 
as k-ras
141
 or mutational inactivation of tumor suppressor proteins such as the Von-Hippel-
Lindau protein (VHL) and PTEN.
142,143
 Finally, VEGF-A expression can also be induced by 
several cytokines and growth factors.
138,144
   
Upon binding of  VEGF-A to its tyrosine kinase receptors VEGFR1 and VEGFR2, a cascade of 
cellular events is initiated, leading to proliferation and migration of endothelial cells, 
production of tissue factor and proteases, vascular permeability and deposition of 
extravascular fibrin which serves as provisional matrix for newly formed endothelial 
cells.
50,53,145
 Although VEGFR1 has the higher affinity for VEGF-A, VEGFR2 is tyrosine-
phosphorylated more efficiently upon ligand binding and mediates almost all observed 
endothelial cell responses to VEGF-A
55,146
, at least during tumor angiogenesis.  
The VEGF-A transcript is alternatively spliced to yield multiple isoforms counting 121, 145, 
165, 183, 189 and 206 amino acid residues.
57,147,148
 The larger of these isoforms contain 
basically charged domains, encoded for by exons 6a, 6b and 7, which confer binding 
affinity towards negatively charged extracellular matrix and cell surface components such 
as heparan sulphate proteoglycans. Hence, these isoforms are, at least partly, tethered by 
the extracellular matrix. VEGF121 lacks these exons and is freely diffusible. The exon 7-
encoded domain in VEGF165 results also in binding of this isoform to the non-signaling co-
receptor neuropilin-1 (NP-1). Since NP-1 also has affinity for VEGFR2, the hypothesis has 
been put forward that NP-1 enhances the formation of the VEGF-VEGFR2 complex, 
explaining the increased potency of VEGF165 relative to VEGF121 to activate VEGFR2 in 
vitro.
149
 NP-1 is essential for angiogenesis: NP-1 knock-out mice, as well as mice expressing 
solely VEGF120 (the mouse VEGF-A isoforms count one amino acid residue less than their 
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human counterparts) are characterized by a maldeveloped vasculature and die in 
utero.
150-152
 On the other hand, transgenic mice that express VEGF164 as the only isoform 
develop normally.
150,152,153
 
Only little information about the in vivo activities of the individual isoforms in tumor 
biology is available, the main reason being that during tumor growth the multiple isoforms 
are expressed simultaneously. We recently published that, in a mouse model of brain 
metastases of melanoma which selectively express VEGF-A121, 165 or 189, VEGF-A165 and 
VEGF-A189 induced angiogenic responses whereas VEGF-A121 was unable to do so. This 
isoform only induced permeability and dilatation of peritumoral pre-existent vessels.
77
 
Interestingly, despite the absence of angiogenesis, VEGF-A121 did induce endothelial 
proliferation with a potency similar to VEGF-A165, suggesting that endothelial VEGFR2 was 
equally activated by all isoforms. Importantly, despite the absence of sprouting 
angiogenesis the “vasomodulation” activities of VEGF121 led to increased blood supply and, 
consequently, higher tumor growth rates. 
In clinical practice, tumors present with very heterogeneous vascular beds. Tumors may 
be homogenously well vascularized, but may also be sparsely vascularized with more or 
less necrotic regions. The question emerges why the latter tumors fail to mount a proper 
angiogenic response. Here we approached this question by correlating spatiotemporal 
expression patterns of distinct VEGF-A-isoforms to vascular phenotypes in a panel of 
primary and metastatic brain tumors. We show that tumors develop qualitatively different 
vascular phenotypes, depending on whether VEGF-A expression is constitutive or hypoxia-
induced. Our results show that a classical tumor neovascular bed (high density of dilated 
and sprouting vessels) is characteristic for tumors that constitutively express VEGF-A 
whereas hypoxia-induced VEGF-A expression results in vasomodulation rather than 
neovascularization.  
 
 
Materials and Methods 
 
Tissue samples 
Twenty primary and metastatic brain tumors were selected from the archives of the 
Department of Pathology of the University Medical Centre St Radboud. Tumors consisted 
of low grade gliomas (n=6), glioblastoma multiforme (n=3), and metastases of melanoma 
(n=4), adenocarcinoma (n=4), alveolar soft part sarcoma (n=1) and renal cell carcinoma 
(n=1). Both frozen and formalin-fixed tumor tissues were used for analyses. Tumors were 
diagnosed by qualified pathologists. 
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VEGF-A mRNA In Situ Hybridization (ISH) 
Single-stranded sense and antisense digoxigenin-labelled VEGF RNA probes were 
generated by in vitro transcription of VEGF-A165 cDNA in vector pGEM-T (Promega , 
Madison, WI) with respectively T7 and Sp6 RNA polymerase (Roche, Almere, The 
Netherlands) according to the manufacturer´s instructions. Paraffin-embedded tumor 
sections of 4 µm were dewaxed and treated with proteinase K (Roche) at 37°C for 15 
minutes and post-fixed in formaldehyde at room temperature for 30 minutes. Non-specific 
binding sites were blocked by incubation with acetic anhydride (Sigma Chemical Co., 
Zwijndrecht, The Netherlands) at room temperature. Overnight hybridization with 
digoxigenin-labelled RNA probes was performed at 60°C with 100 ng/ml probe.  After 
hybridization and subsequent washing, single stranded non-hybridized RNA was degraded 
with RNAse T1 (2 units/ml) at 37°C for 30 minutes. After subsequent pre-incubation with 
normal sheep serum, the slides were incubated with alkaline phosphatase-conjugated 
sheep anti-digoxigenin antibody (Roche) at room temperature for 1 hour. Alkaline 
phosphatase was visualized using nitro blue tetrazolium (NBT; Roche) and 5-bromo-4-
chloro-3-indolyl phosphate (BCIP; Roche) as substrate. Specificity of hybridisations was 
always verified by performing control hybridizations with sense probe.  
 
Immunohistochemistry  
Immunohistochemical stainings were performed according to standard protocols. In short, 
sections of 4 µm were prepared from paraffin-embedded brain tumors and 
immunostained with antibodies against the following antigens: CD31 (to detect 
endothelial cells, Dako, Glostrup, Denmark), α-SMA (α-smooth muscle actin, to detect 
activated pericytes, Sigma, Zwijndrecht, The Netherlands), Glut-1 (glucose transporter-1, a 
brain-endothelial specific protein and a hypoxia marker, Dako), MIB-1 (anti-proliferation 
antigen Ki67, Dako) and HIF-1α (Chemicon, Temecula, CA). After deparaffinization and 
blocking of endogenous peroxidase activity, antigen retrieval was performed by boiling in 
10 mM citrate buffer, except for the sections stained with anti-αSMA. Non-specific binding 
sites were blocked by incubation with normal horse or goat serum. Slides were incubated 
overnight at 4°C with primary antibodies in PBS/1% BSA. After washing, primary 
antibodies were detected by sequential incubations with biotinylated secondary antibody 
(Vector, Burlingame, CA) in PBS-BSA and avidin-biotin peroxidase complex  (Vector). 
Finally, the peroxidase was visualized by the 3-amino-9-ethylcarbazole (ScyTek, Utah, USA) 
peroxidase reaction with hematoxylin as counterstain. 
 
Quantitative analysis of vascular density and morphology, relation to hypoxia 
Sections of four representative tumors (sarcoma, renal cell carcinoma and two 
melanomas) were subjected to extensive quantitative analysis. CD31-stained sections 
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were analyzed using a digital image analysis system (KS400, Carl Zeiss, Germany), 
essentially as described before.
154
 Numbers of isolated CD31-positive structures were 
counted as separate vessels. Also, the average diameter was determined for each 
individual vessel, based on digital distance transforms. In the two melanomas, the mean 
minimal distance between vessels and VEGF-A-expressing tumor cells (from the ISH 
analysis) was determined. In the same tumors, the mean minimum distance between 
vessels and Glut-1-positive hypoxic tumor cells was measured. This was done for twenty 
six vessels in one of the melanomas. Student T-tests were used for statistical analysis. 
 
Reverse Transcriptase Polymerase Chain Reaction (RT-PCR) 
Total RNA was isolated from 30 frozen 20 µm tumor sections using TRIzol Reagent (Life 
Technologies, Breda, The Netherlands) according to the manufacturer´s protocol. RNA 
integrity was checked by 1.0% agarose gel electrophoresis. RNA samples (1 μg) were 
reverse-transcribed at 42°C for 90 minutes using Moloney-mouse-leukemia virus reverse 
transcriptase (Promega, Leiden, The Netherlands). Two μl of the reaction product were 
subjected to standard PCR amplification using High Fidelity Taq polymerase (Roche) and 
VEGF-A-primers 5`-GCA CCC ATG GCA GAA GGA GGA-3` (sense) and 5`-TCA CCG CCT CGG 
CTT GTC AC-3` (exon 8 specific, antisense). The PCR was made semi-quantitive by first 
establishing an optimal number of cycles where amplification was in the linear range.  
This primer set amplifies all VEGF-A isoforms simultaneously, except VEGF165b. Expected 
product lengths with this primer set are 367 bp (VEGF-121), 436 bp (VEGF-145), 496 bp 
(VEGF165) and 568 bp (VEGF189). cDNAs were also subjected to a PCR for PBGD as control 
house keeping gene. Levels of the individual isoforms relative to PBGD were quantified by 
densitometry. 
 
 
Results 
 
Spatial distribution of VEGF-A expression  
To investigate the distribution of VEGF-A expression in our panel of tumors, in situ 
hybridizations (ISH) were performed. We considered VEGF-A expression as hypoxia-
induced when ISH profiles correlated with the distribution of HIF-1α and one of its target 
genes Glut-1
155
 in immunohistochemical stainings on serial sections. When VEGF-A 
expression could be detected in non-hypoxic tumor cells, expression was considered as 
constitutive.  
Three groups could be distinguished. In one group, consisting of the sarcoma and renal 
cell carcinoma metastases and the glioblastomas (GBM), the majority of viable tumor cells 
expressed high levels of VEGF-A (Figure 1A,D,G). VEGF-A expression was not related to 
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hypoxia as no Glut-1 or HIF-1α expression was detected in VEGF-A expressing tumor cells 
(Figure 1B,E,H, note that the staining in panel B is due to erythrocytes, whereas the Glut-1 
staining in panel 1H is partly confined to pre-existent vasculature with a functional blood 
brain barrier). In GBM, VEGF-A expression was heterogeneous but could not be related to 
hypoxia. The high VEGF-A expression levels in sarcoma and renal cell carcinoma 
metastases and parts of the GBM are consistent with the high vascular densities, as 
indicated by the CD31 staining in Figure 1C,F,I (note that in GBM the high vessel density is 
seen in the regions that express VEGF-A). Taken together, these results strongly suggest 
that VEGF-A expression in this group of tumors was the result of a genetic event, rather 
than hypoxia. 
 
 
 
Figure 1. Representative examples of spatial distribution of VEGF-A expression (A,D,G), hypoxia (B,E,H) and 
blood vessels (C,F,I) in brain metastases of sarcoma (A-C) and  renal cell carcinoma (D-F) and in glioblastoma 
multiforme (G-I). VEGF-A transcripts were highlighted by in situ hybridization with an antisense VEGF-A RNA 
probe, hypoxia was  demonstrated by immunohistochemistry using an anti-Glut-1 antibody, vessels were 
stained with an antibody against CD31. Note in B, E and H that no Glut-1 positive tumor cells are present. 
The positivity in these sections is due to erythrocytes in dilated vessels. In the GBM some blood vessels also 
stain positive, indicating that these are in fact pre-existent capillaries with a functional blood brain barrier. 
The arrow in I points at a glomeruloid proliferation. These stainings show that in this group of tumors there 
is no correlation between hypoxia and VEGF-expression. 
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In the second group, consisting of metastases of adenocarcinoma and melanoma, VEGF-A 
expression was heterogeneous. In this group, VEGF-A expression co-localized with Glut-1 
expression (compare Figure 2A with 2B and 2D with 2E). Especially in melanomas, VEGF-A 
expression occurred at regular, concentric distances from dilated vessels, exactly the 
tumor areas that were subject to hypoxia, as revealed by the Glut-1 staining (Figure 2B) 
and HIF-1  stainings (not shown) suggesting  that in these tumor lesions VEGF-A 
expression was induced by hypoxia. Indeed, the mean distance between vessels and Glut-
1 expressing tumor cells and that between vessels and VEGF-A expressing cells did not 
differ significantly (85±16 µm vs. 78±16 µm, p=0.12), further confirming the hypoxia-
induced origin of VEGF-A.  
 
 
 
Figure 2. Spatial distribution of VEGF-A expression as determined by VEGF-A ISH (A,D,G), hypoxia (Glut-1 
immunostaining, B,E,H) and blood vessels (CD31 immunostaining, C,F,I) in brain metastases of melanoma (A-
C), adenocarcinoma (D-F), and in low grade glioma. In melanoma and adenocarcinoma metastases, there is 
a clear co-localization of Glut-1 expression and VEGF-A expression, suggesting that in these tumor types 
VEGF-A is expressed as a response to hypoxia. In melanoma the hypoxic areas are confined to concentric 
regions at regular distances from dilated blood vessels, in the adenocarcinoma metastases the hypoxia and 
VEGF-A expression occurred primarily in epithelial cells distant from the fibrovascular regions (arrows). The 
blood vessels in the low grade astrocytoma are positive for Glut-1, indicating that these are pre-existent 
brain capillaries with a functional blood brain barrier. Note that the sections shown are obtained from the 
same tumor regions. Due to technical reasons, however, these are not exact serial sections.  
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VEGF-A mRNA transcripts in adenocarcinoma metastases were predominantly detected 
distant from the fibrovascular core, and also here VEGF-A expression correlated with Glut-
1 expression, again suggesting that VEGF-A was induced as a response to hypoxia.  
Finally, in low grade gliomas we only incidently observed low levels of VEGF-A (Figure 2G-
I). Hypoxia was not observed in these tumors (see Glut-1 staining in figure 2H), consistent 
with the infiltrative nature of these tumors which enables the tumors to grow via co-
option of pre-existent vessels. Note that these pre-existent blood vessels all express Glut-
1, indicative of blood-brain barrier characteristics and, thus, a pre-existent nature. 
To examine which isoforms of VEGF-A were expressed by the respective tumors, RT-PCR 
was performed using a primerset that enables simultaneous detection of the major VEGF-
A isoforms. Except for the low grade gliomas, which expressed barely-detectable levels of 
VEGF-A, all tumors expressed all major VEGF-A isoforms, although the ratios between the 
isoforms differed between the tumors (Table 1). 
 
Table 1.  Levels of the individual VEGF-A isoforms, relative to the house keeping gene PBGD. 
 
 VEGF-121 VEGF-145 VEGF-165 VEGF-189 
Low grade gliomas 0.28 n.d. 0.26 0.19 
Melanoma metastases 0.47 n.d. 0.39 0.27 
Adenocarcinoma metastases 1.92 0.95 1.26 0.76 
Glioblastomas Multiforme 2.02 1.34 2.40 1.17 
Metastasis of sarcoma/RCC 2.28 1.73 2.98 1.63 
 
The sarcoma metastasis and the GBM expressed the highest levels of VEGF-A, which is 
consistent with our in situ hybridization data (Figure 3). These tumors expressed 
predominantly VEGF-A165 and VEGF-A121, but significant amounts of the 145 and 189 
isoforms were also detected. The renal cell carcinoma showed prominent expression of 
VEGF-A121 and VEGF-A165 and less expression of the 145 and 189 aa isoforms. 
All four melanoma metastases examined expressed approximately equal levels of the 121 
and 165 isoforms. Levels of VEGF-A in these tumors were less than in the GBM, sarcoma 
and renal cell carcinoma samples. Again, this is consistent with our in situ hybridization 
data which showed that VEGF-A expression was restricted to relatively small areas of 
hypoxia. The adenocarcinomas in this study expressed all four isoforms of VEGF-A, but 
VEGF-A165 and VEGF-A121 were the most prominent ones. 
Finally, in the group of low grade gliomas we could detect in only two samples very low 
expression levels of the 121 and 165 isoforms. In the other five samples no VEGF-A 
transcripts could be detected. This is consistent with the absence of detectable 
angiogenesis in these tumors (see also Figure 2G-I) and lack of VEGF-A transcripts, as 
observed in the situ hybridization. 
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Vascular morphology of brain tumors  
Based on immunohistochemical stainings with anti-CD31 and anti-α smooth muscle actin 
(data not shown) to visualize blood vessels in our panel of brain tumors, we could group 
the tumors according to VEGF-A expression profiles: 
 
1) constitutive VEGF-A expression 
This group of tumors, consisting of the sarcoma and renal cell carcinoma metastases and 
regions within the GBMs, presented with a high density of dilated and tortuous blood 
vessels (Figure 1C,F,I and Figure 4A), the classical hallmarks of angiogenic tumors. Vessels 
were mostly negative for Glut-1 (compare Figure 1C to 1B and 1F to 1E), indicating that 
they lacked specific characteristics of brain capillaries and were newly formed. A subset of 
blood vessels in the GBM specimens stained positive for Glut-1. These may represent pre-
existent vessels that are co-opted by the tumor cells, but it may also be that the astrocytic 
nature of GBM induces blood-brain characteristics in some of the tumor vessels.
156
 It must 
be noted that small areas of necrosis within GBM were generally surrounded by hypoxic 
tumor cells which also expressed VEGF-A (not shown). Therefore, in GBMs a mixture of 
hypoxia-induced VEGF-A expression and constitutive expression occurs. The vast majority 
of the tumor vessels stained positive for α-smooth muscle actin, indicative of a high 
degree of coverage by activated pericytes. In the GBM, regions with glomeruloid 
microvascular proliferation were observed (see arrow in figure 1I). The GBM was different 
from the sarcoma and renal cell carcinoma in that VEGF-A expression was heterogeneous 
Figure 3. RT-PCR using exon 4 and exon 8 specific VEGF primers, allowing simultaneous detection of the 
major VEGF-A isoforms (see text). The house keeping gene PBGD was used as a control. The variety in PBGD 
PCR products is due to the differences in RNA quality of the archival tumor material. 
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within the tumor. This is also reflected in heterogeneity in vascularization, as shown in 
Figure 1I.  
 
 
 
 
 
 
 
 
2) hypoxia-mediated VEGF-A expression 
The blood vessels in all four melanoma metastases in our study were of a remarkably 
different phenotype as compared to those in the tumors of the first group. The melanoma 
lesions presented with regularly dilated vessels, more or less homogeneously distributed 
throughout the tumors, without indications for sprouting angiogenesis (Fig. 2C and Figure 
4B). The majority of these vessels stained positive for α-smooth muscle actin (not shown). 
In general, these vessels were negative for Glut-1 but occasionally vessels with a mosaic 
composition of Glut-1-positive and negative endothelial cells could be observed in the 
tumor periphery (not shown). This suggests that mother endothelial cells (Glut-1 positive 
and derived from pre-existent brain capillaries) and daughter endothelial cells (Glut-1 
negative) co-existed in these vessels, suggesting endothelial cell proliferation in the 
absence of neo-angiogenesis. Interestingly, similar mosaic vessels were observed in Mel57 
melanoma brain lesions, expressing  VEGF-A121 as the only isoform.
77
 Tumor cells located 
at regular distances from vessels were hypoxic as revealed by Glut-1 staining (Fig. 2B). The 
blood vessels in the adenocarcinoma metastases were also dilated. Interestingly, 
Figure 4. A) Automated analysis of vessels in brain metastases of sarcoma (sarcomas met), renal cell 
carcinoma (RCC met) and two melanomas (mel met 1 and 2). Note the high vessel densities in sarcoma and 
renal cell carcinoma, whereas the vessel densities in melanoma metastases are much lower. B) mean vessel 
diameter in the same tumors. Note that the mean vessel diameter in the melanomas was much higher than 
in the other tumors, confirming the immunohistochemical stainings in figure 2. 
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occasionally signs of sprouting angiogenesis were observed in the fibrovascular 
components of these tumors (Fig. 2F). Again, vessels were predominantly negative for 
Glut-1, indicating that endothelial cell proliferation had occured in these tumors (Fig. 2E).  
 
3) low to undetectable VEGF-A expression 
Finally, in our set of low grade gliomas we observed only occasionally a slight vessel 
dilatation (Fig. 2H, I). Vessels stained positive for α-smooth muscle actin (α-SMA, not 
shown) and Glut-1, indicating that these relatively mature vessels had a functional blood-
brain-barriere (BBB) and were presumably pre-existent brain vessels. Prominent vascular 
changes were not detected, nor were hypoxia and necrosis in the examined specimens.  
 
 
Tumor cell proliferation 
Interestingly, we found no correlation between the vascular densities and the 
proliferation indices of the tumors in this study. The sarcoma metastasis, which was the 
most vascularized tumor with the highest VEGF-A expression, had a proliferation index of 
only 1% as indicated by staining for the Ki67 nuclear antigen (Figure 5A), whereas the 
renal cell carcinoma had a proliferation index of more than 60%. In the GBM samples, MIB 
staining was heterogeneous, and often proliferating vessel-associated cells, presumably 
endothelial cells and pericytes, could be observed (arrows in Figure 5F). Whereas the four 
melanoma metastases in our study showed very similar vascular phenotypes, the MIB 
proliferation indices varied from less than 1% to more than 80% (Figure 5D and E). The 
adenocarcinomas also had very high proliferation indices (ranging from 40-90%, see Figure 
5C). Finally, in the low grade gliomas Ki67-positivity was limited to less than 5-10% of 
tumor cells (not shown). 
 
 
 
Discussion 
 
We previously reported that in a mouse brain metastases model of the human  melanoma 
cell line Mel57, the VEGF-A isoforms 121, 165 and 189 contribute differentially to the 
process of tumor vascularisation.
77
 Tumors that exclusively expressed VEGF-A121 were 
characterized by a relative absence of intratumoral blood vessels, whereas highly dilated 
and activated, supposedly pre-existent vessels were concentrated in a peritumoral rim. In 
sharp contrast, VEGF-A165 and VEGF-A189 induced the formation of an intratumoral 
neovascular bed consisting of irregularly dilated and leaky vessels. In VEGF-A165 expressing 
tumors vasodilatation was more prominent as compared to VEGF189 tumors. In the 
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present study we sought to extrapolate these findings to the human situation by 
comparing expression profiles of distinct VEGF-A-isoforms with tumor vascular 
phenotypes in a set of human primary and metastatic brain tumors. 
 
 
 
 
 
 
Figure 5. Proliferation indices of tumors as revealed by MIB-1 staining. Shown are brain metastases of 
sarcoma (A), renal cell carcinoma (B), adenocarcinoma (C), melanoma (D,E) and a GBM (F). 
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Multiple VEGF-A isoforms were expressed simultaneously in most tumors. In four of the 
low grade gliomas low VEGF-A expression was detected, both by in situ hybridization and 
RT-PCR. This is in accordance with the absence of vascular effects in these tumors. 
Typically, low grade gliomas are infiltrative and slowly growing tumors, which is also 
apparent from the low proliferation indices.
82
 Supposedly, the blood supply from the pre-
existent vascular bed in and around these tumors sufficed for growth of these relatively 
quiescent tumors. This situation is remarkably similar to that in which VEGF-A negative 
Mel57 melanoma cells are grown in brain.
76
 In all other tumors examined in this study, 
VEGF-A transcripts could be readily detected by RT-PCR. Without exception, VEGF-A121 and 
VEGF-A165 were the predominant isoforms, and the occurrence of these was always 
related to prominent vascular changes. The tumors that presented with the highest 
expression levels were the metastases of sarcoma, renal cell carcinoma and regions within 
the GBMs. It has to be realized, however, that these tumors expressed VEGF-A 
homogeneously throughout the tumor, whereas in the tumors with the relatively lower 
VEGF-A expression, the melanomas and the adenocarcinomas, expression was confined to 
hypoxic tumor cells (a subpopulation, estimated to comprise 10% of the total tumor area). 
Taking this factor into account, it is reasonable to assume that the VEGF-A expression 
levels per tumor cell are comparable between the different tumors. Only minor 
differences between the ratios of the isoforms could be detected. The sarcoma metastasis 
and two of the glioblastomas multiforme were the only tumors in which significantly more 
VEGF-A165 than the other isoforms could be detected. In two of the adenocarcinoma 
metastases, VEGF-A121 dominated over VEGF-A165. These differences were not reflected in 
the vascular morphologies of these tumors. 
Despite the absence of dramatic differences in VEGF-A expression levels and ratios of 
VEGF-A isoforms between the tumors, the low grade gliomas excluded, there were 
profound differences between the vascular architectures of the tumors. 
In the sarcoma and renal cell carcinoma metastases where VEGF-A was homogeneously 
distributed throughout the tumor, also in apparently normoxic areas, vessel densities 
were always high and vessels lacked expression of Glut-1. Apart from being a marker for 
hypoxic cells, Glut-1 is also expressed on the endothelium of brain capillaries with a 
functional blood-brain barrier. We already demonstrated in a mouse model of brain 
metastasis that the absence of Glut-1 on tumor vessels is an indication that such vessels 
are the product of neovascularization, whereas tumor vessels that do express Glut-1 are 
actually incorporated pre-existent brain capillaries.
77
 Incorporation of pre-existent, Glut-1 
positive blood vessels was indeed observed in the grade II gliomas in our study.  
Unlike primary brain tumors that have the tendency to show infiltrative growth, 
metastases in brain generally grow expansively, showing little infiltration in the brain 
parenchyma.
82
 Therefore these tumors can hardly thrive on pre-existent vasculature and 
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are dependent on neovascularization. Indeed, the vessels in these tumors all lacked Glut-1 
expression. In GBM, Glut-1 was expressed on a subset of tumor vessels. High grade 
astrocytomas are characterized by the presence of necrotic areas, areas of active 
angiogenesis, but also areas of infiltration.
82
 It is therefore possible that the Glut-1 positive 
vessels that we detected were indeed incorporated pre-existent vessels. However, since 
the blood-brain barrier is induced by contacts between astrocytes and brain capillaries, we 
can not exclude the possibility that these vessels are actually newly formed, and that the 
astrocytic tumor cells induced expression of  Glut-1.
156
 
In the melanoma- and adenocarcinoma metastases, VEGF-A expression was induced by 
hypoxia, as revealed by the colocalization of VEGF-A mRNA and the hypoxia-marker Glut-
1. In these tumors the vasculature was less tortuous and more organized. This was 
especially evident in the melanoma metastases which presented with a low density of  
highly dilated vessels with no signs of sprouting angiogenesis. Interestingly, these vessels 
sometimes had a mosaic phenotype for Glut-1, a phenomenon that we previously 
described in brain lesions of transgenic melanoma cells expressing VEGF-A121. We propose 
that these vessels are modulated, pre-existent vessels in which endothelial proliferation 
results in Glut-1-positive mother cells and Glut-1-negative daughter cells.  
How can the differences between vascular phenotypes between the groups of tumors be 
explained when similar levels of similar VEGF-A isoforms are expressed by tumor cells? 
From the results of this study we hypothesize that the mechanism underlying VEGF-A 
expression, i.e. hypoxia-induced or constitutive, is responsible for the vascular phenotype 
in brain tumors. When VEGF-A expression occurs in tumor cells that have become hypoxic 
because during growth the distance to the most nearby vessels has become too large, a 
situation develops where multiple isoforms are expressed but only the freely diffusible 
VEGF-A121 may be able to make contact to distant endothelial cells and activate these. The 
larger isoforms are tethered by the extracellular matrix and are thus physically unable to 
activate the endothelial cells in distant vessels (figure 6A). Our previous results on VEGF-
A121 -expressing Mel57 brain lesions cells would then predict that vessel activation and 
dilatation, rather than neovascularization, occurs. This is indeed what we observe in 
tumors with hypoxia-induced VEGF-A expression (melanoma and adenocarcinoma 
metastases), where a relatively low density of highly dilated blood vessels is present.  
This situation is fundamentally different from that in which tumor cells constitutively 
express multiple VEGF-A isoforms. Upon extravasation, tumor cells in the early stages of 
outgrowth will be in direct contact with blood vessels, and therefore all isoforms will be 
capable of inducing vascular effects. Because we know from our animal work that VEGF-
A165 and VEGF-A189 induce a neovascular bed, it is anticipated that in such cases highly 
angiogenic phenotypes are observed. The continuous angiogenesis during tumor growth 
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explains the absence of hypoxia and necrosis in these tumors. This concept is illustrated in 
figure 6B. 
 
 
 
 
 
 
It is commonly accepted that ECM-bound VEGF-A165 and VEGF-A189 act as a biological 
reservoir of growth factors which can be quickly released on demand by proteolytic 
digestion with metalloproteinases or plasmin.
157,158
 Digestion results in the release of  
aminoterminal fragments of 113 and 110 amino acids, which contain all receptor binding 
domains. A recent paper by Lee et al.
159
 described that the aminoterminal VEGF-A 
fragments induced receptor activation and endothelial proliferation, giving rise to 
endothelial sheets in 3D in vitro cell cultures, whereas VEGF-A165 induced endothelial 
proliferation and migration, resulting in tubular structures. These activities could be 
translated to vessel dilatation and sprouting angiogenesis, respectively, in the in vivo 
Figure 6. Proposed model of development of vascular phenotypes in tumors which express VEGF-A in 
response to hypoxia (A) or constitutively (B). In the former situation, only the small molecular weight 
isoforms (VEGF-A121 or proteolytic cleavage products of the larger isoforms) can exert their effects on the 
vasculature, whereas in tumors that constitutively express VEGF-A, all isoforms can exert their effects on 
blood vessels, resulting in classical angiogenesis. Hypoxic cells are indicated as dark grey. 
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situation, very similar to what we previously described in our mouse model of VEGF-A 
transgenic brain metastasis. In fact, we have also been able to show that a truncated 
VEGF-A110 protein induced a tumor vascular phenotype similar to VEGF-A121 (manuscript in 
preparation). Thus, soluble VEGF-A isoforms, whether in the form of VEGF-A121 or 
proteolytic digests of larger isoforms that are tethered in the tumor center, act as 
vasodilators and have little potency to induce sprouting angiogenesis. 
In the adenocarcinomas we found moderate expression of VEGF-A145, an isoform which is 
also tethered in the extracellular matrix.
56
 Whether VEGF-A145 is also a substrate for 
plasmin or MMPs has not been investigated. At this moment there is no reason to assume 
that VEGF-A145 would behave differently from the other large VEGF-A- isoforms. 
The underlying reasons for the differential angiogenic potencies of VEGF-A121 and VEGF-
A165 are poorly understood. NP-1 binding by VEGF-A165 may be a  factor. However, NP-
involvement is contradicted by the fact that a novel VEGF-A splice variant, VEGF-A165b lacks 
significant angiogenic activity despite the presence of an intact exon 7 and all receptor 
binding domains.
160
  Another explanation may be the higher affinity of VEGF-A165 for 
matrix components, resulting in higher local concentrations and consequently increased 
potency. It has been proposed that matrix-bound VEGF-A promotes endothelial cell 
adhesion and migration through an integrin-dependent (α3β1 and αvβ3) pathway.
161
 
Obviously, this would require a direct association of matrix-bound VEGF-A and blood 
vessels, a situation that is not expected to occur in tumors in which VEGF-A expression is 
induced by hypoxia, distant from vessels. 
Central hypoxia in tumors has generally been considered as the major factor leading to 
VEGF-A expression. Surprisingly, we found here that in tumors where VEGF-A expression is 
the result of central hypoxia, a vascular phenotype develops which does not conform to 
the hallmarks of angiogenesis. Instead, prototype tumor vascular beds with tortuous, 
dilated and highly branched vessels were only observed in tumors where VEGF-A 
expression was constitutive. The specific genetic defects in our panel of tumors which 
resulted in VEGF-A expression was not subject of this investigation. It is however well 
known that over 80% of renal cell carcinomas are relelated to mutations in the Von Hippel 
Lindau (VHL) protein, resulting in attenuated breakdown and accumulation of the VEGF-A 
transcription factor HIF-1α.
142
 In GBMs,  PTEN mutations or EGFR amplifications are 
frequently found that result in high VEGF-A expression levels.
143
 
It must be noted here that there may be distinct differences in hypoxia-sensitivity of 
tumor cells. Sensitive cells will start expressing VEGF-A at relatively higher pO2  (i.e. at 
shorter distances from the most nearby vessels) and may therefore deliver more VEGF-
A165 to where the action is needed, generating a more angiogenic phenotype. Whether the 
melanoma and adenocarcinoma metastases in our study are exceptionally hypoxia-
insensitive is however unlikely: hypoxia-induced Glut-1 expression was always detected at  
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approximately 100 µm from the tumor vessels, the diffusion distance of oxygen through 
tissues.
162
   
 
Our findings may have therapeutic consequences. Both vasomodulation in the tumors 
with hypoxia-induced VEGF-A and neo-angiogenesis in the constitivtively-expressing 
tumors are dependent on the interaction between VEGF-A with VEGF receptors. Anti-
angiogenic therapies, directed at interference with VEGF and its receptors would 
therefore likely inhibit both processes. However, specific interference with the interaction 
between VEGF-A165 and neuropilin, for example by exon 7-derived peptides,
163
 would 
probably prevent neo-angiogenesis by inhibiting endothelial migration, but not the small-
isoforms-induced vasomodulation. These issues have to be taken into account when 
developing future therapies. 
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Abstract 
 
We previously reported that during mouse embryogenesis, plexin D1 (plxnD1) is expressed 
on neuronal and endothelial cells. Endothelial cells gradually loose plxnD1 expression 
during development. Here we describe, using in situ hybridization, that endothelial plxnD1 
expression is regained during tumor angiogenesis in a mouse model of brain metastasis. 
Importantly, we found PLXND1 expression also in a number of human brain tumors, both 
of primary and metastatic origin. Apart from the tumor vasculature, abundant expression 
was also found on tumor cells. Via panning of a phage display library, we isolated two 
phages that carry single domain antibodies with specific affinity towards a PLXND1-specific 
peptide. Immunohistochemistry with these single domain antibodies on the same tumors 
that were used for in situ hybridization, confirmed PLXND1 expression on the protein 
level. Furthermore, both these phages and the derived antibodies specifically homed to 
vessels in brain lesions of angiogenic melanoma in mice after intravenous injection. 
These results show that PLXND1 is a clinically relevant marker of tumor vasculature that 
can be targeted via intravenous injections. 
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Introduction 
 
It is commonly accepted that, to grow beyond a size of 2-3 mm
3
, tumors have to recruit a 
neovasculature via angiogenesis.
42,132
 Tumors accomplish this via expression of Vascular 
Endothelial Growth Factor-A (VEGF-A), either induced by hypoxia in the tumor centre
57
 or 
as a result of malfunctioning tumor suppressor gene products or activated proto-
oncogenes.
143,164
 A number of compounds that target the VEGF-A signaling pathway has 
been developed with the aim to inhibit angiogenesis and, consequently, tumor growth.
165
 
Although such anti-angiogenic therapies have been effective in animal tumor models
63,116
, 
translation to the clinical level has so far proven to be less successful.
166
 
For this, there is a number of possible explanations. In clinically relevant situations, tumors 
may have been growing for months or even years at the time of diagnosis, and a 
significant proportion of the vasculature may be more or less mature and thus insensitive 
to angiogenesis inhibition. This situation is in sharp contrast to that in most animal models 
in which, as a rule, aggressive, fast-growing tumors are studied. Furthermore, patients 
that are candidates for anti-angiogenic therapy are typically patients with disseminated, 
uncontrollable cancer. We and others described that growth of metastases may not 
always be strictly dependent on angiogenesis.
75,167,168
 Because most metastases are blood-
borne, they grow out in organs with intrinsically high vessel densities like liver, lung and 
brain where they can grow in an angiogenesis-independent fashion by co-option of pre-
existent vessels.
75,76,78
 We have recently reported that an angiogenesis inhibitor that very 
effectively inhibits tumor growth in a number of subcutaneous tumor models,
63
 does not 
inhibit growth of infiltrative tumors in mouse brain. Moreover, upon treatment of mice 
carrying highly angiogenic brain tumors, angiogenesis inhibition resulted again not in 
tumor inhibition, but rather in a phenotypic shift towards co-option and infiltration.
117
 
These results imply that anti-angiogenic therapy should, ideally, be supplemented by 
vascular targeting therapies in which the existing tumor vascular bed is attacked, resulting 
in secondary tumor cell death due to disruption of the tumor’s blood supply.
166
 To 
accomplish effective vascular targeting therapy, markers have to be identified that have 
specificity for tumor vasculature. Much effort has already been put in this, but with 
varying success. Effective vascular tumor targeting has been accomplished using single 
chain antibodies, directed against the fibronectin ED-B domain, which is selectively 
expressed and deposited in the extracellular matrix of newly formed vessels in angiogenic 
tumors.
124,125
 Targeting of ανβ3-integrin (the expression of which is restricted to immature 
vessels) using Vitaxin yielded disappointing results,
169
 whereas endoglin-expression was 
not specific for tumor blood vessels.
130
 
Plexins comprise a family of membrane proteins that are receptors for the semaphorins, a 
family of secreted and membrane-bound Ligands.
170
 Class 3 semaphorins are potent axon 
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repellants and are as such involved in morphogenesis of the nervous system (for review, 
see
171,172
). These semaphorins activate plexins via binding of neuropilins in a 
multicomponent complex.
173
 
We previously identified and characterized plexin D1 (plxnD1) as a plexin which is not only 
expressed in neuronal cells, but also in the vasculature during early stages of 
development.
174
 In adult vasculature, plxnD1 is absent. Recently, proof for a functional 
role of plxnD1 during vascular and cardiovascular morphogenesis was provided using 
zebrafish mutants and knock-out mice.
175,176
 PlxnD1 is a receptor for  Semaphorin 3E, and, 
unlike other members of the plexin family, does not require neuropilins for Semaphorin 
3E-mediated signaling.
177
 
The high expression levels of plxnD1 in angiogenic vessels during embryogenesis, led us to 
investigate whether this protein is also expressed during tumor-associated angiogenesis. 
We found that plxnD1 was indeed expressed at high levels in tumor vessels of 
intracerebral Mel57-VEGF-A tumors,
77
 but not in unaffected brain vessels. Importantly, 
human tumors of different origin also expressed the protein in their vessels indicating that 
PLXND1 expression is not restricted to early stages of angiogenesis. Interestingly, tumor 
cells also frequently express PLXND1, making this protein a unique candidate for tumor 
targeting therapies as it is expected to target both vessels and tumor cells. Intravenous 
injection of M13 phages displaying anti-PLXND1 single domain antibodies (sdabs) or the 
respective soluble sdabs, led to accumulation on tumor vessels but not on normal brain 
vessels. Thus, PLXND1 may be a promising target for anti-vascular and anti-tumor 
therapies.  
 
 
Materials and Methods 
 
Phage display 
A phage display library was constructed by RT-PCR from Llama B-lymphocytes essentially 
as described.
178,179
 VHH-single domain antibody (sdab) fragments were ligated into 
phagemid vector pHENIXHis8VSV (Raats, unpublished results), resulting in a fusion 
product with a 8*His-tag and a VSV-G-tag at the C-terminus.
180
 After electroporation in E. 
coli TG1 cells, ampicillin-resistant colonies were collected and pooled. The library had a 
complexity of 8x10
8 
clones. Eighty percent of plasmids contained full-length sdab insert as 
determined by PCR analysis and immunological dot-blot-detection of the VSV-G-tag in 
sdabs (see below). The phage library was propagated as phagemids in E. coli TG1 bacteria. 
Phage particles were rescued by infection with trypsin sensitive helper phage M13K07.
181
 
Phages were purified and concentrated from the culture supernatant by precipitation with 
20% PEG-2.5 M NaCl as described.
182
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Selection of PLXND1-binding phage-sdab 
Immunotubes (Nunc, Roskilde, Denmark) were coated overnight at 4
o
C with 5 μg/mL KLH-
conjugated peptide (H2N-ALEIQRRFPSPTPTNC-CONH2, corresponding to amino acids 1-16 
of the mature human PLXND1 protein, accession no. AY116661) in 50 mM NaHCO3 (pH 
9.6). Of note, the glutamic acid on position 3 in this peptide is a lysine in the mouse 
sequence, the remaining amino acids are homologous to mouse plxnd1. After washing 
with PBS/0.05% Tween 20 (PBST), non-specific binding sites were blocked with 5% marvel 
in PBST (MPBST, 1 hr at room temperature (RT)) and 10
13
 phage particles from the library 
stock were incubated with the immobilized peptide for 90 min at RT. After rigorous 
washing with PBST and PBS, bound phages were eluted by trypsin treatment (10 mg/ml, 
30 min RT). After trypsin inactivation with 1% newborn calf serum, the eluate was used to 
infect log-phase TG1 cells to amplify PLXND1-binding phages and calculate number of 
binders.  
To enrich for binding phages, four rounds of selection were performed. From the second 
round on, selections were performed against unconjugated peptides, immobilized on 
DNA-binding plates (Costar) to prevent selection of KLH-binders. 
 
Analysis of phage specificity by ELISA 
Individual PLXND1-binding phages with PCR-confirmed full-length sdab inserts were tested 
for specificity. Wells of DNA-binding plates or immunoplates (Nunc) were coated 
overnight at 4
o
C with PLXND1-peptide or an irrelevant peptide (1 μg/well in PBS/0.5 M 
NaCl pH 9.0), BSA (1 μg/well in 50 mM NaHCO3 pH 9.6) or human IgG (1 μg/well in 50 mM 
NaHCO3 pH 9.6). After blocking non-specific binding sites with MPBST, wells were 
incubated with phages in MPBST for 1 hr at RT and non-bound phages removed by 
rigorous washing. Bound phages were detected using HRP-conjugated anti-M13 
(Amersham Pharmacia Biotech, Piscataway, NJ, USA) and tetramethylbenzidine (TMB; 
BioMérieux B.V., Netherlands). The reaction was terminated with 2M H2SO4 and 
enzymatic activity quantified by measuring absorbance at 450 nm using an ELISA reader.  
 
Soluble sdab expression of Plexin D1 specific clones   
Expression of soluble sdabs was induced in log-phase TG1 cells by culturing at 30
o
C in 
2xTYA medium/1 mM IPTG. Sdabs were collected by osmotic lysis using ice-cold TES buffer 
(200mM TrisHCl, 0.5 mM EDTA, 500 mM sucrose) containing a protease inhibitor cocktail 
(Roche, Basel, Switzerland). Sdab concentrations were estimated via dot-blot analysis 
using the mouse monoclonal anti-VSV-G P5D4, alkaline phosphatase-conjugated rabbit 
anti-mouse immunoglobulin (Dako, Denmark) and NBT/BCIP staining. Sdabs were tested in 
ELISA for PLXND1-peptide specificity. 
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BIAcore analysis 
A BIAcore 2000 (Uppsala, Sweden) biosensor was used to determine binding affinities of 
the sdabs. The sensor chip and protein coupling chemicals were purchased from Biacore 
AB. PLXND1-peptide-KLH conjugate (27 µg/ml in Na-Acetate, pH 4.0) or BSA (1 µg/ml in 
Na-Acetate, pH 5.0) was coupled to activated CM5 surfaces using N-ethyl-N'- 
(dimethylaminopropyl) carbodiimide, N-hydroxysuccinimide, under conditions 
recommended by the manufacturer. Unreacted groups were inactivated by 1 M 
ethanolamine, pH 8.5. Kinetic measurements were performed at 25
o
C with a flow rate of 
10 l/min in HBS-EP buffer (10 mM Hepes, pH 7.4, 150 mM NaCl, 3 mM EDTA, 0.005% 
surfactant P20). Six concentrations of Ni-affinity-purified sdabs (in the range of 1 mM to 
50µM) were used to determine the dissociation constants (Kd values) of the interaction 
with the PLXND1-peptide. After each experiment, regeneration of the sensor surface was 
performed with 10 mM NaOH. Specific binding, defined by binding to a PLXND1-surface 
minus binding to a control BSA-surface, was analyzed using the BIAevaluation 4.1 software 
and a 1:1 Langmuir binding model. 
 
In situ hybridization (ISH)  
Generation of dig-labelled sense and antisense mouse plxnD1 RNA probes was described 
before.
174
 A 600 bases human sense and antisense PLXND1 RNA probe, located in the 3’-
untranslated region, was generated by transcription from a PCR product which was 
flanked by T7 and T3 promoters. Hybridizations were performed using standard protocols. 
 
Immunohistochemistry 
Four μm sections of archival, paraffin-embedded or frozen brain tumor tissue of different 
origin (glioblastoma multiforme and brain metastases of melanoma and sarcoma) were 
immunostained with anti-PLXND1 sdabs. Also cerebral mouse xenografts of the human 
melanoma cell line Mel57-VEGF-A
77
 were stained with these sdabs. Following 
deparaffinization, endogenous peroxidase activity was blocked by incubation with 3% 
H2O2. Antigen retrieval was performed by treatment with pronase according to standard 
protocols. Subsequently, slides were pre-incubated with  normal horse or goat serum (to 
block non-specific binding sites in sections of human and mouse tissues, respectively), 
followed by incubation with sdabs for 1 hr. Sdabs were detected by sequential 1 hr 
incubations with a mouse or rabbit anti-VSV-G antiserum (Sigma-Aldrich Chemie B.V., 
Zwijndrecht, The Netherlands), biotinylated anti-mouse or anti-rabbit antibody as 
appropriate (Vector, Burlingame, CA), and avidin-biotin peroxidase complex  (Vector, 
Burlingame, CA). Finally, peroxidase was visualized by the 3-amino-9-ethylcarbazole 
(ScyTek, Utah, USA) peroxidase reaction with haematoxylin as counterstain. All steps were 
performed at RT. The blood vessel origin of PLXND1 expression was confirmed by 
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performing stainings on serial sections with sdabs and anti-human or anti-mouse (as 
appropriate) anti-CD31 antibody (DAKO, Glostrup, Denmark (anti-human CD31), Hycult 
Uden, The Netherlands (anti-mouse CD34)). 
 
Animal experiments  
All experiments were approved by the Animal Experiment Committee of  
the Nijmegen University. The hematogenous brain metastasis protocol has been described 
previously.
183
 In short, 2x10
5 
stably transfected Mel57 cells expressing the VEGF-A165 
isoform were microsurgically injected into the right internal carotid artery of BALB/C nude 
mice. After 18 days, when  animals showed neurological symptoms, CE-MRI was routinely 
performed to confirm presence of tumor.
77
 Mice were used 1 day later for intravenous 
injections of phages or single domain antibodies. 
 
In vivo homing of plxnd1-binding phages and corresponding sdabs  
10
12 
PLXND1-binding phages of clones A12, F8 or
 
non-relevant phages were injected in the 
tail vein of nude mice, carrying established Mel57-VEGF-A165  brain metastases (n=2 for 
A12, n=4 for F8, n=3 for control phage). In two other groups of mice, we intravenously 
injected 30 µg sdab F8 or a control sdab (n=2  for each group). After 5 minutes, mice were 
anesthesized using isoflurane, the chests were opened, and non-bound phages were 
washed from the system by cardiac perfusion with 15 ml of phosphate buffered saline 
(PBS). Then, mice were sacrificed by cervical dislocation, and parts of brains, hearts, lungs, 
livers, spleens and kidneys were snap frozen in liquid nitrogen. Other parts were fixed in 
formalin to be paraffin-embedded. After short hematoxylin staining, tumors were 
dissected from 10 μm brain sections using laser capture dissection microscopy. Equivalent 
areas were dissected from unaffected brain, contralateral to the tumor. Subsequently, 
TG1 cells were infected with phages, eluted by trypsin treatment from dissected samples. 
Numbers of colony-forming phages were counted and used as a measure of tumor 
homing. To qualitatively assess tumor homing by phages or sdabs, 4 µm sections were 
stained with anti-M13 p8 antibody (Abcam Limited, Cambridge, UK) to detect bound 
phages, or anti-VSV-G antibodies (Sigma-Aldrich) to detect single domain antibodies.  
 
 
Results  
 
PLXND1 RNA expression in animal and human tumors  
To explore whether endothelial plxnD1 expression is a common feature of activated 
endothelial cells or is restricted to developing vasculature during embryogenesis as we 
described previously,
174
 we subjected brains of mice, carrying highly angiogenic Mel57-
Ch a p t e r  3   
 
54 Tumor specific expression of Plexin D1 
 
VEGF-A lesions, to ISH analysis using a mouse plxnD1-specific probe. Vessels in these 
lesions, but not in unaffected brain tissue, expressed high levels of the transcript (Figure 
1A, inset shows a CD34 staining). To explore the clinical relevance of this finding, we 
subjected a number of different human brain tumors and normal brain to ISH using a 
human-specific PLXND1 probe. Vessels in brain metastasis of sarcoma (Figure 1B) and 
melanoma (Figure 1C), as well as a number of other tumor types (not shown), expressed 
high levels of PXLND1 RNA.  
 
 
 
 
Figure 1. A) ISH analysis of a cerebral Mel57-VEGF lesion using a mouse-specific plxnd1 RNA probe.  
Note the strong positivity of tumor vessels (arrows) whereas brain capillaries, distant from the lesions, are 
negative (compare the ISH profile with the CD34 staining in the inset). B-D) Human PLXND1-specific ISH 
analyses of a brain metastasis of sarcoma (B), melanoma (C) and normal brain (D). Insets show  
CD31 stainings of serial sections. Control ISH using sense probes were negative (not shown). Note in B and C 
that PLXND1 expression is not confined to the blood vessels: also in tumor cells high levels of the PLXND1 
transcript are found. t=tumor, V=vessel 
In normal human brain, no vessel-associated expression of PLXND1 was detected (Figure 1D). ISH revealed 
that tumor cells themselves also were often strongly positive for PLXND1 (compare ISH profiles with the 
CD31 stainings in the insets in Figure 1B and 1C). Also primary brain tumors were found to be positive for 
PLXND1 both on blood vessels and tumor cells (not shown).  
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Isolation of anti-PLXND1-sdabs 
To confirm expression of PLXND1 on the protein level, we first selected PLXND1-binding 
VHH-single domain antibodies (sdabs) from a pHENIXHis8VSV-vector-based Llama phage 
display library. During the four consecutive rounds of selection, a gradual enrichment of 
phages with PLXND1 affinity (up to 1,400-fold) was observed, indicating that specific 
binders were present (not shown). Ultimately, 100 individual phages were analyzed for 
binding to unconjugated PLXND1-peptide in an ELISA-based assay. Seven independent 
clones, as revealed by BstN1 fingerprinting (not shown), showed specific affinity for the 
PLXND1-peptide. Phages A12 and F8 were chosen for further analysis because the derived 
sdabs recognized PLXND1 in immunohistochemical stainings better than the other sdabs 
(see below). Sequence analysis revealed that A12 and F8 were independent clones, with 
homology in the CDR1 to CDR3 domains of approximately 40%. These phages, but not an 
irrelevant sdab-phage or M13 helper phage, bound specifically to PLXND1-peptide but not 
BSA, IgG or an irrelevant peptide (Figure 2A). Furthermore, soluble sdabs derived from 
these phages also bound specifically to the PLXND1-peptide (figure 2B).  
 
 
 
 
 
  
Figure 2. Specificity of phages (A) and corresponding sdabs (B) A12 and F8 for peptide H2N-
ALEIQRRFPSPTPTNC-CONH2. In A, 10
10 phages were allowed to bind to PLXND1-peptide, BSA, human IgG or 
irrelevant peptide as described in the text. After rigorous washing, bound phages were detected using an 
anti-M13 antibody. In B, similar incubations were performed but now with soluble sdabs. After washing, 
bound sdabs were detected and semi-quantified via the VSV-G-tag.  
The binding kinetics of the sdabs/PLXND1-peptide interactions were determined by BIAcore analysis. 
Analysis of the binding data with the 1:1 Langmuir binding model showed a good fit for the sdab binding to 
the PLXND1-peptide consistent with a 1:1 binding interaction (data not shown). The Kd values of the sdabs 
were found to be 2.4 x 10-8 M  and 3.9 x 10-8 M for sdabs A12 and F8, respectively.  
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Immunohistochemical analysis  
To confirm that sdabs A12 and F8 specifically recognize PLXND1 not only in vitro as a 
peptide, but also in immunohistochemical stainings, we first stained mouse embryos of 
different developmental stages, in which  plxnd1 expression was previously analyzed by 
ISH.
174
 ISH and immunohistochemistry grossly correlated to each other. Especially in the 
growth plate of trabecular bone, a site of active angiogenesis, blood vessels stained 
strongly positive both in ISH and immunohistochemistry using plxnD1-recognizing sdabs 
(Figure 3A, the inset  shows corresponding plxnd1- ISH). 
We went on to use sdabs A12 and F8 for immunohistochemistry on different mouse and 
human tumors. Indeed, immunostainings with sdabs A12 and F8 confirmed the ISHs 
shown in Figure 1. Vessels and, to a lesser extent, tumor cells in cerebral angiogenic Mel57 
tumors stained positive (figure 3B and not shown). Also in the human sarcoma and 
melanoma brain metastases (Figures 3C and D), vessels as well as tumor cells stained 
positive with sdab A12. Interestingly, and consistent with the imperfect homology 
between the human peptide used for antibody selection and its mouse equivalent, sdabs 
appeared more efficient in detecting human than mouse plxnD1 (compare Figures 3B with 
C and D). Furthermore, sdab F8 was more efficient than A12 in detecting mouse plxnd1. 
The positivity of the tumor cells in Mel57-VEGF-A tumors prompted us to investigate 
expression of PLXND1 in cultured Mel57-VEGF-A cells. Both by RT-PCR using PLXND1 
specific primers and immunostainings with sdab A12, we found that tumor cells expressed 
the protein in vitro also (not shown).  
The presence of PLXND1 on tumor- but not normal vessels suggests that this protein may 
be a suitable target for in vivo delivery of diagnostic and therapeutic compounds to 
tumors. To test this, we injected mice, carrying established Mel57-VEGF-A brain tumors, 
with 10
12
 colony forming units of phage A12, F8 or a non-relevant phage in the tail vein, 
and washed non-bound phages from the circulation by cardiac perfusion. After removal 
and snap-freezing of part of the brains, areas containing tumor or unaffected brain tissue 
from the contralateral hemisphere were dissected using a laser-capture dissection 
microscope and analyzed for phage content.  
As illustrated in Figure 4D, after intravenous injection of phage F8, significantly more 
phages were eluted from brain lesions than from comparable areas of normal brain tissue. 
Consistent with the apparently higher affinity of sdab F8 towards mouse plxnD1, more F8 
than A12 phages were eluted from tumor. Immunostaining of frozen sections of the same 
brains with anti-M13 antibodies confirmed the presence of blood vessel-bound phages in 
tumor but not in normal brain (compare the anti-M13 staining in Figure 4A with the anti-
CD31 staining of a serial section in Figure 4B, arrows point at a plxnd1-negative, normal 
vessel). Upon intravenous injection of an irrelevant phage, no vessel-associated phages 
could be detected (inset in Figure 4A).  
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Tumor targeting by phages is clinically less relevant. Therefore we continued by testing 
whether purified sdabs are also able to target tumor vasculature in vivo. After intravenous 
injection of sdab F8, this antibody could be detected on tumor vessels by anti-VSV-G 
immunostaining (Figure 4C). Importantly, no non-specific homing to normal brain vessels 
could be observed (not shown). Upon intravenous injection of an irrelevant sdab, no 
vessel-associated sdabs could be detected. However, we observed some staining in the 
interstitium of Mel57-VEGF-A tumors (inset in Figure 4C). This is to be expected because 
the leaky tumor vessels are permeable to the small-sized sdabs.  
Figure 3. Immunohistochemistry using sdab A12 and F8. A) Growth plate of a trabecular bone in a mouse 
embryo (E16.5), stained with sdab A12. Note the immunoreactivity in the blood vessels which is consistent 
with ISH for plxnd1 (inset). B) Immunostaining with sdab F8 of a Mel57-VEGF-A165 lesion in mouse brain. A 
similar expression profile is seen as in the ISH depicted in figure 1A. Vessels stain positive (arrows) while 
tumor cells are moderately positive. C) and D) show immunostainings with sdab A12 of the sarcoma (C) and 
melanoma (D) brain metastases, of which PLXND1 ISHs are shown in Figure 1. The insets in C and D show 
control stainings with anti-VSV antibody only. V=vessel.  
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Previous work already revealed that small amounts of the plxnD1 transcript can be 
detected in adult normal tissues, especially heart, lung and liver. To investigate targeting 
of these organs by sdab F8, we performed anti-VSV-G immunostainings of frozen sections. 
No sdabs could be found associated with normal heart, kidney, liver, spleen and lung (not 
shown).  
 
 
 
 
Figure 4. In vivo targeting: homing of phage A12, F8 or an irrelevant phage to Mel57-VEGF165 brain lesions. 
Tumor-bearing mice were injected with 1012 phages in the tail vein as described in the text. Mice were 
sacrificed, brains removed and frozen sections were analyzed for phage content and distribution. A) M13 
staining of a frozen section of brain Mel57-VEGF165  lesions. Phages are clearly vessel-associated, as 
evidenced by the anti-CD31 immunostaining on a serial section, shown in B). The arrows point at a CD34-
positive vessel, distant from the lesion, which is not highlighted by anti-M13 staining. The inset in (A) shows 
a control experiment where an irrelevant phage was injected. C) Distribution of sdab F8 after intravenous 
injection in tumor bearing mice. Sdabs are visualized by immunohistochemistry using an anti-VSV antibody. 
Note that the sdab is detected in tumor vessels but not in normal brain capillaries. The inset shows the 
control experiment where an irrelevant sdab was injected. An interstitial localization was observed, 
consistent with the leaky nature of the vessels in these tumors. D) Quantification of phage homing. Tumor 
tissue was dissected from 10 µm frozen sections using laser capture dissection microscopy. Number of 
colony-forming phages (cfp) were counted after infection of TG1 cells. Twenty-fold more F8 phages were 
eluted from tumors than from comparable areas of unaffected brain tissue.  
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Discussion  
 
In previous work we described plxnd1 expression in a subset of neuronal cell types and in 
endothelial cells during developmental angiogenesis.
174
 Very recently, plxnD1 knock-down 
in mice and zebrafish has been described to result in maldevelopment of the 
vasculature.
175,176
 These data suggest a role for plxnD1 in vascular patterning, analogous to 
that of other plexin family members in axonal patterning (for review, see
172,184
). Here we 
demonstrate that endothelial expression of  plxnD1 is not restricted to vasculature during 
development but also occurs in the vascular bed of tumors. Intriguingly, we found that 
PLXND1 is also frequently expressed at high levels in tumor cells in a variety of tumor 
types. This expression profile makes PLXND1 a potentially powerful target for diagnostic 
and therapeutic purposes in oncology. To our knowledge, this is the first example of a 
protein that is specifically expressed on both tumor vessels and tumor cells, allowing 
simultaneous targeting of different tumor compartments. Indeed, we could show that 
phages carrying single domain antibodies against PLXND1 on their surface effectively and 
specifically homed to cerebral melanoma metastases in mice after i.v. injection. These 
phages were all vessel-associated. When single domain antibodies were injected we found 
accumulation in the tumor vasculature, and to a lesser extent also in the tumor 
interstitium. This interstitial localization could be partly attributed to non-specific 
extravasation of the small-sized sdabs from leaky tumor vessels, since irrelevant control 
sdabs showed a similar localization. Importantly, the tumor vessel-association of  anti-
PLXND1 sdabs was specific, since control sdabs did not accumulate in vasculature. Anti-
PLXND1 antibodies may be suitable vehicles to deliver cytotoxic agents to tumors, 
especially since leaky tumor vessels will allow extravasation of targeting antibodies, 
thereby enabling a second wave of action against the PLXND1-expressing tumor cells 
themselves. In order to be efficient tumor vessel-targeting vehicles, affinity of anti-
PLXND1 antibodies should be as high as possible, whereas targeting of the tumor cell 
compartment may be more efficient with smaller, lower affinity antibodies with predicted 
high tumor penetrance.
185
 Whether the Kd values of our sdabs of 20-30 nM allow 
therapeutic targeting of either tumor compartment is not known at the moment. It is 
however expected that mouse monoclonal targeting antibodies will be more succesful for 
these purposes. These are currently under development.  
The rather disappointing results with anti-angiogenic compounds in clinical trials, which 
may be related to angiogenesis-independent tumor growth in vessel-dense organs,
117
 
suggest that vascular targeting therapies may  be more effective than anti-angiogenic 
therapies. This stresses the importance of identifying molecular beacons that are 
specifically expressed in a wide range of tumors. Few of such molecules have been 
identified so far. An alternatively spliced fibronectin molecule is deposited in the 
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basement membrane of newly formed vessels, and single chain antibodies against this 
protein have been succesfully used to detect clinical tumors in whole body scintigraphs.
124
 
RGD-motif containing peptides have been used to target integrin αvβ3,
127,186
 resulting in 
endothelial apoptosis and anti-tumor activity in animal models,  but expression of this 
integrin is restricted to early stages of angiogenesis. Since mature tumor vessels may 
therefore be less sensitive to such targeting, it may be more relevant to identify target 
markers that fulfil the prerequisite of being expressed in mature human tumors. PLXND1 
appears to be such a marker. In a number of brain tumors, both primary tumors and 
metastases, the protein is abundantly expressed. In fact, we have not yet been able to 
identify a PLXND1-negative tumor. Nevertheless, a more extensive analysis of PLXND1-
expression and distribution in a variety of human tumor types will be needed to make 
more rigorous statements about the usefulness of PLXND1 as a tumor marker in the clinic. 
A functional role of PLXND1 in developmental angiogenesis is now well established.
175,176
 
Whether PLXND1 is functionally involved in vessel morphogenesis during tumor 
angiogenesis as well, is an intriguing question. If so, targeting of this protein may well lead 
to a functional blockade and consequently an anti-angiogenic effect. This aspect is 
currently under investigation in our lab. Whether PLXND1 on tumor cells is functionally 
important, is also not known. Intriguingly, Gu et al. recently published that Semaphorin 3E 
is a ligand for PLXND1.
177
 Since Semaphorin 3E has been identified in microarray 
experiments as a protein involved in tumor invasion and metastasis,
187
 this opens up the 
interesting possibility that a PLXND1/Semaphorin 3E loop is involved in aggressive tumor 
behaviour. In this context, neutralization of PLXND1 may directly inhibit tumor invasion 
and metastasis. 
PLXND1-expression is not absolutely tumor-specific. We and others have previously shown 
that low levels of the PLXND1 transcript can be found in normal adult heart, liver and 
testis.
174
 Immunohistochemical analysis and in situ hybridization revealed that the cells 
that are responsible for these expression levels are mostly macrophages. Interestingly, 
these cells are characterized by their migratory potential. Taken together, this opens up 
the possibility that PLXND1 has a more general function in cell migration.  
In conclusion, we have demonstrated that plxnD1 is expressed in tumor- but not normal 
vasculature, as well as tumor cells in a wide range of tumor types. The expression 
patterns, and emerging data on PLXND1 function in vascular morphogenesis and possibly 
tumor cell behavior, highlight this protein as a potentially powerful tool for future 
diagnosis and therapy in oncology. 
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Abstract 
 
Plexin D1 (PLXND1) is ubiquitously expressed on tumor vessels and tumor cells in a 
number of human tumor types. If and how PLXND1 expression functionally contributes to 
tumor development is not known. Expression of semaphorin 3E (Sema3E), one of the 
ligands for PLXND1, has previously been described to correlate with invasive behaviour 
and metastasis, suggesting that the PLXND1-Sema3E couple is responsible for tumor 
progression. Here we investigated PLXND1 and Sema3E expression during tumor 
progression in melanoma. PLXND1 was not expressed by melanocytic cells in naevi and 
melanomas in situ, whereas expression increased with invasion level according to Clark. 
Furthermore, 89% of the metastatic melanomas showed membranous PLXND1-staining of 
tumor cells. Surprisingly, expression of Sema3E was inversely correlated with tumor 
progression, with predominantly no detectable staining in melanoma metastasis. To 
functionally assess the effects of Sema3E expression on tumor development, we 
overexpressed Sema3E in a xenograft model of metastatic melanoma. Sema3E expression 
dramatically decreased metastatic potential. These results show that PLXND1 expression 
during tumor development is strongly correlated to invasive behaviour and metastasis, 
but exclude Sema3E as an activating ligand. 
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Introduction 
 
Cutaneous melanoma is a highly malignant tumor derived from pigment-producing 
melanocytes in the epidermis. Melanoma frequently develops in a sequence of steps from 
benign proliferative naevi to atypical naevi, non-invasive in situ melanomas (lesions 
confined to the epidermis), invasive melanomas and finally to metastases. Clinically, 
melanomas begin as pigmented lesions that enlarge along an imaginary radius of an 
imperfect circle, the so-called radial growth phase (RGP).
188
 At the time of diagnosis many 
melanomas have progressed to the next phase of progression or vertical growth phase 
(VGP) that is characterized by invasion of the papillary and reticular dermis.
188
 Whereas 
the relatively indolent RGP melanomas rarely give rise to metastases, VGP melanomas do 
have the tendency to metastasize.
189
 Furthermore, progression from RGP to VGP 
melanoma is accompanied by angiogenesis.
190,191
 Stage of disease is usually determined 
histopathologically by both the maximum vertical tumor thickness (Breslow index) and 
tumor invasion level (Clark classification).
192
  
Many studies focused on the identification of differentiation markers to distinguish naevi 
from melanomas. These include mostly non-specific markers related to cell survival, cell 
adhesion and extracellular matrix changes,
193-196
 general processes that contribute to 
tumor growth and metastasis. 
Plexins encode large transmembrane proteins that are receptors for neuropilins and 
semaphorins, a family of secreted or membrane-associated proteins.
170,197
 Class 3 
semaphorins have been mostly studied in the developing nervous system, where they 
regulate axonal guidance via activation of plexin/neuropilin complexes.
171,173,184,198
 The 
widespread expression of both plexins and semaphorins during embryogenesis, also 
outside the nervous system, suggests a more general role in physiological and pathological 
processes.
199,200
 We previously demonstrated that Plexin D1 (PLXND1) is expressed by 
vascular endothelial cells during developmental angiogenesis.
174
 Loss of PLXND1 function 
in mice and zebrafish leads to lethality, due to maldevelopment of the cardiovascular 
system, indicating a functional role of PLXND1 in vascular patterning.
175,176
 Recently we 
demonstrated that PLXND1 is also specifically expressed on vascular endothelium during 
tumor-associated angiogenesis in both animal tumor models and a number of human 
brain tumors, both of primary and metastatic origin.
201
 Interestingly, in the examined 
metastatic brain tumors, including a melanoma metastasis, we observed abundant specific 
expression of PLXND1 on tumor cells too.
201
 PLXND1 contains in its intracellular domain 
consensus motifs for Rho-guanine nucleotide exchange factors (GEFs). A predicted effect 
of PLXND1 activation is therefore induction of cytoskeletal rearrangements, translating 
into cellular migration and invasion. These processes are fundamental in both 
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angiogenesis and tumor metastasis, suggesting that PLXND1 is functionally involved in 
tumor development in multiple ways. 
Three candidate ligands for PLXND1 have been identified. Semaphorin 3C (Sema3C) binds 
with high affinity to a Neuropilin-1/PLXND1 complex,
176
 whereas binding of semaphorin 3E 
(Sema3E) or semaphorin 4A (Sema4A) to PLXND1 does not require the presence of 
neuropilin.
177,202
 Interestingly, Sema3E was identified from array analyses as a protein 
involved in tumor invasion, progression and metastasis.
187
 Collectively, these data suggest 
an involvement of a PLXND1/Sema3E complex in tumor angiogenesis, tumor cell invasion 
and metastasis.  
Here we have addressed this hypothesis in two independent ways. First, we analyzed 
PLXND1 and Sema3E expression by immunohistochemistry on a series of cutaneous 
melanocytic lesions representing different stages of melanoma progression. Secondly, we 
examined the effects of overexpression of Sema3E in a melanoma metastasis model.  
Our results show that PLXND1 expression correlates with tumor invasion level and 
metastasis in a melanoma progression series. In contrast, Sema3E expression showed a 
negative association with melanoma progression. This inverse correlation was 
corroborated in functional studies, which revealed that Sema3E expression, in contrast to 
Sema3C, resulted in an altered tumor vascular phenotype and significantly reduced 
metastatic potential. 
 
 
Materials and Methods 
 
Tissue samples 
Formalin-fixed, paraffin-embedded tissue specimens were obtained from the archive of 
the Department of Pathology of the Radboud University Nijmegen Medical Centre. This 
study included naevocellular naevi (n=19), dysplastic naevi (n=10), melanomas in situ 
(n=5), primary cutaneous melanomas (n=22) and disseminated melanomas, including skin 
(n=4), lymph node (n=9), brain (n=5) and lung (n=1) metastases. All primary melanomas 
were classified by qualified pathologists and graded according to Clark’s criteria (II, n=7; III, 
n=5; IV, n=10) and Breslow thickness. 
 
Immunohistochemistry  
Tissue sections (4 μm) were dewaxed and endogenous peroxidase activity was quenched 
with 3% H2O2 in PBS. Antigen retrieval was performed by digestion with pronase for 9 
minutes at 37°C. Subsequently, tissues were pre-incubated with normal horse serum to 
block non-specific binding sites, followed by incubation for 1 hr with single domain 
antibody A12, which was previously selected against a PLXND1-specific peptide.
201
 Single 
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domain antibodies were detected by sequential incubations with the mouse monoclonal 
anti-VSV antibody P5D4, biotinylated anti-mouse IgG (Vector, Burlingame, CA), and avidin-
biotin peroxidase complex (Vector) for 1 hr, 30 minutes and 45 minutes respectively. 
Peroxidase was visualized by the 3-amino-9-ethylcarbazole (ScyTek, Logan, UT) peroxidase 
reaction and counterstained with haematoxylin. All incubations were performed at room 
temperature.  
Fifty of the 75 human melanocytic lesions analyzed for PLXND1 expression were 
immunostained for Sema3E according to standard protocols. In short, antigen retrieval 
was performed by boiling in 10 mM citrate buffer. Non-specific binding sites were blocked 
by incubation with normal horse serum. Slides were incubated overnight at 4°C with goat 
anti-Sema3E (Abcam Limited, Cambridge, UK), and subsequently detected by sequential 
incubations with biotinylated anti-goat IgG antibody (Vector) and avidin-biotin peroxidase 
complex (Vector). 
For immunohistochemical analysis of experimental tumors, tissues (tumor, lung) were 
formalin fixed and used for (immuno)histological analysis using rat anti-mouse CD34 
(Hycult Biotechnology, Uden, The Netherlands), rabbit anti-mouse Ki-67 (Dianova, 
Hamburg, Germany), rabbit anti-laminin (Dako, Glostrup, Denmark), rabbit anti-GFP (a 
kind gift of Huib Croes, Department of Cell Biology, Radboud University Nijmegen Medical 
Center, The Netherlands) and mouse anti-thrombospondin (Abcam Limited). 
To determine metastatic deposits in lungs of mice carrying subcutaneous tumors, lungs 
were cut in five to six slices and arranged in tissue blocks in such a way that in one section 
a representative overview through the lungs is obtained. Numbers of metastases were 
counted in H&E stained sections. Differences in metastatic load between tumor groups 
were studied using Mann-Whitney U test. Statistics were performed using SPSS software 
(SPSS Inc, Chicago, Il, USA). 
 
Cell lines and transfections 
Mel57 human melanoma cells were cultured in DMEM (Cambrex Bioscience, Verviers, 
Belgium) supplemented with 10% fetal calf serum (Cambrex), 100 U/ml penicillin and 100 
μg/ml streptomycin (Cambrex) at 37°C at 5% CO2. cDNA encoding VEGF-A165 (human 
origin) was cloned in pIREShyg essentially as described.
76
 Human Sema3E cDNA was 
obtained by RT-PCR on glioblastoma RNA, using primers HpaI-Sema3E (5’-
CGTTAACAGGGCTTGGACGG–3’) and BstX1-Sema3E (5’-CCAGCACACTGGTCAGGAGTCCAGCGT-3’) 
and cloned in the EcoRV/BstXI sites of vector pIRESneo (Clontech, Palo Alto, CA) to 
generate plasmid pIRESneoSema3E. In parallel, Sema3C was PCR cloned in pIRESneo. 
Mel57 melanoma cells, stably transfected with pIREShyg-VEGF-A165 were supertransfected 
with plasmid pIRESneoSema3E or pIRESneoSema3C using Fugene reagent (Roche, Almere, 
The Netherlands). Two days after transfection, cells were put under hygromycin and 
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neomycin selection pressure until colonies could be expanded. Similarly, double 
transfectants of Mel57 were generated expressing VEGF-A165 and EGFP as control. The 
presence of recombinant VEGF-A, Sema3E and Sema3C in conditioned medium was 
confirmed by Western blot analysis using VEGF-A20 antibody (Santa Cruz Biotechnology, 
Santa Cruz, CA), goat anti-Sema3E antibody (Abcam Limited) and sheep anti-Sema3C 
antibody (R&D Systems, Oxon, UK) respectively.  
 
Animals  
All animal experiments were approved by the Animal Experiment Committee of the 
Radboud University. Specific pathogen-free, male BALB/c nude mice, 6–8 weeks of age 
were housed under specific pathogen-free conditions (five mice/cage, temperature 20–
24°C; relative humidity 50–60%; 15 air changes per hour; light–dark periods 14 h/10 h). 
Water and food (RMH, Hope Farms, the Netherlands) were available to the animals ad 
libitum. 
 
Metastasis model 
Groups of mice were injected subcutaneously in the flank with 2x10
6
 Mel57-VEGF-
A/Sema3E cells (n=9), Mel57-VEGF-A/Sema3C cells (n=9) or Mel57-VEGF-A/EFGP cells 
(n=8) in 200 µl PBS, essentially as described.
203
 To be able to analyze mono- or 
multicellular origin of metastases, we tagged the tumors by co-injecting 4x10
5
 Mel57-EGFP 
cells. Tumor growth was monitored twice weekly and volumes calculated as height x 
depth x width. Mice were sacrificed after development of severe cachexia owing to tumor 
load, which was 28 and 37 days post subcutaneous injection of Mel57-VEGF-A/EGFP and 
Mel57-VEGF-A/Sema3(C/E) cells respectively. One out of nine animals carrying a Mel57-
VEGF-A/Sema3E tumor had to be sacrificed two days earlier because of severe ascites and 
tumor deposits on the peritoneum. Before sacrifice, blood plasma was collected for 
determination of circulating VEGF-A levels by an in house developed ELISA.
204
 
 
Expression of extracellular matrix and adhesion molecules  
Total RNA was isolated from 30 frozen 20 µm sections of subcutaneous Mel57-VEGF-A 
(n=5) and Mel57-VEGF-A/Sema3E (n=5) tumors using TRIzol reagent (Invitrogen, Carlsbad, 
CA) according to the manufacturer's protocol and treated with DNaseI (NEB, Ipswich, MA). 
RNA samples (1 μg) were reverse transcribed using MMLV  reverse transcriptase 
(Promega, Leiden, The Netherlands) according to the manufacturer’s  instructions. In each 
individual sample, cDNA quality was assessed by PCR for  β-actin and VEGF-A . Of each 
tumor group, cDNAs were pooled and subjected to the Human Extracellular Matrix and 
Adhesion Molecules RT
2 
Profiler Array™ (Superarray Bioscience Corporation, Frederick, 
MD). Amplification was  performed in a volume of 25 µl containing 1 µl of template cDNA, 
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12.5 µl of RT
2
 Real-Time SYBR Green/ROX PCR master mix, 10.5 µl of H2O, and 1 µl RT
2
 
primer set. Amplification was carried out for 40 cycles (95°C for 15 seconds, 60°C for 1 
minute) on an ABI 7000 Real-Time PCR System (Applied Biosystems). For data analysis the 
2
−ΔΔCt
 method
205
 was used with normalization of raw data to the housekeeping gene 
glyceraldehyde-3-phosphate dehydrogenase (GAPDH). Fold change values are presented 
as difference in expression due to Sema3E-overexpression in Mel57-VEGF xenografts. Cut 
off values for significant up- or downregulation were chosen as 3 and 0.3, respectively.   
 
 
Results 
 
PLXND1 and Sema3E expression in human melanocytic lesions 
 
(Dysplastic) naevi  
We analyzed PLXND1 and Sema3E expression in benign melanocytic lesions, primary 
melanomas of different stage and melanoma metastases to determine if this 
receptor/ligand couple could be involved in tumor progression. 
As shown by immunohistochemistry with single domain antibody A12, PLXND1 expression 
was absent in melanocytes in both naevocellular naevi and dysplastic naevi (Figure 1A and 
B respectively). Furthermore, no vessel-associated PLXND1 expression was observed in 
naevi. In the majority of naevi we observed immunoreactivity on cells which appeared to 
be subsets of macrophages (arrow in figure 1A) as determined by CD68 staining (not 
shown) and fibroblast-like cells (arrowhead in figure 1A). Whereas PLXND1 was not 
expressed by melanocytes, Sema3E was abundantly expressed in melanocytes in 
approximately 80% and 75% of the naevocellular (Fig. 1C) and dysplastic (Fig. 1D) naevi 
respectively. The vasculature in all but one dysplastic naevi also stained positive for 
Sema3E (arrows in figure 1D). 
 
Primary cutaneous melanoma  
Tumor cells in melanomas in situ were negative for PLXND1 (Table 1). However, 73% of 
the primary cutaneous melanomas exhibited membranous PLXND1 expression by tumor 
cells. The PLXND1 expression pattern varied per tissue sample from focal to homogeneous 
throughout the tumor. PLXND1 expression by tumor cells increased during progression 
from Clark II to IV (Table 1), with 43% of Clark II melanomas (Fig. 2A) and 100% of Clark IV 
melanomas (Fig. 2B) showing tumor cell-associated PLXND1 to some extent. Also within 
tumors, the percentage of PLXND1-positive melanoma cells increased with Clark level 
(Table 1). In 40% of Clark IV primary cutaneous melanomas, all tumor cells expressed 
PLXND1 (Fig. 2B). 
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Whereas PLXND1 expression on tumor cells correlated with Clark level, we did not find a 
correlation between tumor cell PLXND1 expression and tumor thickness according to the 
Breslow index. However, vascular expression of PLXND1 did increase with tumor 
thickness. PLXND1-positive tumor vessels were absent in primary cutaneous melanoma 
thinner than 2 mm, while 83% of the lesions (Clark IV melanomas) thicker than 2 mm 
showed PLXND1-positive tumor vessels (Table 2). The arrows in figure 2B point at PLXND1-
positive tumor vessels in a Clark IV melanoma with a Breslow thickness of 3.2 mm. Even in 
a Clark IV melanoma with a Breslow thickness of 0.65 mm, tumor vessels were negative 
(arrow in figure 2C). 
Figure 1. Immunohistochemical analysis of PLXND1 and Sema3E expression in naevi. PLXND1 is not detected 
in melanocytes in naevocellular (A) and dysplastic (B) naevi. Note the PLXND1-positivity of macrophage- 
(arrow in A) and fibroblast-like (arrowhead in A) cells. Melanocytes in naevocellular (C) and dysplastic (D) 
naevi abundantly express Sema3E. Note that vessels in a dysplastic naevus express Sema3E (arrows in D).  
  
 
 
 
C
h
a
p
te
r 4
 
 
P
LX
N
D
1
 an
d
 Sem
a3E d
u
rin
g tu
m
o
r p
ro
gressio
n 
7
1
 
 
 
Table 1. Membranous PLXND1 expression in melanocytic cells in benign naevi, primary cutaneous melanomas, and melanoma metastases 
 
% Positive 
melanocytic cells 
Naevi 
naevocellularis 
Dysplastic 
naevi 
Melanomas  
in situ 
Primary Melanomas Melanoma metastases 
Clark II Clark III Clark IV Skin Lymph node Brain Lung 
0 19 10 5 4 2  1 1   
1-25     2 2     
26-50      2  1   
51-75    1  1     
76-99    2 1 1     
100      4 3 7 5 1 
N+/Nt
* 0/19 0/10 0/5 3/7 3/5 10/10 3/4 8/9 5/5 1/1 
% 0% 0% 0% 43% 60% 100% 75% 89% 100% 100% 
 
* Number of PLXND1 positive lesions (N+) per total number of examined lesions (Nt) 
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Table 2. PLXND1 expression in Clark IV melanomas 
 Breslow thickness 
 < 2 mm ≥ 2 mm 
Melanoma cells 4 6 
Tumor vasculature 0 5 
Figure 2. PLXND1 expression in primary melanomas and a melanoma metastasis as revealed by 
immunostaining with single domain antibody A12. Shown are PLXND1 positive tumor cells in a Clark II 
melanoma (A), Clark IV melanomas (B and C) and a lymph node metastasis (D). Note in B that tumor vessels 
in a melanoma with a Breslow thickness of 3.2 mm express PLXND1 (arrows), while PLXND1 is absent in the 
vasculature of a Clark IV melanoma with a Breslow thickness of 0.65 mm (arrow in C). The insets in B, C and 
D show Sema3E staining in a Clark IV melanoma (B), a Clark II melanoma (C) and a lymph node metastasis 
(D).  
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The increase in PLXND1 expression was not paralleled by Sema3E expression which was 
not significantly different between Clark II, III and IV melanomas (Table 3). The inset in 
Figure 2B shows an example of a PLXND1-positive Clark IV melanoma in which no Sema3E 
expression is detected. Interestingly, blood vessels in Clark II (inset in Fig. 2C) and Clark III 
melanomas stained positive for Sema3E, whereas in Clark IV lesions Sema3E-negative 
vessels were present too. 
 
Melanoma metastases 
Approximately 90% of the melanoma metastases showed PLXND1 immunoreactivity  
(Table 1). A homogeneous expression pattern on all melanoma cells was observed in 75% 
and 78% of the skin and lymph node (Fig. 2D) metastases respectively, while only one 
lymph node metastasis showed focal PLXND1 expression by tumor cells (not shown).  
Consistent with our earlier observations, PLXND1 was abundantly expressed by both 
melanoma cells and tumor vessels in brain and lung metastases. In contrast, both the 
number of melanoma metastases expressing Sema3E and the percentage of Sema3E-
positive melanoma cells in individual lesions were reduced compared to primary 
cutaneous melanomas (Table 3). Only 36% of the melanoma metastases in our series 
exhibited tumor cell expression of Sema3E, which furthermore was restricted to only a 
small number of melanoma cells in 60% of these metastases. In 64% of the melanoma 
metastases, blood vessels were negative for Sema3E whereas in the remaining 36%, 
Sema3E was expressed in less than 25% of the tumor vessels.  
 
 
Sema3E inhibits VEGF-A induced micronodular growth in subcutaneous angiogenic 
melanoma xenografts 
The unexpected inverse correlation between PLXND1 expression and its ligand Sema3E in 
melanoma progression series prompted us to examine whether expression of Sema3E  
functionally affects tumor development and metastatic behaviour of  VEGF-A-expressing 
subcutaneous Mel57 melanoma xenografts.
203
 In these xenografts, tumor cells stain 
positive with our anti-PLXND1 single domain antibody (Fig. 3A). In addition we analyzed 
the effects of expression of Sema3C, the Neuropilin-1 dependent PLXND1 ligand, on tumor 
development and metastasis of these subcutaneous xenografts. Mel57-VEGF-A/Sema3E 
and Mel57-VEGF-A/Sema3C xenografts showed similar growth rates and developed 
somewhat delayed as compared to control Mel57-VEGF-A/EGFP xenografts (Fig 3B). Mice 
were sacrificed when tumors had reached comparable sizes.  
All mice exhibited comparable elevated VEGF-A levels in their plasma (3-5 ng/ml) 
suggesting that effects on tumor growth, morphology and metastatic phenotype were due 
to Sema3 expression and not to low VEGF-A production by the tumor cells.
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Table 3. Sema3E expression in melanocytic cells in benign naevi, primary cutaneous melanomas, and melanoma metastases 
 
% Positive 
melanocytic cells 
Naevi 
naevocellularis 
Dysplastic 
naevi 
Melanomas  
in situ 
Primary Melanomas Melanoma metastases 
Clark II Clark III Clark IV Skin Lymph node Brain 
0 2 1  1 1 1 2 5 2 
1-25    1  2 2 1  
26-50      1  1 1 
51-75          
76-99 1   1      
100 8 3 4 3 3 3    
N+/Nt
* 9/11 3/4 4/4 5/6 3/4 6/7 2/4 2/7 1/3 
% 82% 75% 100% 83% 75% 86% 50% 29% 33% 
 
 
* Number of Sema3E positive lesions (N+) per total number of examined lesions (Nt)  
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In addition, VEGF-A expression in the xenografts was confirmed by mRNA in situ 
hybridization (not shown). Sema3E and Sema3C expression was determined by 
immunostainings on Mel57-VEGF-A/Sema3E (inset in Fig. 3C) and -/Sema3C (inset in Fig. 
3E) xenografts respectively. Whereas VEGF-A expressing Mel57 xenografts grew with a 
characteristic micronodular phenotype,
203
 the architecture of these tumors was 
remarkably different when Sema3E was co-expressed (Fig. 3C). Mel57-VEGF-A/Sema3E 
xenografts consisted of a well vascularized rim of viable tumor cells (Fig. 3D), while 
centrally these tumors were sparsely vascularized with numerous necrotic areas. This 
phenotype was not observed when Sema3C instead of Sema3E was co-expressed (Fig. 3E 
and F). Staining for the proliferation marker Ki-67 with mouse Ki67-specific antibodies 
revealed that, although Sema3E reduced tumor angiogenesis, VEGF-A-induced 
proliferation of vascular cells in the tumor rim was unaffected in Mel57-VEGF-A xenografts 
co-expressing Sema3E (not shown).  
 
Sema3E reduces metastatic potential of subcutaneous Mel57-VEGF-A xenografts 
We previously established that Mel57-VEGF-A tumors metastasize by shedding 
multicellular tumor fragments, surrounded by vessel wall  elements, into the circulation 
which eventually grow to large lung tumors, initially in pulmonary arteries.
203
 The 
multicellular origin of these metastases was assessed by tagging tumor xenografts with 
EGFP-expressing tumor cells. This principle was also applied in the current experiments. 
To investigate whether Sema3E affects metastatic capacity of Mel57 xenografts, we 
analyzed metastatic burden, composition and localization of lung lesions. In mice carrying 
subcutaneous Mel57-VEGF-A/Sema3E xenografts, metastatic load in the pulmonary 
vessels was significantly reduced compared to Mel57-VEGF-A/EGFP (p=0.022) and -
/Sema3C tumors (p=0.006) (Fig. 4A). Whereas Mel57-VEGF-A/Sema3C xenografts 
exhibited the typical metastatic features previously described for Mel57-VEGF-A tumors
203
 
(Fig. 4B), such phenotype was observed in only one mouse carrying a Mel57-VEGF-
A/Sema3E xenograft. In two mice of the Sema3E group, small lung lesions in the tip of the 
lungs were detected (Fig. 4C), which in contrast to lung metastases derived from Mel57-
VEGF-A/Sema3C xenografts, lacked coverage by the vessel wall elements laminin (not 
shown) and endothelial cells (inset in Fig. 4C). 
Because we co-injected EGFP-tagged Mel57 cells, we could judge whether metastases 
were of multicellular or monoclonal origin. EGFP immunostainings revealed that the 
composition of most lung lesions derived from Mel57-VEGF-A/Sema3C xenografts was 
polyclonal with both Mel57-VEGF-A/Sema3C and Mel57-EGFP cells (Fig. 4D) whereas the 
two Mel57-VEGF-A/Sema3E derived lesions located in the lung tip were composed of 
EGFP negative tumor cells (Fig. 4E), suggesting that these originated from clonal expansion 
of single tumor cells rather than tumor emboli. 
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Figure 3. Analysis of subcutaneous Mel57-VEGF-A xenografts co-expressing Sema3E or Sema3C. A) shows 
PLXND1 expression in subcutaneous Mel57-VEGF-A xenografts as revealed by immunohistochemistry using 
single domain antibody A12. Both Mel57-VEGF-A cells and endothelium express PLXND1 (the inset shows a 
negative control staining with anti-VSV-G antibody). B) Tumor growth curves of Sema3E () and 
Sema3C(▲)-expressing Mel57-VEGF-A xenografts and control Mel57-VEGF-A/EGFP lesions (). Tumor 
volumes are calculated as height x depth x width. Note that the xenografts co-expressing Sema3(C/E) show 
comparable growth rates. Histological analysis of subcutaneous Mel57-VEGF-A/Sema3E and -/Sema3C 
tumors by H&E staining (C and E) and anti-CD34 staining (D and F). Note the absence of micronodular 
transformation in Sema3E-expressing tumors (C and D), while Mel57-VEGF-A/Sema3C xenografts show the 
typically VEGF-A induced micronodular growth pattern (E and F). In contrast to Mel57-VEGF-A/Sema3C 
xenografts, Sema3E-expressing tumors only show a  well vascularized tumor rim. The insets in C and E show 
Sema3E and Sema3C immunostainings on Mel57-VEGF-A/Sema3E (C) and -/Sema3C (E) xenografts 
respectively.  
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Subcutaneous Mel57-VEGF-A/Sema3E xenografts display down-regulated expression of 
Thrombospondin 1 and Extracellular matrix protein 1 
Both angiogenesis and metastasis highly depend on extracellular matrix remodeling and 
establishing and disrupting cell-cell interactions. We therefore compared expression 
profiles of a number of extracellular matrix and adhesion molecules in Mel57-VEGF-A and 
Figure 4. Analysis of  metastatic burden, localization and composition. A) Metastasis count of mice carrying 
different subcutaneous Mel57-VEGF-A xenografts. Lung lesions were counted after H&E staining. Note that 
in mice carrying subcutaneous Mel57-VEGF-A/Sema3E xenografts metastatic burden is significantly reduced 
compared to Mel57-VEGF-A/EGFP (p=0.022) and -/Sema3C tumors (p=0.006). In contrast, metastatic load in 
mice carrying Sema3C expressing tumors is not significantly different from Mel57-VEGF-A/EGFP xenografts 
(p=0.289). Histochemical analysis of lung metastases by H&E staining (B and C) and anti-CD34 staining 
(insets) show that lung metastases derived from Mel57-VEGF-A/Sema3C xenografts (B) are predominantly 
located in the larger branches of the pulmonary vessels. Note in C that the small lesion in the tip of the lung 
derived from a Mel57-VEGF-A/Sema3E tumor is not surrounded by endothelial cells (inset in C). EGFP 
immunostainings on lung metastases derived from Mel57-VEGF-A/Sema3C (D) and -/Sema3E (E) xenografts 
tagged with EGFP-expressing tumor cells. Note that most lung metatases derived from Mel57-VEGF-
A/Sema3C xenografts are of multicellular origin with both Mel57-VEGF-A/Sema3C and Mel57-EGFP cells (D), 
while the EGFP-negative lung lesion in a mice carrying a subcutaneous Mel57-VEGF-A/Sema3E xenograft 
likely originates from clonal expansion of a single tumor cell (E).  
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Mel57-VEGF-A/Sema3E tumors using the Superarray RT
2
 profiler kit. Detectable PCR 
products, defined as requiring <30 cycles, were obtained for 41 out of 83 genes analyzed. 
Neither of the tested genes were significantly upregulated in tumors expressing Sema3E 
as compared to Mel57-VEGF-A tumors. However, we found that thrombospondin 1 
(THBS1) and Extracellular matrix protein 1 (ECM1) were expressed at significantly lower 
levels (respectively 3.8- and 3.6-fold lower as compared to Mel57-VEGF-A xenografts, 
Figure 5A). To validate the RT-PCR array results we examined THBS expression at the 
protein level using immunohistochemistry on frozen sections of Mel57-VEGF-A and 
Mel57-VEGF-A/Sema3E tumors. In accordance with our array data these immunostainings 
revealed that THBS is abundantly expressed in Mel57-VEGF-A xenografts (Fig. 5B), while 
this protein is hardly detectable in Mel57-VEGF-A/Sema3E tumors (Fig. 5C). Note that our 
staining protocol, using a mouse monoclonal THBS antibody, inevitably also results in 
aspecifical staining of mouse IgG in necrotic areas in both tumors (see negative control 
stainings with anti-mouse secondary antibody only, insets). Comparison with these control 
staining clearly shows that THBS is associated with the network of vessel wall elements in 
Mel57-VEGF-A lesions. Importantly, in these xenografts THBS is expressed by Mel57-VEGF-
A cells (magnification in B), while tumors cells overexpressing Sema3E lack THBS 
expression (magnification in C). 
 
 
Discussion   
 
Previous studies have suggested a functional role of PLXND1 in developmental 
angiogenesis.
175,176
 In later stages of embryonic development, endothelial cells loose 
PLXND1 expression and expression is absent in adult endothelial cells.
174
 We 
demonstrated that PLXND1 is re-expressed on vasculature during tumor-associated 
angiogenesis in both animal tumor models and a number of human brain tumors.
201
 Here 
we show that PLXND1 is expressed by the tumor vasculature in primary melanomas 
thicker than 2 mm. Transition from micro- to deeply invasive melanoma is accompanied 
by angiogenesis
190,191
 which augments vascular invasion of melanoma cells.
206
 Thus, our 
findings confirm our previous observation that PLXND1 is expressed on angiogenic 
endothelium and not in quiescent vasculature. PLXND1 was also abundantly expressed by 
tumor cells, including metastatic melanoma cells. The presence of consensus motifs for 
Rac-Rho signaling in the intracellular domain of PLXND1
174
 is consistent with a possible 
regulatory role in cellular migration and, thus, tumor progression. Here we show using a 
single domain antibody against the most aminoterminal part of PLXND1 that expression of 
this protein in melanocytic lesions is indeed correlated with malignancy stage, being 
absent in benign lesions and ubiquitous in metastatic cancer. 
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Figure 5. Fold-changes in mRNA expression of extracellular matrix and adhesion molecules in Sema3E 
overexpressing tumors relative to the control subcutaneous Mel57-VEGF-A lesions as revealed by RT-PCR 
array analysis (A). Columns represent fold changes in expression in Sema3E-expressing tumors relative to 
subcutaneous Mel57-VEGF-A lesions. Upper columns (>1.00) represent molecules whose mRNA expression 
is up-regulated, lower columns (<1.00) molecules whose expression is down-regulated. 
Immunohistochemical analysis of THBS expression in subcutaneous Mel57-VEGF-A (B) and Mel57-VEGF-
A/Sema3E xenografts (C). In contrast to Mel57-VEGF-A/Sema3E lesions THBS is abundantly expressed in 
Mel57-VEGF-A tumors (the insets show negative control stainings with anti-mouse antibody). Note in B that 
THBS expression is clearly associated with the network of vessel wall elements and tumor cells.  
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An inverse relationship was observed with Sema3E, one of the PLXND1 ligands, which was 
largely absent in metastatic lesions. The hypothesis that emerges from these data, that 
Sema3E expression is linked to decreased metastatic potential could be validated in a 
functional melanoma metastasis assay.  
The role of Sema3E in tumor biology has been matter of debate in the literature. Originally 
this protein was discovered via array-analyses as being correlated to metastatic mamma 
carcinoma.
187
 In a follow-up study Christensen et al. showed by RT-PCR that Sema3E was 
expressed by 69% of human mamma carcinoma metastases and overexpression resulted 
in increased tumor growth in lungs.
207
 It has to be realized however, that in these 
experiments tumor cells were injected directly in the circulation. The initial and possibly 
rate-limiting steps of metastasis, invasive growth in extracellular matrix and entry into the 
vasculature, were thus lacking in these experiments. 
An inhibitory role of Sema3E for cell migration has also been described. Sema3E acts via 
PLXND1 to serve as a chemorepellant for endothelial cells
177,202
 and inhibits 
neoangiogenesis in vivo.
202
 Sema4A, which binds to the same region of PLXND1 as 
Sema3E, suppresses VEGF-A-mediated angiogenesis by downregulating Rac-GTP-
dependent cytoskeletal rearrangement
202
 and it is conceivable that Sema3E has a similar 
mode of action. This notion is supported by our finding that Mel57 xenografts 
overexpressing Sema3E and VEGF-A, display large areas of central necrosis, consistent 
with poor angiogenesis. Yet, in vasculature in vital parts of Mel57 VEGF-A/Sema3E 
xenografts proliferating endothelial cells were observed, indicating that VEGF-A was still 
able to activate VEGF receptors on endothelial cells. We previously showed that 
metastasis from Mel57-VEGF-A xenografts develop by bulging of tumor nodules into 
dilated vessels, a process which is accompanied by gradual coverage of these nodules by 
endothelial cells.
203
 For this process, both endothelial proliferation and migration are 
indispensable. Our data are therefore consistent with a model in which lack of 
metastasising capacity is due to impaired migration of endothelial cells.  
The dualistic chemorepellant/chemo-attractant properties which are contained within 
Sema3E appear to be controlled by proteolytic processing, converting a repelling full 
length Sema3E into an inducer of invasiveness.
207
 The antibody used in our current study 
recognizes both full length Sema3E and the p61 degradation product. The absence of any 
immunoreactivity in metastatic cancer cells thus places doubt on whether similar 
proteolytic mechanisms are relevant for regulating Sema3E activity in melanoma. It has 
recently been described that the presence or absence of neuropilin may also be an 
important factor, determining the guidance properties of the Sema3E/PLXND1 complex.
208
 
Interestingly, immunostainings on our melanoma progression series revealed that 
membranous expression of Neuropilin-1 was almost exclusively observed in melanoma 
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metastases and to a much lesser extent in primary melanomas (not shown), ruling out an 
involvement for Neuropilin-1 in regulating Sema3E activity.  
To obtain more insight in the underlying mechanisms of angiogenesis and metastasis 
inhibition by Sema3E, we examined expression levels of a series of genes involved in 
extracellular matrix remodelling and cell adhesion. THBS1 and ECM1 were significantly 
down-regulated in Sema3E overexpressing xenografts. It must be noted that we examined 
gene expression in tumor xenografts consisting of a mix of tumor and stromal cells. 
Although we can therefore not determine to which cell types the differences in gene 
expression can be attributed, validation of the array results by immunohistochemistry 
revealed that Sema3E overexpression results in lack of THBS expression by Mel57 cells. 
THBS is a secreted protein which interacts with different types of collagen
209,210
 and 
laminin
210
. These matrix proteins are major components of the vascular network 
surrounding Mel57-VEGF-A tumor noduli
203
 which explains the localization of THBS in 
Mel57-VEGF-A xenografts. Thus, our observations are in agreement with a model in which 
THBS is secreted by Mel57-VEGF-A cells followed by retention by vessel wall elements 
generating a bioreservoir of THBS. It remains to be established which mechanisms underly 
downregulation of THBS by Sema3E on the cellular level. 
The role of THBS1 in tumor progression is controversial. Whereas this protein is generally 
presented as an angiogenesis inhibitor, it has also been reported that THBS1 promotes 
melanoma invasiveness and metastasis via modulation of melanoma-matrix interactions 
(for review, see
211
). Interestingly, in clinical cutaneous melanomas, THBS1 expression 
correlates with microvessel density, tumor thickness and the presence of vascular 
invasion.
212
 Our results are thus in agreement with a pro-angiogenic and pro-metastatic 
effect of THBS1 in melanoma progression. We also found ECM1 to be down-regulated in 
Sema3E expressing Mel57 tumors. Expression of ECM1 is closely associated with early 
stages of angiogenesis during embryonic development and this protein has also been 
shown to be expressed by tumor cells.
213,214
 Concordant with our results, ECM1 expression 
is associated with metastatic behaviour.
214
  
Several other class 3 semaphorins and plexins have been found to affect tumor growth 
and invasion. Whereas Sema3A, 3B and 3F are described to be functional inhibitors of 
tumorigenesis and involved in inhibition of tumor cell spread,
215-217
 binding of Sema4D to 
its high affinity receptor plexin B1 contributes to invasive tumor growth and metastasis via 
activation of Met and Ron receptors.
218,219
 Although we showed here that PLXND1 
expression is correlated with tumor invasion and metastasis in melanoma progression 
series, we could not reveal which of its ligands functionally contributes to tumor 
progression and metastasis. Overexpression of Sema3C, one of the other PLXND1 ligands, 
did not affect metastasis of Mel57 xenografts. In addition, immunostainings on a number 
of human melanocytic lesions revealed that Sema3C was equally expressed in both benign 
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and malignant tissue samples (not shown). Taken together, based on our data we consider 
it unlikely that binding of Sema3C to a Neuropilin-1/PLXND1 complex contributes to tumor 
progression.  
The correlation between PLXND1 expression and level of melanoma invasion makes this 
protein a potentially valuable diagnostic marker. PLXND1 can aid to distinguish primary 
cutaneous melanomas from naevi with a sensitivity of 73%. The observation that PLXND1 
is expressed in both tumor vessels and tumor cells in melanoma metastases may also have 
therapeutic relevance since the protein may be used for simultaneous targeting of 
different tumor compartments of metastatic melanomas, i.e. melanoma cells and the 
tumor vasculature.
201
  
In conclusion, PLXND1 expression correlates with malignancy grade in tumors but the 
ligand responsible for PLXND1 activation still has to be identified. Sema3E expression 
inhibits angiogenesis and metastasis in melanoma, possibly via downregulation of matrix-
associated proteins such as thrombospondin 1 and extracellular matrix protein-1. It 
remains to be elucidated whether Sema3E exerts its effect by competitive inhibition of as 
yet unknown activating PLXND1 ligands. 
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Abstract 
 
Plexin D1 is expressed on both tumor-associated endothelium and malignant cells in a 
number of clinical brain tumors. Recently we demonstrated that Plexin D1 expression is 
correlated with tumor invasion level and metastasis in a human melanoma progression 
series. Here we examined Plexin D1 expression in clinical solid tumors (n=77) of different 
origin, a selection of pre-malignant lesions (n=29) and a variety of non-tumor related 
tissues (n=52) by immunohistochemistry. Signals were verified in a selection of tissues via 
mRNA in situ hybridization. Plexin D1 is abundantly expressed on both activated 
established tumor vasculature and malignant cells in the majority of primary and 
metastatic clinical tumors, as well as on macrophages and fibroblasts. Importantly, in non-
tumor related tissues Plexin D1 expression is restricted to a subset of, presumably 
activated, fibroblasts and macrophages. This expression profile highlights Plexin D1 as a 
potentially valuable therapeutic target in clinical solid tumors, enabling simultaneous 
targeting of different tumor compartments.   
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Introduction 
 
Interference with a tumor’s blood supply is an attractive approach to inhibit tumor growth 
and dissemination. Thereto, many research focused on targeting the angiogenic process 
via inhibition of the Vascular endothelial Growth Factor (VEGF-A)  pathway.  
Despite promising results in animal tumor models in which anti-VEGF therapy translates 
into potent anti-tumor effects,
60-62
 implementation of these therapies for a number of 
tumor types in the clinic has now learned that they, either or not in combination with 
chemotherapy, do increase quality of life or modestly prolong survival,
108,220-222
 but lack 
curative effects.
123,166
 This discrepancy may be partly due to the high heterogeneity of the 
vasculature
223-225
: in established clinical tumors all possible maturation stages may be  
represented, only a small fraction of which may be susceptible to VEGF inhibition.
73
 This 
situation contrasts that in fast growing animal tumors in which the entire population of 
tumor vessels may be in a synchronized maturation stage. In addition, we and others 
described that in organs with intrinsically high vessel densities, tumors and metastases are 
able to grow in an angiogenesis-independent fashion via co-option of pre-existing blood 
vessels.
75,76,78,167,168
 This provides tumors with a route of escape which makes them 
(partially) unsusceptible to anti-angiogenic compounds. Even more, anti-angiogenesis may 
drive a shift in brain tumors from an angiogenic to a co-opting phenotype.
117,120,226
 
Therefore, vascular targeting therapy in which the existing tumor vascular bed, angiogenic 
or pre-existent, is attacked with the aim to induce acute tumor-specific coagulation may 
be an attractive additional approach to deprive a tumor from blood supply. To apply 
vascular targeting therapies, targetable markers that discriminate tumor vessels from 
normal vasculature are needed. We previously described that Plexin D1 (PLXND1) could be 
such a target.
201
  
PLXND1 belongs to a family of large transmembrane proteins that are receptors for 
neuropilins and semaphorins.
170,197
 Plexins are involved in regulation of axonal patterning 
during embryonic development.
171,173,184,198
 Apart from neuronal cells, PLXND1 is also 
expressed by vascular endothelial cells during embryogenesis
174
 and is of pivotal 
importance for vascular patterning, as illustrated by the fact that  PLXND1 knock-down in 
mice and zebrafish results in abnormal development of the cardiovascular system.
175,176,227
 
We previously demonstrated that PLXND1 is also specifically expressed on vascular 
endothelium during tumor-associated angiogenesis in a mouse xenograft model of 
cerebral melanoma metastasis and in a number of human brain tumors, both of primary 
and metastatic origin.
201
 Importantly, expression of this protein was also found on tumor 
cells in these tumors,
201
 and this expression correlates with malignancy grade in a human 
melanoma progression series: whereas PLXND1 is abundantly expressed in both invasive 
primary and disseminated melanomas, both in the vasculature and in tumor cells, its 
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expression was absent in benign melanocytic lesions and melanomas in situ, except for 
expression on macrophages and fibroblasts.
228
   
PLXND1 contains in its intracellular domain consensus Rac/RhoA signalling motifs,
174
 
suggestive of a role in cytoskeletal rearrangements and cell motility, processes which are 
fundamental for both tumor angiogenesis and metastasis. PLXND1 may thus be 
functionally involved in tumor development in multiple ways.  
The expression profile of PLXND1 suggests that it may be a valuable tumor target for 
established solid tumors, allowing simultaneous targeting of different tumor 
compartments, i.e. vessels and tumor cells. To examine whether PLXND1 might be 
clinically useful as a pan-tumor vessel and pan-tumor cell target in solid tumors we 
analyzed PLXND1 expression in a wide range of human tumors of different origin and 
various pre-malignant and non-tumor related tissues by immunohistochemistry and mRNA 
in situ hybridization. 
 
 
Methods 
 
Tissue samples 
Primary and metastatic tumor tissues of different origin (n=77), among them 15 paired 
samples of human primary and metastatic lesions and various pre-malignant lesions 
(n=29), were selected from the archives of the Department of Pathology and Radiology of 
the Radboud University Nijmegen Medical Centre. Furthermore, non-tumor related tissues 
(n=52) were obtained. 
 
Immunohistochemistry 
After deparaffinization and blocking of endogenous peroxidase activity, antigen retrieval 
was performed by treatment with pronase according to standard protocols.
228
 Non-
specific binding sites were blocked by incubation with 20% normal horse serum. Slides 
were incubated for 1 hr with single domain antibody A12, which was previously selected 
against a PLXND1-specific peptide.
201
 A12 was detected by sequential incubations with the 
mouse anti-VSV-G P5D4, biotinylated anti-mouse IgG (Vector, Burlingame, CA), and avidin-
biotin peroxidase complex (Vector). Peroxidase was visualized by the 3-amino-9-
ethylcarbazole (ScyTek, Logan, UT) peroxidase reaction, with haematoxylin as 
counterstain. All incubations were performed at room temperature. Blood vessel origin 
was confirmed by endothelial stainings on serial sections with anti-human CD31 antibody 
(DAKO, Glostrup, Denmark).  
In a selection of tissues, macrophage identity was confirmed by double staining for 
PLXND1 and CD68. In short, the above mentioned avidin-biotin peroxidase procedure was 
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used to detect PLXND1 via rabbit anti-VSV-G antiserum (Sigma Chemical Co., Zwijndrecht, 
The Netherlands). Following visualization, avidin-biotin was blocked according to standard 
protocols. Slides were successively incubated with normal horse serum, mouse anti-
human CD68 antibody (DAKO) overnight at 4
o
C, biotinylated anti-mouse IgG (Vector) and 
avidin-biotin alkaline phosphatase (AP) complex (Vector) at RT. AP was visualized with a 
mixture of naphthol phosphate (Sigma), levamisole (Sigma), and Fast Blue (Sigma).  
 
PLXND1 mRNA In Situ Hybridization 
To explore whether the PLXND1 transcript is also specifically present in malignant tissues, 
we performed mRNA in situ hybridizations on 28 of the 158 paraffin-embedded tissues 
analyzed by immunohistochemistry (malignant lesions, n=15; benign samples, n=13) as 
previously described.
201
 In brief, digoxigenin-labelled sense and antisense human PLXND1 
RNA probes, located in the 3’-untranslated region, were generated by in vitro transcription 
from a PLXND1 PCR product which was flanked by T7 and T3 promoters as described.
174
 
Following deparaffinization, 4 µm tumor sections were treated with proteinase K (Roche, 
Almere, The Netherlands) at 37°C for 15 minutes and post-fixed in formaldehyde. Non-
specific binding sites were blocked by incubation with acetic anhydride (Sigma) at room 
temperature. Tissues were hybridized with digoxigenin-labelled RNA probes at 63°C with 
200 ng/ml probe. Single stranded non-hybridized RNA was degraded with RNAse T1 (2 
units/ml) at 37°C for 30 minutes. After subsequent pre-incubation with normal sheep 
serum, the slides were incubated with alkaline phosphatase-conjugated sheep anti-
digoxigenin antibody (Roche) at room temperature for 1 hour. Alkaline phosphatase was 
visualized using nitro blue tetrazolium (NBT; Roche) and 5-bromo-4-chloro-3-indolyl 
phosphate (BCIP; Roche) as substrate with nuclear fast red as counterstain. Specificity of 
hybridizations was verified by performing control hybridizations with sense probe. 
 
 
 
Results 
 
To explore whether PLXND1 may be clinically useful as a pan-tumor endothelium and a 
pan-tumor cell target we examined the expression profile of this protein in a large variety 
of human tissue samples. As summarized in Table 1, PLXND1 is abundantly expressed in 
both the vasculature and malignant cells in the majority of clinical tumors, whereas in pre-
malignant lesions the protein is present at lower levels or, like in benign tissues, almost 
completely absent (Table 2).  
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Table 1. Plexin D1 expression in solid malignancies 
Malignant tissue 
PLXND1 expression 
Remarks 
Endothelial 
cells 
Tumor 
cells 
Subset of 
macrophages 
Subset of 
fibroblasts 
      
Paired samples 
    
 
 Medullary breast carcinoma (n=1) - - + + 
Plasma cells 
also positive 
Lymph node metastasis (n=1) Subset - + n.d.  
      
 Ductal breast carcinoma (n=8) + + + + Some plasma cells  
also positive 
Lymph node metastasis (n=8) + + + +  
      
 Adenocarcinoma of colon (n=4) + + + +  
Liver metastasis (n=4) + + + +  
      
 Alveolar soft part sarcoma of femur (n=1) + + n.d. n.d.  
Brain metastasis (n=1) + + n.d. n.d.  
      
 Renal cell carcinoma (n=1) + + n.d. n.d.  
Brain metastasis (n=1) + + n.d. n.d.  
      
Non-paired samples      
Adenocarcinoma  of coecum (n=1) + + + -  
Adenocarcinoma of oesophagus (n=1) + + + -  
Adenocarcinoma of ovary (n=1) Subset + + +  
Adenocarcinoma of prostate (n=1) + + - -  
Adenocarcinoma of rectum (n=5) + + + +  
Brain metastasis of adenocarcinoma (n=4) + + n.d. n.d.  
Liver metastasis of adenocarcinoma colon (n=8) + + + +  
Ovary metastasis of adenocarcinoma colon (n=1) - + - -  
      
Low grade astrocytoma (n=2) Subset Subset n.d. n.d.  
Glioblastoma Multiforme (n=3) + + n.d. n.d.  
Medulloblastoma (n=1) + + n.d. n.d.  
      
Neuro-endocrine tumor of lung  (n=2) + + + n.d.  
      
Medullary breast carcinoma of (n=4) + + + + 
2 samples negative 
vessels and tumor cells  
Lymph node metastasis of ductal breast carcinoma (n=1) Subset + - -  
      
Squamous cell carcinoma of cervix (n=5) Subset + + - 
1 sample negative 
vessels and tumor cells 
Squamous cell carcinoma of vulva (n=5) - - + +  
      
Urothelial cell carcinoma of prostate (n=2) + + + -  
      
 
+, corresponding cell type expresses PLXND1   
-, PLXND1 expression is absent in corresponding cell type 
 n.d., corresponding cell type is not detected 
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Table 2. Plexin D1 expression in pre-malignant and non-tumor related tissues 
Tissue 
PLXND1 expression 
Remarks 
Endothelial 
cells 
Subsets of 
macrophages 
Subsets of 
fibroblasts 
     
Pre-malignant samples     
Ductal carcinoma in situ of breast (n=5) + + + Weak staining of tumor cells 
Lobular carcinoma in situ of breast (n=3) Weak + + Weak staining of tumor cells 
     
Vulvar intraepithelial neoplasia (VIN)     
 Classic VIN III, HPV negative (n=5) - + +  
 Classic VIN III, HPV positive (n=8) - + +  
 Differentiated VIN III (n=8) - + n.d.  
     
Non-tumor related samples     
Bladder (n=1) - + -  
Blood vessel     
 Atherosclerosis (n=6) - + -  
 Fatty streaks (n=1) - + -  
Bone marrow (n=2) n.d. - -  
Brain     
 Cortex (n=1) - n.d. n.d. Some neurons perinuclear staining 
 Alzheimer and CAA (n=1) - n.d n.d.  
 Multiple Sclerosis (n=2)  - n.d n.d.  
Breast     
 Normal breast (n=2) - - - Some epithelial cells  perinuclear staining 
 Ductal hyperplasia (n=1) - + - Focal epithelial cells perinuclear staining 
Endometrium     
 Proliferation phase (n=5) Subset (n=3) + n.d.  
 Secretion phase (n=4) - + n.d.  
 Secretion/menstruation phase (n=1) - + n.d.  
 Endometriosis interna (n=1) - + n.d.  
Heart (n=1) - n.d n.d Myocytes  perinuclear staining 
Large intestine (n=1) - + + Some epithelial cells perinuclear staining 
Liver (n=1) - + n.d. Some hepatocytes perinuclear staining 
Lung (n=2) - + n.d.  
Oesophagus (n=1) - + -  
Pancreas (n=1)  - n.d n.d. Perinuclear staining in Islets of Langerhans   
Pituitary gland (n=1) - n.d. n.d. Some epithelial cells  perinuclear staining 
Prostate (n=1)  - - n.d. Some epithelial cells perinuclear staining 
Small intestine (n=1) - + + Some epithelial cells perinuclear staining 
Spleen (n=1) - + n.d.  
Thyroid gland (n=1) - + n.d. Some epithelial cells perinuclear staining 
Vulva     
 Normal vulva (n=6) - + +  
 Lichen sclerosus (n=6) - + +  
     
 
+, corresponding cell type expresses PLXND1   
-, PLXND1 expression is absent in corresponding cell type 
 n.d., corresponding cell type is not detected 
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Figure 1 shows vascular (arrows) and tumor cell expression of PLXND1 in representative 
samples of  brain metastasis of adenocarcinoma (A), glioblastoma multiforme (B), neuro-
endocrine lung tumor (C), ovarian adenocarcinoma (D), and prostatic urothelial cell 
carcinoma (E). The insets in A and B show corresponding in situ hybridization signals. 
Vascular and tumor cell-associated PLXND1 expression was absent in 3 out of 5 medullary 
breast carcinomas, one out of 5 cervical squamous cell carcinomas, and all examined 
vulvar squamous cell carcinomas (Table 1). A representative sample of vulvar squamous 
cell carcinoma is shown in figure 1F. In addition, two low grade astrocytomas showed 
infrequent vascular and tumor cell-associated PLXND1 expression (Table 1).  
 
 
 
As shown in figure 2A through F no significant differences in staining pattern and intensity 
of vascular structures (arrows) and malignant cells could be observed between primary 
ductal breast carcinoma (A) and a corresponding lymph node metastasis (B), colon 
adenocarcinoma (C) and a corresponding liver metastasis (D) and renal cell carcinoma (E) 
Figure 1. 
Immunohistochemical 
analysis of PLXND1 
expression in 
representative clinical 
tumor samples. PLXND1 
is abundantly expressed 
in adenocarcinoma brain 
metastases (A), 
glioblastomas 
multiforme (B), neuro-
endocrine lung tumors 
(C), an ovarian 
adenocarcinoma (D), and 
prostatic urothelial cell 
carcinomas (E). The 
arrows point at PLXND1-
positive vasculature. 
PLXND1 is absent in both 
tumor vasculature 
(arrowheads) and tumor 
cells in vulvar squamous 
cell carcinomas (F). The 
insets in A and B show 
corresponding PLXND1 
mRNA in situ 
hybridization analyses.  
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and a corresponding brain metastasis (F, the inset shows corresponding in situ 
hybridization signal).  
 
 
 
 
 
 
To examine whether PLXND1 is expressed on angiogenic vessels under physiological 
conditions, we also investigated expression in endometrium. In 3 out of 5 proliferative 
phase endometria some vessels stained positive for PLXND1 (Table 2). Figure 2G and H 
show lack of PLXND1 protein and transcript (insets) in normal human cerebral cortex and 
heart tissue. The granular staining pattern in cerebral neurons (G) and cardiac myocytes 
Figure 2. 
Immunohistochemical 
analysis of PLXND1 
expression in 
representative clinical 
tumor samples. PLXND1 
is expressed at high 
levels in primary ductal 
breast carcinomas (A) 
and corresponding 
lymph node metastases 
(B), colon 
adenocarcinomas (C) 
and corresponding liver 
metastases (D) and a 
renal cell carcinoma (E) 
and corresponding brain 
metastasis (F). The 
arrows point at PLXND1-
expressing tumor 
vessels. PLXND1 is not 
detected in normal 
human cerebral cortex 
(G) and heart (H) tissue 
samples. The insets in F, 
G and H show 
corresponding PLXND1 
mRNA in situ 
hybridization analyses. 
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(H) is presumably due to aspecific binding of single domain antibodies to lipofuscine as 
this is observed with other non-related single domain antibodies too (not shown). 
Apart from tumor-associated endothelium and tumor cells, PLXND1 expression was also 
observed in subsets of fibroblast- and macrophage-like cells in both tumor samples and 
pre-malignant and non-tumor related tissues. Identity of macrophages was confirmed by 
double staining a selection of analyzed tissues for PLXND1 and CD68 (not shown).   
 
 
Discussion 
 
In previous work we showed that PLXND1 is expressed in endothelial cells during 
developmental and tumor-associated angiogenesis.
174,201
 Besides vascular expression, high 
PLXND1 expression was also found on tumor cells in cerebral melanoma metastases. 
Whereas a role of PLXND1 in vessel patterning during development is well 
established,
175,176,227
 the functional consequences of PLXND1 expression on tumor cells 
and vessels are less clear. We recently demonstrated that PLXND1 expression is correlated 
with tumor invasion and metastasis in a human melanoma progression series.
228
 However, 
the PLXND1 ligands Semaphorin 3E and 4A inhibit, rather than promote, (tumor) 
angiogenesis.
202,228
 Moreover, Semaphorin 3E even exhibits anti-tumor and anti-
metastatic properties.
228,229
 
Here we show that PLXND1 is expressed at high levels on activated established tumor 
vasculature in a variety of primary and metastatic human malignancies, whereas in benign 
tissues PLXND1 expression is restricted to a subset of, presumably activated, fibroblasts 
and macrophages. These results are in agreement with our previous observations in 
clinical brain tumors of different origin
201
 and a series of cutaneous melanocytic lesions 
representing different stages of melanoma progression.
228
 So, for subsets of tumor types 
in which vessel activation has occurred, PLXND1 may be a valuable candidate protein for 
vascular targeting approaches. Indeed, the anti-PLXND1 single domain antibody A12 
homes to and accumulates in tumor vessels.
201
  
Successful vascular targeting has also been achieved with agents directed against 
molecules of which expression is restricted to vessels in early stages of angiogenesis. 
Examples are the L19 single chain antibody, directed against the ED-B fragment of 
fibronectin which targets vasculature in actively growing tumors,
124
 whereas this single 
chain antibody is unable to detect quiescent endothelium in low grade malignancies.
125
 
Targeted radiotherapy with radiolabeled RGD peptides, recognizing integrin αvβ3 on 
newly formed endothelial cells, led to reduced growth of xenografts in mouse models of 
cancer.
126-128
 Furthermore, chimeric proteins, consisting of antibodies against the tumor 
vessel marker vascular cell adhesion molecule 1 (VCAM-1), fused to soluble Tissue Factor, 
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induced tumor specific blood clotting, tumor necrosis and growth delay in different 
xenograft models.
129
  
Due to vessel heterogeneity in tumors
223-225,230
 it is unlikely that one single marker will 
behave as a targetable pan-tumor-endothelial antigen, but appropriate mixtures of 
different tumor vessel targeting agents, including anti-PLXND1 antibodies, may allow 
specific targeting of the majority of tumor vessels. For instance, to effectively starve 
tumors like low grade gliomas, which (partly) thrive on quiescent vasculature, targeting 
agents that recognize co-opted vessels in infiltrative tumor areas need to be developed. It 
remains to be seen whether such targets can be identified and, if so, whether such 
strategy holds promise for treatment of  brain tumors, as it will include some toxicity for 
interspersed normal brain in infiltrative tumor areas.  
Apart from vascular PLXND1 expression in tumors, the protein is also abundantly 
expressed on tumor cells in a wide range of clinical solid tumors which reinforces this 
membrane protein as a tumor target, since it allows simultaneous targeting of different 
tumor compartments with one compound.  Since all tumor metastases tested, except for 
one lymph node metastasis of a medullary breast carcinoma, expressed high levels of this 
protein, both on vessels and tumor cells, a PLXND1-directed seek-and-destroy strategy 
may therefore indeed be feasible. 
Despite its abundant expression in many different tumor types PLXND1 was not expressed 
on tumor cells and vessels in a subset of medullary breast carcinomas. Interestingly, these 
relatively rare tumors generally have a favorable prognosis.
231
 It is tempting to speculate 
that PLXND1 expression is generally correlated with increased malignancy grade. The only 
other tumor type in our series which lacked vascular and tumor cell-associated PLXND1 
expression was vulvar squamous cell carcinoma. Because the increased microvessel 
density in these tumors suggests angiogenesis,
232
 the lack of PLXND1 on vessels in these 
tumors was unexpected.
201
 Whether a lack of PLXND1 expression on these vessels is 
related to a more mature state can only be speculated upon. Physiological angiogenesis in 
proliferative phase endometria has been described to occur mainly in a non-sprouting 
fashion via vessel elongation
233
 which may explain the appearance of vascular PLXND1 in 
only a small subset of vessels in such tissue.   
We demonstrated that PLXND1 is in general ubiquitously expressed in tumor but not 
normal vasculature, as well as in malignant cells in a wide range of human (tumor) tissues. 
This expression pattern warrants further investigation towards PLXND1 as a therapeutic 
target in oncology. 
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Abstract 
 
Vasculature in clinical tumors is generally heterogeneous with glioblastoma multiforme as 
an extreme example. In these tumors, areas of angiogenesis exist next to large areas in 
which tumor cells diffusely infiltrate the brain. This latter tumor component thrives on 
pre-existent vessels and is not sensitive to angiogenesis inhibition. Therefore, induction of 
coagulation in these pre-existent tumor vessels is an attractive adjuvant approach to anti-
angiogenesis to deprive tumor cells from blood. This requires that tumor specific vascular 
targeting agents (TVTAs) become available. Here we describe a novel TVTA, nanobody C-
C7, which was isolated  by in vivo biopanning of a phage display library in the E98 
orthotopic mouse model of glioma. Using C-C7 as a bait in yeast two hybrid screens, we 
identified dynactin-1-p150
glued
 as its binding partner. This protein is specifically expressed 
on subsets of blood vessels in cerebral and subcutaneous tumor xenografts of different 
origin, but not on normal brain vessels. C-C7 also recognizes human dynactin-1-p150
glued
 in 
vessels in clinical glioma. In conclusion, nanobody phage display in combination with 
yeast-2-hybrid screening is a powerful technique to identify novel targetable tumor vessel 
markers. The heterogeneity of tumor vasculature suggests that cocktails of  anti-vascular 
targeting agents are needed. Anti-p150
glued
 antibodies are candidate to be included in such 
cocktails. 
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Introduction 
  
In order to grow and disseminate, tumors depend on an adequate blood supply.
132
 
Interference with the tumor vasculature is therefore a promising anti-tumor therapy. 
Many research focused on inhibition of angiogenesis using antibodies against Vascular 
Endothelial Growth Factor-A (VEGF-A), the most potent angiogenic factor, or tyrosine 
kinase inhibitors which specifically interfere with angiogenic receptor signalling. A number 
of clinical trials on different tumor types have now shown beneficial effects of such 
therapies, either or not in combination with chemotherapy, on patient performance and 
progression free survival
234
 and culminated in registration of anti-VEGF compounds for 
treatment of multiple tumor types. However, it is now well recognized that anti-
angiogenesis does not cure cancer nor turns cancer into chronic disease.
235
 One of the 
underlying causes is tumor vessel heterogeneity which is especially prominent in 
glioblastoma multiforme (GBM), a highly malignant astrocytic brain tumor.
82
 One hallmark 
of GBM is the presence of large areas of diffuse infiltrative growth in which tumor cells 
thrive on pre-existent vessels (co-option) without the need for angiogenesis. One of the 
other characteristics of GBM is however prominent focal angiogenesis and this has been 
the rationale for preclinical and clinical testing of anti-VEGF therapy for recurrent GBM as 
well. Such studies have shown effective inhibition of angiogenesis, however without 
affecting tumor progression in areas of diffuse infiltrative growth.
120,226,236
 This growth 
pattern thus provides tumors with a route of escape from anti-angiogenic therapies.
123,234
  
Anti-angiogenic therapies may be improved by combination with vascular targeting 
strategies, which aim at destruction of endothelial cells in tumor vessels and subsequent 
coagulation. Such approach requires that tumor vascular targeting agents (TVTAs) are 
developed with high enough specificity for tumor vasculature. Available TVTAs [e.g. RGD 
peptides targeting endothelial αvβ3 integrin,
237
 the L19 single chain antibody that targets 
the ED-B fragment of fibronectin,
124
 anti-V-CAM antibodies,
129
 anti-plexinD1 antibodies
201
] 
are directed against newly formed vessels and do not target tumor vessels in more 
matured stages of development. 
Biopanning of peptide or single chain-antibody phage display libraries is a powerful 
technique which allows identification and isolation of tumor endothelium binding 
partners.
238-240
 Nanobodies
®  
are recombinant antibodies, cloned from cameloid IgG2 and 3 
heavy chain antibodies (V-HH) and consist of a single polypeptide chain, making this class 
of antibodies suitable for display on phages without significant loss of affinity.
241
 Their 
small size (15-18 kDa) and stability make nanobodies to an attractive class of diagnostic 
and therapeutic compounds. Nanobodies against epidermal growth factor receptor (EGFR) 
or carcinoembryonic antigen (CEA) have already successfully been used for in vivo 
diagnosis and therapy.
242,243
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In a search for relevant nanobody-based TVTAs we performed in vivo biopannings with a 
nanobody phage display library in mice carrying orthotopic xenografts of the human 
glioma xenograft line E98.
121
 We here describe nanobody C-C7 which specifically binds to 
tumor vessels in mouse and human  gliomas. The C-C7 target was identified as the 
p150
glued
 subunit of dynactin-1 in yeast two hybrid (Y2H)  screens. 
 
 
Materials and Methods 
 
Tumor models 
The E98 glioma xenograft line is maintained as subcutaneous tumors in Balb/c nude 
mice.
121
 E98 tumor homogenates were injected in the cerebrum essentially as previously 
described.
121
 Characteristically, after approximately 21 days mice start to display weight 
loss and neurological symptoms due to tumor growth. When tumor-related symptoms 
were apparent, mice were used for in vivo biopanning. 
 
In vivo selection of tumor vessel binding phages in mouse cerebral E98 xenografts 
All experiments were approved by the Animal Experiment Committee of the Radboud 
University Nijmegen. Two hundred µl of phosphate buffered saline (PBS) containing 10
12
 
phages of a nanobody-displaying phage library (cloned from lymphocytes of Llama glama 
in phagemid pHENIX-HIS-VSV
201
) were injected in the tail vein of nude mice, carrying 
cerebral E98 tumors (n=2). Phages were allowed to circulate for 15 minutes. Mice were 
subsequently put under deep anaesthesia with a mixture of isoflurane/N2O and chests 
were opened. Cardiac perfusion was performed with 10 ml sterile 0.9% NaCl solution to 
remove unbound phages from the circulation. Brains were removed and snap frozen in 
liquid nitrogen. Sections of 4 µm were stained with anti-M13 p8 antibody (Abcam Limited, 
Cambridge, UK) to assess phage distribution. Using a laser dissection microscope (Leica AS 
LMD, Wetzlar, Germany) tumor areas were dissected from 10 μm brain sections and 
collected. Phages were eluted by incubation with trypsin (10 mg/ml in PBS) for 30 min at 
room temperature. Following infection in 10 ml of log-phase E. coli TG1 culture, bacteria 
were plated on 2xTY plates containing 100 mg/L ampicillin and 2% glucose. After overnight 
incubation, individual clones were picked and analyzed via colony-PCR for the presence of 
full-length nanobody insert using flanking primers M13fw (5`-TCA CAC AGG AAA CAG CTA 
TGA-3`) and M13rev (5`-GTA ACG ATC TAA AGT TTT GTC G-3`). Subsequently, PCR 
products were digested with the 4-cutter restriction enzyme BstNI to analyze the diversity 
of the phage population. Expression of soluble nanobodies by independent clones was 
induced in log-phase TG1 cells by culturing at 30
o
C in 2xTY medium, containing 100 mg/L 
ampicillin and 1 mmol/L IPTG.  
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Expression of nanobodies was verified by dot blot analysis of medium using anti-VSV 
antibodies, as previously described.
201
 Based on combined data of full length PCR, BstNI 
restriction and dotblot analysis, clones were selected for high-yield expression and 
subsequent immunohistochemical stainings. For that purpose, expression of nanobodies 
was induced in 200 ml log-phase TG1 cells with 1 mmol/L IPTG for 2 hours after which 
antibodies were isolated from the periplasm by osmotic lysis as described previously.
201
  
 
Immunohistochemistry 
Nanobodies were tested in immunostainings on 4 μm sections of paraffin-embedded 
tissue sections. Following deparaffinization, endogenous peroxidase activity was blocked 
by incubation with 3% H2O2. Antigen retrieval was performed by boiling in 10 mmol/L 
citrate buffer. Sections were pre-incubated with normal goat serum to block non-specific 
binding sites, followed by overnight incubation with nanobody at 4
0
C. Detection was 
performed by sequential incubations with rabbit anti-VSV-G antibody (Sigma-Aldrich 
Chemie B.V., Zwijndrecht, The Netherlands), biotinylated anti-rabbit antibody (Vector, 
Burlingame, CA) and avidin-biotin peroxidase complex (Vector, Burlingame, CA).  
Peroxidase was visualized with 3-amino-9-ethylcarbazole (ScyTek, Utah, USA) with 
haematoxylin as counterstain. Tumor vessels in serial sections were visualized with anti-
mouse anti-CD34 antibody (Hycult, Uden, The Netherlands). 
Tumor vessel specificity of selected nanobodies was assessed by staining on normal 
mouse tissues (heart, kidney, liver, lung and spleen) and tumor xenografts of different 
origin (intracerebral E98 and U87 gliomas, brain metastases of Mel57-VEGF165 
melanoma,
117
 subcutaneous xenografts of these tumor lines and of the colon carcinoma 
cell lines C26 and C38
244
). Primary human brain tumors, classified as grade II (n=2) and 
grade IV (n=7) gliomas, as well as normal brain tissue (n=2) from the archive of our 
department were also stained. In that case, nanobodies were detected via mouse 
monoclonal antibody anti-VSV-G P5D4.  
Dynactin-1-p150
glued
 expression was verified by immunohistochemistry with a rabbit anti-
dynactin-1 antibody (Abcam, Cambridge, UK). 
 
Y2H screens 
All cloning steps were performed using  the Gateway System (Invitrogen, Carlsbad, CA). 
The cDNA encoding nanobody C-C7 (without pelB leader) was flanked by attB sites via PCR 
and cloned in vector pDONR201 before transfer into destination vector pBD-GAL4-
CAM/DEST, generating a fusion protein with the GAL4 DNA binding domain. After 
sequence-verification this vector was transfected into yeast strain PJ69 (A-mating type) 
using standard protocols.
245
 Generation of a randomly primed bovine retina cDNA library 
in pAD-GAL4, transfected in PJ69 (α-mating type, 2x10
6
 clones) has been described 
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before.
245
 The yeast strain containing pBD-GAL4-C-C7 was mated with this library and 
diploid cells in which C-C7-prey interactions led to functional GAL4 transcription factor, 
were selected based on histidine and adenine prototrophy
 
and transactivation of ß-
galactosidase activity. Production of ß-galactosidase
 
by activation of the LacZ reporter 
gene was detected by
 
a filter-lift assay.
245
 From positive yeast clones, pAD-GAL4 library 
expression plasmids were rescued and amplified in E.coli. Plasmids were sequenced using 
flanking forward and reverse primers. Sequences were blasted 
(http://www.ncbi.nlm.nih.gov/blast/Blast.cgi) and aligned with multalin software 
(http://bioinfo.genotoul.fr/multalin/multalin.html). All sequenced clones contained intact 
reading frames in fusion with the GAL4-activation domain. 
 
Verification of the C-C7-dynactin-1 interaction 
The carboxyterminal part of dynactin-1-p150
glued
 was RT-PCR cloned from human 
glioblastoma cDNA using primers attB1-dyn 2532 (5’-AAA AAG CAG GCT TCA CCA TGG CAG 
CTG CTG CTG CC-3’, sense) and attB2-dyn 3837 (AGA AAG CTG GGT GTT AGG AGA TGA 
GGC GAC TGT G-3’, antisense). attB1 and attB2 sites were extended in a second PCR and 
products were cloned via pDONR201 in p3xflg-CMV (Invitrogen) to generate p3xflg-CMV-
dyn 2532-3837. Plasmid was transfected into COS1 cells in eight-well glass slides (Lab-
Tek™ Chamber Slide™ System, Nunc, Roskilde, Denmark). Forty-eight hours later, cells 
were fixed with acetone and incubated with nanobody C-C7 for 1 hr, followed by 
sequential incubations with mouse anti-VSV and goat-anti-mouse FITC (Invitrogen, 
Carlsbad, CA). After washing, slides were stained with rabbit-anti-dynactin-1 which was 
detected with donkey-anti-rabbit TRITC (Invitrogen, Carlsbad, CA). Images were processed 
on a Leica Discovery Fluorescence Microscope and a Leica confocal microscope. Image 
processing was performed with Leica software. 
 
RT-PCR 
To examine levels of the dynactin-1 p150
glued
 transcript or its splice variant p135
glued
, PCR 
was performed with Phusion DNA polymerase (Bioké, Leiden, The Netherlands) with 
primer pairs dyn-801fw (ATGGCACAGAGCAAGAG)/dyn-1421rev (GACTGCTCCAGGAGAGG) 
(detecting p150) or the exon 6A specific primer dyn6Afw (ATGATGAGACAGGCACC)/dyn-
1421rev (detecting p135) yielding PCR products of 620 and 280 bp respectively. RT-PCR for 
β-actin served as housekeeping gene control. Conditions were as follows 94
o
C, 10sec; 
58
o
C, 30 sec; 72
o
C 60 sec for 30 or 35 cycles. 
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Results 
 
In vivo selection of tumor vessel binding phages in cerebral E98 xenografts 
A nanobody-displaying phage library
201
 was intravenously injected in mice carrying 
intracerebral E98 xenografts and irrelevant phages were removed from the circulation by 
cardiac perfusion. Already after the first round of biopanning, anti-M13 immunostainings 
demonstrated a surprisingly tumor-specific vessel localization of phages (compare anti-
M13 with anti-CD31 immunostaining in Figure 1A and 1B respectively). After collection of 
tumor areas from brain sections by laser capture dissection microscopy and subsequent 
trypsin treatment, a total of 453 colony-forming phages was rescued of which 192 clones 
were randomly picked and analysed for full length nanobody expression and diversity. Dot 
blot analysis revealed that 95% of clones expressed nanobodies and restriction enzyme 
finger print analysis resulted in five different restriction patterns (not shown). Due to the 
small variation on the nucleotide level between nanobodies, sequence differences within 
these groups may still be expected. Therefore, we arbitrarily chose to analyze from each 
group the 30% of clones with highest nanobody expression levels.  
 
 
 
 
 
Immunohistochemistry 
Immunohistochemical stainings were performed on sections of intracerebral E98 
xenografts to select for nanobodies which specifically recognize tumor vessels. Because 
evaluation of vessel staining requires optimal morphology, we chose to perform 
immunostainings on sections of formalin-fixed, paraffin-embedded  tissues and accepted 
Figure 1. Phage distribution in orthotopic glioma xenografts after in vivo biopanning. Procedures are 
described in Materials and Methods. After sacrifice, brains were removed and serial frozen sections of E98 
glioma xenografts were analyzed for phage distribution by anti-M13 (A) or anti-CD31 (B) immunostaining. 
Note that phages are clearly more associated with tumor vasculature than normal vessels. N=normal, 
T=tumor 
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that potentially interesting nanobodies (recognizing conformational epitopes that are 
disrupted during formalin fixation) were lost during analyses. Positive staining of tumor 
vessels was observed with 27 of the 39 analysed nanobodies of which 10 also recognized 
unaffected mouse brain vessels. The remaining 17 stained subsets of tumor vessels (not 
shown). Of these, C-C7 showed most prominent staining of tumor vasculature in E98 
xenografts and was analyzed in more detail. As illustrated in Figure 2, C-C7 stained both 
small and medium sized tumor vessels in the diffuse infiltrative component (Fig. 2A), but 
also the (neo)vasculature in the compact tumor areas (not shown). Interestingly, not all 
tumor associated vessels were recognized (compare the C-C7 staining patterns with the 
anti-CD34 staining of serial sections in the inset in Fig. 2A). Nanobody C-C7 did not stain 
normal vasculature in mouse brain (Fig. 2B), heart, kidney, liver, lung and spleen (not 
shown). The observation that C-C7 stained only a subset of tumor vessels prompted us to 
further characterize C-C7 by immunohistochemistry in other mouse tumor models.  
 
 
  
Whereas the nanobody showed prominent staining of the vasculature in angiogenic brain 
metastases of the human melanoma cell line Mel57-VEGF165
77
 (Fig 2C), intracerebral 
Figure 2. Immunohistochemical analysis of nanobody C-C7 reactivity in cerebral E98 xenografts (A), 
unaffected mouse brain parenchyma (B), a brain metastasis of Mel57-VEGF165 melanoma (C) and a cerebral 
U87 xenograft (D).  C-C7 recognizes subsets of tumor vessels in both diffuse infiltrative E98 tumor, while 
normal mouse brain vessels and the vasculature of intracerebral U87 glioma are negative. Insets in A, B and 
D show CD34 immunostainings of serial sections. N=normal, T=tumor, V=vessel. 
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mouse xenografts of the human glioma cell line U87 did not show any staining (Fig. 2D, 
the inset in this panel shows a CD34 vascular staining). To examine whether or not 
vascular expression of the C-C7 target is restricted to brain tumors, we also 
immunostained subcutaneous xenografts of glioma (U87 and E98), melanoma (Mel57-
VEGF165) and colon carcinoma (C26 and C38
244
). Consistent with the absence of C-C7 
immunoreactivity in intracerebral U87 tumors, vessels in subcutaneous U87 xenografts 
were negative (not shown). The vasculature of subcutaneous Mel57-VEGF165, E98, C26 and 
C38 xenografts did show expression of the C-C7 ligand (not shown). These data illustrate 
that reactivity towards C-C7 is not limited to blood vessels in brain tumors.  
To investigate whether nanobody C-C7 might have clinical relevance, we proceeded by 
staining a number of clinical samples of grade II and grade IV astrocytomas as well as 
unaffected human brain with this nanobody. A subset of tumor vessels in GBMs (see 
representative example in Fig. 3A) and one low grade glioma (Fig. 3B) was recognized. We 
could not detect C-C7 reactivity in the other low grade glioma (Fig. 3C), nor did C-C7 stain 
normal human brain vessels (Fig. 3D). 
 
 
 
 
Figure 3.  C-C7 also recognizes human tumor blood vessels. Shown are immunostaining with nanobody C-C7 
of human GBM (A), low grade glioma (B,C) and normal brain (D). Subsets of vessels are strongly positive for 
C-C7 (A-B), while C-C7 reactivity is absent in the vasculature of a low grade glioma (C) and normal brain 
endothelium (D).  
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C-C7 can be used as TVTA 
To confirm the ability of C-C7 to target tumor vasculature, we injected monoclonal phages 
displaying C-C7 in mice carrying orthotopic E98 xenografts, using the in vivo biopanning 
protocol which was used for its selection. Figure 4 shows that phages displaying C-C7 
accumulate in subsets of vessels in E98 xenografts, but not in normal brain blood vessels 
(compare the phage localization in Fig. 4A with the anti-CD31 staining of a serial section in 
Fig. 4B). Control phages did not show such specific tumor vessel localization (not shown). 
 
 
 
 
 
C-C7 recognizes an endothelial protein of 150 kDa 
To identify the C-C7 ligand, we first prepared western blots of RIPA extracts of the rat 
brain endothelial cell line GP8.
246
 Staining of these blots with C-C7 (Figure 5A, lane 3), but 
not irrelevant nanobodies (lanes 1 and 2) revealed that it recognized a protein of 
approximately 150 kDa. Attempts to immunoprecipitate the ligand for standard proteomic 
analysis were unsuccessful, possibly due to a relatively low number of C-C7 binding sites in 
cultured endothelial cells and tumor extracts. 
 
C-C7 recogizes the carboxyterminal domain of dynactin-1-p150
glued
  
To unravel the identity of its interacting ligand, we used C-C7 as bait in a Y2H screen 
against an expression library of bovine retina, using histidine (HIS3), adenine and β-
galactosidase (LacZ) as reporter genes.
245
 Six positive interactors were identified. 
Sequence analysis and blast searches revealed that 3 of these represented the 
carboxyterminal part of the p150
glued
 subunit of dynactin-1. Clones 21 and 26 were 
Figure 4. In vivo targeting of phages displaying C-C7 to cerebral E98 xenografts. Monoclonal C-C7 phages 
were injected in mice with orthotopic E98 xenografts and phage distribution analyzed by M13 staining after 
cardiac perfusion. (A) Frozen brain sections stained for M13 phages. Phages displaying C-C7 home to a 
subset of tumor vessels in E98 xenografts, but not to normal brain vessels, as evidenced by the anti-CD31 
immunostaining on a serial section (B).  
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composed of the carboxyterminal 432 amino acids of dynactin-1 (aa 808-1240) and 
included 150 nucleotides of the 3’-untranslated region, while another one, clone 22, 
spanned aa 890-1238 of the bovine sequence (Figure 5B). A comparison of bovine 
dynactin-1-p150
glued
  with the human homologue revealed 96% sequence identity in this 
region.  
 
 
  
 
To validate p150
glued
 as the C-C7 target, we proceeded by staining E98 tumor xenografts 
and clinical glioma samples with a commercially available anti-human dynactin-1-p150
glued
 
antibody. In all tumors examined, this antibody gave a similar staining profile as nanobody 
C-C7 (see figure 6 for a representative example of staining with anti-dynactin (A) and C-C7 
(B). 
Figure 5. Identification of dynactin-1 p150glued as the C-C7 ligand. A) Western blot analysis of GP8 cell extract 
with C-C7. Nanobody C-C7 (lane 3) but not two irrelevant single domain antibodies (lanes 1 and 2)  
recognizes an endothelial protein of approximately 150 kDa (arrow). B) Structural domains in p150glued and 
recognized domains of C-C7. The aminoterminal domains contain a CAP-Gly domain and and a coiled-coil 
domain which are responsible for microtubule (MT) binding and dynein binding (DIC=dynein intermediate 
chain). A second coiled-coil domain, encompassing a binding site for Arp1, is present in the carboxyterminal 
part of the protein and mediates binding to membrane components. 
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To further confirm the interaction between C-C7 and human dynactin-1-p150
glued
, the 
region encompassing aa 816-1278 (human numbering) was RT-PCR-cloned from human 
glioblastoma tissue and transiently expressed in COS-1 cells. Confocal microscopy of 
transfected cells, costained with C-C7 (visualized using FITC) and anti-dynactin-1 
(visualized using TRITC) showed that both antibodies co-localized to cytoplasmic vesicular 
structures (Fig. 7).  
 
 
  
 
Expression of dynactin-1-p150
glued
 in tumors and tissues is not ubiquitous 
Dynactin-p150
glued
 has been proposed to function in microtubule-guided transport of 
vesicles,
247
 organization of microtubule-organizing centres during mitosis,
248
 establishment 
of gap junctions
249
 and has been proposed to be involved in organization of Weibel-Palade 
bodies in endothelial cells
250
 and disruption of the endothelial barrier and vessel 
Figure 7. Immunolocalization of  the carboxyterminal domain of dynactin-1-p150glued in transfected COS-1 
cells, as illustrated by costaining with C-C7 (green) and  commercial anti-dynactin (red). Cells were 
transiently transfected with p3xflg-CMV-dyn-2532-3837 and analysed two days later with a confocal 
microscope. Both antibodies colocalize as shown in the merged figure. 
Figure 6. Comparative immunohistochemistry with a commercial anti-dynactin-1-p150glued antibody (A) and 
C-C7 (B) on serial sections of a high grade glioma. Note that both antibodies react similarly in these tissues. 
Control stainings were negative (not shown). 
 Ch a p t e r  6  
 
Dynactin-p150glued as a novel tumor vessel marker 109 
 
leakage.
251
 The functional involvement in such basic cellular processes suggests possibly 
ubiquitous expression patterns which appears to be not concordant with the tumor-vessel 
specific immunostaining profiles which we observed. Therefore, we performed RT-PCR for 
p150
glued
 and its recently described splice variant p135
glued252
 in a set of normal tissues and 
tumors. Consistent with previous reports, we found detectable expression levels in a 30-
cycle PCR of both p150 and p135 transcripts in brain,
253
 whereas in other normal tissues 
expression was negligible (not shown). Low expression levels of p150
glued
, which required 
35 PCR cycles to be detected, were found in ovary, thyroid gland, kidney, lung, uterus, and 
liver (Figure 8). Except for brain, p135 was not detected in normal tissues. Low but 
detectable levels of p150
glued
 expression were observed in 2/4 astrocytomas, 8/10 
adenocarcinomas and 3/3 renal cell carcinomas. p135 was observed in only one 
glioblastoma. 
 
 
 
 
 
 
 
 
 
These results show that, under normal conditions, the p135 and p150 proteins are not 
ubiquitously expressed and confirm our immunohistochemical stainings with C-C7 and 
other anti-p150
glued 
antibodies. We attribute the low expression levels in tumors to the 
relatively limited number of endothelial cells in tumors. 
 
Figure 8. p150 and p135 expression in tumors and normal tissues. Most prominent expression is found in 
brain, probably neurons. Thirty-five cycles of PCR were needed to detect p150glued  in other normal tissues 
and tumors. 
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Discussion 
 
In human tumors the vasculature is in general highly heterogeneous with vessels in 
different stages of maturation or, in vessel dense tissues, co-opted vessels.
75,223
 Prototype 
tumors with heterogeneous vasculature are high grade gliomas which partly grow by 
infiltration along pre-existent vessels or along white matter tracts, whereas areas with 
abundant angiogenesis are also present.
82
 The diffuse infiltrative growth of human gliomas 
and the intact blood brain barrier in these areas contribute to their poor response to 
conventional tumor therapies.
81,82
 In addition, it was previously demonstrated that in 
animal models of orthotopic GBM, such tumors do not adequately respond to anti-
angiogenic therapies because diffuse infiltrative progression does not strictly depend on 
angiogenesis
120,226
 a result which was recently corroborated in clinical studies.
123,236
 
Therefore, a combination of different vascular targeting strategies aimed at complete 
destruction of the tumor’s vascular bed is probably needed to effectively deprive these 
tumors from blood. However, the possibility for vascular targeting is at the moment 
restricted to vessels in early maturation stages and targeting agents that recognize more 
matured vessels are needed.  
Here we show that TVTAs can be effectively isolated by means of in vivo biopanning of 
nanobody phage display libraries in animal models of cancer. Furthermore, we show for 
the first time that nanobodies can be used as bait in Y2H screens to identify their 
interacting ligands. Since the library that we used in this work, a bovine retina expression 
library, may be considered less relevant for this purpose it is envisioned that in future 
studies, Y2H screens with human glioma prey libraries have an even higher chance on 
success. 
Our in vivo biopanning approach resulted in the isolation of a set of nanobodies of which 
44 percent specifically recognized tumor blood vessels, indicating tumor-specific 
enrichment in only one round of biopanning. Since we stained paraffin sections, this 
percentage is probably an underestimate because antibodies against conformational 
epitopes which are disrupted during formalin fixation, are not included. These results 
suggest that during the in vivo selection procedure, phages which bind to the surplus of 
common epitopes on quiescent endothelial cells in the circulation are competitively 
depleted. In vivo biopanning of phage display libraries therefore appears to be a relatively 
quick and efficient method to identify targeting nanobodies. 
In this study we concentrated on C-C7 because it proved to be the most suitable for 
immunostainings on formalin-fixed tissues. Since this nanobody also recognized tumor 
vessels in clinical samples of glioma, it may be a proper candidate for further development 
for human application. The framework of llama nanobodies is highly homologous to the 
human V-H III gene family
254
 reducing the need for extensive antibody humanization. 
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We found that C-C7 is directed against the carboxyterminus of dynactin-1-p150
glued
, a 
protein which is involved in vesicular trafficking along microtubules, mitotic spindle 
assembly and cell migration.
247,255
 There are several arguments which indicate that the 
identification of dynactin-1-p150
glued
 as the C-C7 ligand is not an artifact. First, different 
independent clones with overlapping dynactin-1 regions were identified in our yeast-two-
hybrid screen, and this protein was not picked up in screens with other nanobodies (not 
shown) indicating that it is not an aspecific abundant interactor. Secondly, C-C7 recognizes 
a protein of 150 kDa on a western blot of endothelial cell extracts which conforms to the 
molecular weight of dynactin-1-p150
glued
. Thirdly, C-C7 and a commercial antibody against 
dynactin-1 react similarly on mouse and human tumor tissues. Finally, C-C7 specifically 
stains COS-1 cells overexpressing the recombinant carboxyterminal domain of p150
glued 
and colocalizes with a validated commercial anti-p150 antibody in transfected cells. 
Interestingly, the immunolocalization of the transfected p150 fragment was similar to 
that, previously observed for the p150
glued
 G59S mutant
252
 which lacks microtubule 
binding activity. Indeed, this was expected as the microtubule-binding region is localized in 
the N-terminal part which was not included in our construct (see Figure 5B).  
The relevance and functional significance of expression of dynactin-1 by tumor endothelial 
cells is not known at this moment. Dynactin-1 is a membrane associated protein complex 
and interacts with dynein, a motor protein which is involved in vesicle trafficking from 
Golgi to endoplasmic reticulum. Vascular permeability, one of the most prominent effects 
brought about by VEGF,
78
 may involve the formation of transcellular membrane channels 
via directed fusion of vesiculo-vacuolar organelles (VVOs).
256
 Combined with reports on a 
functional role of p150
glued
 in regulating endothelial cell permeability,
251
  it is tempting to 
speculate that dynactin-1-p150
glued
 is involved in organization of vesicles into VVOs.  
Whatever its function, the subcellular localization of the dynactin-1 protein complex is 
expected to be cytoplasmic, which does not concur with the in vivo targeting properties of 
C-C7 phages. At this moment it is enigmatic which mechanisms are involved in establishing 
the extracellular localization of p150
glued
. This situation is not unique; unexpected 
membranous expression of other cytoplasmic proteins in tumors has been described 
previously.
257
 One example is tissue transglutaminase which is involved in establishing cell-
matrix interactions.
258
 Of interest, it has been described that microvesicles, released from 
endothelial progenitor cells, are integrated in cell membranes of activated endothelium.
259
 
As such microvessels are likely to be coated with dynactin, re-integration in the membrane 
may indeed result in an extracellular localization. These issues are under investigation.  
Levels of p150
glued
 transcripts were low in our series of tumors. We attribute this to 1) the 
low percentage of endothelial cells in tumors, and 2) heterogeneity of expression, since 
not all tumor vessels are recognized by C-C7. While in certain clinical and preclinical 
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tumors (glioblastoma and VEGF-expressing melanoma) all tumor vessels showed reactivity 
with C-C7, we also identified tumors (e.g. U87 xenografts) which were entirely negative.  
 Tissue- and tumor-specific heterogeneity of the vascular proteome is now widely 
recognized.
260
 A tumor specific vascular signature, composed of distinct surface proteins, 
can aid to design an appropriate mix of different and complementary TVTAs which in 
combination are able to target a significant proportion of tumor blood vessels. Nanobody 
C-C7 may be a good candidate to be included in such a TVTA-cocktail, once p150
glued
 
expression can be verified in individual tumors, e.g. in tumor biopsies. Technology 
platforms have been and still are being developed to use TVTAs to specifically deliver anti-
tumor drugs in high concentrations to the tumor. RGD-conjugated liposomes have been 
successfully used for delivery of dexamethasone to angiogenic endothelial cells.
261
 
Furthermore, targeting antibodies conjugated to soluble tissue factor, induce tumor-
specific blood clotting, tumor necrosis and growth delay.
129,262
 A chimeric nanobody 
against carcinoembryonic antigen (CEA) fused to β-lactamase accumulated in CEA-positive 
tumor xenografts and was successfully used as a therapeutic prodrug.
242
 Additional studies 
are needed to resolve whether similar conjugates of nanobodies against tumor 
vasculature are effective therapeutics. 
In conclusion, in vivo biopanning of phage nanobody-display libraries in animal models of 
cancer in combination with Y2H technology represents a powerful platform to identify 
novel TVTAs and their interacting ligands. We identified C-C7 as a targeting nanobody 
against dynactin-1-p150
glued
 and show that this protein is expressed on tumor vessels. 
Future studies should resolve whether C-C7 conjugates have anti-tumor effects. 
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Abstract 
 
Tumor vasculature is in general highly heterogeneous. This characteristic is most 
prominent in high grade gliomas which present with areas of angiogenic growth, next to 
large areas of diffuse infiltrative growth in which tumor cells thrive on pre-existent brain 
vasculature. This limits the effectiveness of anti-angiogenic compounds as these will not 
affect more matured and co-opted vessels. Therefore, additional destruction of existing 
tumor vasculature may be a promising alternative avenue to effectively deprive tumors 
from blood. This approach requires the identification of novel tumor vascular targeting 
agents which have broad tumor vessel specificities, i.e. are not restricted to newly formed 
vessels.  
Here we describe the generation of a phage library displaying nanobodies which were 
cloned from lymphocytes of a Llama which had been immunized with clinical glioma 
tissue. In vivo biopanning with this library in the orthotopic glioma xenograft models E98 
and E434 resulted in the selection of various nanobodies which specifically recognized 
glioma vessels in corresponding glioma xenografts. Of importance, also nanobodies were 
isolated which discriminated incorporated pre-existent vessels in highly infiltrative 
cerebral E434 xenografts from normal brain vessels. 
Our results suggest that generation of nanobody-displaying immune phage libraries and 
subsequent in vivo biopanning in appropriate animal models is a promising approach for 
identification of novel vascular targeting agents. 
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Introduction 
 
High grade gliomas (WHO grade IV astrocytomas, glioblastoma multiforme [GBM]) are 
aggressive primary brain tumors considered to be among the deadliest of human cancers. 
These tumors are generally characterized by a necrotic core, surrounded by an angiogenic 
rim.
82,83
 Importantly, these cancers always present also with large areas of diffuse 
infiltrative growth, in which tumor cells migrate along white matter tracts or blood 
vessels. This diffuse infiltrative phenotype strongly limits the effectiveness of surgery and 
radiotherapy. In addition, the blood-brain barrier in diffuse infiltrative areas is generally 
intact, contributing to the poor response of these tumors to chemotherapies.
79,81,82
  
The occurrence of angiogenesis in GBM has been rationale for extensive testing of 
angiogenesis inhibitors. However, a number of phase II studies have now revealed that, 
despite inducing a radiological response, these inhibitors do not prolong overall survival 
and allow disease progression,
95,123
 likely because diffuse infiltrative growth is 
angiogenesis-independent and provides a mechanism of escape from anti-angiogenic 
therapies.
79,95,96,118-121,123
  
The phenotypic differences which exist in GBM are reflected in the vasculature, which is 
highly heterogeneous.
223
 Vessels may be angiogenic as well as more mature or co-opted, 
and the latter ones may be unsusceptible to anti-angiogenic therapy.
117
 To bypass 
resistance to anti-angiogenic therapies, additional vascular targeting therapy in which the 
existing tumor vascular bed is attacked with the aim to acutely deprive tumors from blood 
supply may be an attractive option. So far, identified targets with specificity for tumor 
vasculature are restricted to vessels in early stages of maturation.
124,125,201
 Thus, there is a 
need for additional tumor vascular targeting agents which recognize tumor vessels in 
more mature stages. 
One technique which  allows for isolation of such targeting agents is biopanning, the 
procedure of contacting libraries of binding agents with epitopes of interest, and selecting 
and isolating those agents with significant affinity.
17
 In vivo biopannings with peptide 
phage display libraries have been successfully used to obtain organ-specific vascular 
targeting peptides in animal models.
18,19
 In addition, we previously provided proof of 
concept that via in vivo biopanning of phage antibody-display libraries in orthotopic E98 
glioma xenografts,
121,226
 antibodies can be isolated that recognize subsets of tumor vessels 
(submitted). In that work we used a nanobody phage display library, cloned from 
lymphocytes of an immune-naive Llama.
201
 Nanobodies are composed of the variable 
domains of cameloid heavy-chain antibodies which lack a light chain. Because these 
consist of a single polypeptide chain, nanobodies can be cloned and displayed in a phage 
context without significant loss of affinity compared to the originating heavy-chain 
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antibody, making them to an attractive class of compounds.
263
 Nanobodies against EGFR 
have already been successfully used for in vivo tumor targeting purposes.
242,243,264
 
By in vitro biopannings, we previously isolated from our immune-naive library, nanobodies 
Plexin D1 specific with affinities in the range of 10
-8
-10
-9 
M which suffice for immune 
stainings,
201
 but are possibly of too low affinity for effective in vivo applications. Matured 
nanobodies, cloned from immunized animals, will obviously have the advantage of higher 
affinity. Here we describe the construction of a phage library, displaying IgG2 and IgG3 
isotype specific nanobodies which were cloned from lymphocytes after immunization of a 
Llama glama with a homogenate of surgically obtained GBM. We performed in vivo 
biopanning of this phage library in the orthotopic glioma xenograft model E98 and the 
oligodendroglioma xenograft line E434. E98 was used because it displays angiogenic as 
well as co-optive growth,
121
 whereas E434 is a hallmark example of a xenograft which 
exclusively displays diffuse infiltrative growth with no apparent sprouting angiogenesis.
121
 
This approach resulted in the isolation of a number of tumor vessel recognizing 
nanobodies, also against non-angiogenic blood vessels in diffuse infiltrative tumor areas. 
 
 
Materials and Methods 
 
Llama immunization 
All animal experiments were approved by the Animal Experiment Committee of  
the Nijmegen University and informed consent was obtained from patients with newly 
diagnosed GBM who did not receive prior treatment for use of tumor material. A Llama 
glama was immunized with a homogenate of three surgically obtained clinical GBMs, after 
confirmation of absence of reactivity in preserum, as determined by 
immunohistochemical stainings on frozen sections of the same GBMs. GBMs were 
selected that showed only minimal necrosis, as was determined by H&E staining. A total of 
90 mg glioma tissue was homogenized in 2.5 ml sterile 0.9% NaCl solution. The 
homogenate was aliquoted in 500 µl portions and stored at -80°C. For primary 
immunization and boosts, 500 µl homogenate was mixed with 625 µl Stimune
TM
 adjuvant 
(Cedi Diagnostics, Lelystad, The Netherlands). This suspension was injected 
intramuscularly into a Llama. Boost immunizations were performed at day 28, 42, 70, 98 
days after the initial immunization. Serum and blood samples were isolated prior to each 
boost and 126 days after the first immunization. At each time point, leukocyte RNA was 
isolated using the LeukoLOCK
TM
 Total RNA Isolation System (Ambion, Austin, TX) according 
to the manufacturer’s protocol. In addition, to verify immune responses, 4 µm frozen 
clinical GBM sections were immunostained with the sera obtained at each time point, 
according to standard protocols. In short, tissues were pre-incubated with normal goat 
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serum to block non-specific binding sites, followed by overnight incubation at 4°C with 
Llama immune serum or pre-immune serum as control. Llama IgG was detected by 
incubation with horseradish peroxidase conjugated goat anti-Llama IgG antibody (Bethyl 
Laboratories Inc., ITK Diagnostics, Uithoorn, The Netherlands). Peroxidase was visualized 
by the 3-amino-9-ethylcarbazole (ScyTek, Logan, UT) peroxidase reaction and sections 
were counterstained with haematoxylin. 
 
Llama phage display library construction  
Llama nanobodies were RT-PCR cloned in phagemid pHENIX as follows. Total leukocyte 
RNA samples (2 μg) isolated on day 28 after the last boost were reverse-transcribed at 
42°C for 90 minutes using Moloney-mouse-leukemia virus reverse transcriptase (Promega, 
Leiden, The Netherlands). Subsequently, VHH antibody fragments were amplified by PCR 
using Phusion polymerase (Finnzymes, Bioké, Leiden, The Netherlands), forward primer 
FR1 (5’-GAG GTB CAR CTG CAG GAS TCY GG-3’) (PstI restriction site shown in bold italic) 
and hinge specific reverse primers LH49 (AAC AGT TAA GCT TCC GCT TGC GGC CGC TGG 
TTG TGG TTT TGG TGT CTT GGG-3’) and SH48 (5’-AAC AGT TAA GCT TCC GCT TGC GGC CGC 
GGA GCT GGG GTC TTC GCT GTG GTC CG-3’) (NotI restriction sites shown in bold) which 
assured separate amplification of IgG2- and IgG3-encoding VHH fragments respectively.
265
 
Amplified VHH products were agarose gel purified and digested with PstI (New England 
Biolabs, Westburg, Leusden, The Netherlands) and NotI (New England Biolabs). Fragments 
were ligated into pHENIX PstI-NotI vector using Quick Ligase (New England Biolabs). This 
results in VHH chimeras with a His8-VSV-G- tag at the C-terminus.
180
 The phagemid library 
was transformed in electrocompetent E. coli TG1 bacteria. Individual clones were picked 
and analyzed for the presence of full-length insert by standard colony PCR using forward 
primer pHEN-fw (5’-TCA CAC AGG AAA CAG CTA TGA-3’) and reverse primer pHEN-rev (5’-
GTA ACG ATC TAA AGT TTT GTC G-3’). Full-length insert ratio was determined after 
running PCR products on a 1.0% agarose gel.  
Phages were grown from this library by infection with the trypsin sensitive helper phage 
M13K07
181
 and purified from the culture supernatant by precipitation with 20% PEG-2.5 M 
NaCl as previously described.
182
  
 
In vivo selection of tumor vessel binding nanobodies via biopanning of phage display 
libraries 
To grow intracerebral E98 and E434 tumors Balb/c nude mice were transcranially injected 
with the glioblastoma xenograft line E98 (n=2) or the oligodendroglioma line E434 (n=2) 
essentially as previously described.
121
 In short, a mouse carrying a subcutaneous E98 
tumor and one carrying a cerebral E434 xenograft were killed. The tumors were sterile 
removed, minced to small pieces and filtered through a 70 µm mesh nylon filter. The 
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resulting single cell suspensions were subsequently injected through the skull of nude 
mice under deep anesthesia. After respectively 3 and 7 weeks, when mice carrying E98 
and E434 xenografts displayed signs of tumor growth (discomfort, weight loss and 
neurological symptoms), in vivo biopanning was performed as follows: 10
12
 GBM 
nanobody-phages were intravenously injected. Nanobody-displaying phages were allowed 
to circulate and bind to their targets for 15 minutes. Subsequently, mice were 
anaesthetized using 1.3% isoflurane/N2O/O2 and cardiac perfusion was performed with 15 
ml sterile 0.9% NaCl solution to remove unbound phages from the circulation. Mice were 
then sacrificed by decapitation and brains were collected. A small part was formalin-fixed 
and paraffin-embedded, the remainder was snap frozen in liquid nitrogen. Paraffin-
embedded sections (4 µm) were stained with anti-M13 p8 antibody (Abcam Limited, 
Cambridge, UK) to investigate phage distribution in the tumor. In case of E98, tumor areas 
were dissected from 16 frozen brain sections (10 µm) using a laser dissection microscope 
(Leica AS LMD, Wetzlar, Germany), whereas excessive unaffected brain parenchyma was 
scratched manually from 18 frozen E434 brain sections (30 µm). The remaining E434 
tumor areas were collected in a tube. Phages were eluted from the obtained tumor areas 
by trypsin treatment (10 mg/ml, 30 min RT) and infected in 10 ml of log-phase TG1 
culture.  
Ninety-four randomly selected individual clones were picked and analyzed for the 
presence of full-length insert as described above. To prevent analysis of duplicate clones, 
fingerprint analysis was performed by digesting full-length PCR products with the four-
cutter enzymes BstNI and BstU1 followed by electrophoresis on 4% nusive agarose gels. In 
addition, these clones were used for small scale IPTG-induced nanobody production by 
overnight induction with 1 mM IPTG. Nanobody expression levels in the culture 
supernatant were determined via dotblot analysis  using the mouse monoclonal anti-VSV-
G P5D4 and alkaline phosphatase-conjugated rabbit anti-mouse immunoglobulin (Dako, 
Glostrup, Denmark). Alkaline phosphatase was visualized using nitro blue tetrazolium 
(NBT; Roche, Almere, The Netherlands) and 5-bromo-4-chloro-3-indolyl phosphate (BCIP; 
Roche) as substrate. Based on the collective data, clones were selected for further analysis 
by immunohistochemistry. High level expression of soluble nanobodies was induced in 
log-phase TG1 cells by culturing at 30
o
C in 2xTYA/1 mM IPTG. Nanobodies were collected 
by osmotic lysis as described.
201
  
 
Immunohistochemistry 
Soluble nanobodies, obtained via osmotic lysis of TG1 cells, were tested in 
immunostainings on 4 μm sections of paraffin-embedded cerebral mouse xenografts (E98 
or E434). Following deparaffinization, endogenous peroxidase activity was blocked by 
incubation with 3% H2O2. Antigen retrieval was performed by boiling in 10 mM citrate 
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buffer for 10 minutes, using a microwave oven set at 180 Watt. Slides were pre-incubated 
with normal goat serum to block non-specific binding sites, followed by overnight 
incubation with nanobodies at 4°C. Subsequently, detection was performed by the 
following incubations at room temperature: 1 hr rabbit anti-VSV-G antiserum (Sigma-
Aldrich, Zwijndrecht, The Netherlands), 30 minutes biotinylated anti-rabbit antibody 
(Vector, Burlingame, CA), and 45 minutes avidin-biotin peroxidase complex  (Vector). 
Finally, visualization was performed by the 3-amino-9-ethylcarbazole (ScyTek) peroxidase 
reaction with haematoxylin as counterstain.  
 
 
Results 
 
Immunohistochemical evaluation of Llama immune response 
Sera obtained at five different time points after initial immunization of a Llama with a 
homogenate of clinical GBM tissues were tested on the same GBM tissues used for 
immunization. Whereas preserum was completely negative, after each immunization 
boost increasing immunoreactivity was seen on tumor cells and extracellular matrix 
components of the GBMs with optimal responses after the fourth boost (not shown). 
Therefore, leukocyte RNA isolated after this boost immunization, was used for generation 
of a nanobody phage display library. The combined IgG2 and IgG3 nanobody library had a 
size of 10
7
 clones of which 88 percent contained a full length insert (data not shown).  
 
In vivo selection of tumor vessel binding phages in cerebral E98 and E434 mouse 
xenografts 
A suspension of 10
12
 phages was intravenously injected in tumor-bearing mice for in vivo 
biopanning and irrelevant phages were washed from the circulation by cardiac perfusion, 
after allowing relevant phages to bind for a period of 10 minutes. Figure 1 shows anti-M13 
immunostainings on intracerebral E98 (a) and E434 (b) xenografts. These stainings show a 
prominent tumor vessel localization of phages (arrowheads in figure 1a and 1b). We 
observed almost no phages associated with normal brain vessels (compare the phage 
localizations with the anti-CD34 staining of serial sections of E98 and E434 xenografts in 
Fig. 1c and d respectively). The arrows in figure 1c and 1d point at vessels which are not 
highlighted by anti-M13 staining. Approximately 2800 and 3400 colony-forming phages 
were rescued from tumor sections from mice carrying E98 and E434 xenografts 
respectively. From the phage populations which were rescued from each xenograft, 94 
individual clones were randomly picked for fingerprint analysis and nanobody production. 
Remaining colonies were collected and pooled and stored as sub-libraries for future 
rounds of in vivo biopanning. Fingerprint analyses identified 20 and 15 distinct groups of 
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nanobodies, binding to E98 and E434 vasculature, respectively (Table 1). From each group, 
one clone was selected for nanobody production and immunohistochemical analysis on 
sections of the corresponding glioma xenografts.  
 
 
 
 
Immunohistochemistry  
Because evaluation of vessel staining requires optimal morphology, we performed 
immunostainings with nanobodies on paraffin-embedded sections of cerebral E98 or E434 
mouse xenografts. We accepted here that potentially interesting nanobodies, reactive 
against epitopes which are lost during fixation, were lost during analyses. Of the 20 
nanobodies which were rescued from the E98 biopanning experiments, 15 (75%) showed 
positive staining of subsets of tumor vessels in E98 xenografts. Figure 2 shows 
Figure 1. Phage distribution in cerebral glioma xenografts after in vivo biopanning of an immune Llama 
phage  library. Paraffin-embedded sections of E98 (a) and E434 (b) xenografts were analyzed for phage 
localization by M13 immunostainings. As evidenced by anti-CD34 immunostainings on serial sections of E98 
(c) and E434 (d) xenografts phages are clearly associated with the tumor vasculature (arrowheads in figure 
1a and 1b), whereas vessels in unaffected brain parenchyma are not highlighted by anti-M13 staining 
(arrows in figure 1c and 1d). Note the CD34 up-regulation on tumor-associated endothelial cells compared 
to normal brain capillaries (c and d).  
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representative immunostainings with clones obtained from group A (a) and D (b). 
Similarly, 8 of the 15 nanobodies (53%), isolated from in vivo biopanning on E434 
xenografts, stained positive on E434 vasculature (Fig. 2c and d for clones obtained from 
group IX and VIII respectively). As shown in the insets in figure 2 these nanobodies did not 
stain vessels in unaffected brain areas. 
 
   Table 1. Percentage E98 and E434 vessel binding clones per  
   restriction pattern of full length PCR products  
Glioma 
xenograft model 
Restriction 
pattern 
% Clones with 
restriction pattern 
E98 
A 28% 
B 5% 
C 2% 
D 5% 
E 5% 
F 3% 
G 2% 
H 2% 
I 3% 
J 13% 
K 11% 
L 2% 
M 2% 
N 3% 
O 3% 
P 3% 
Q 2% 
R 2% 
S 2% 
T 3% 
434 
I 2% 
II 12% 
III 4% 
IV 14% 
V 22% 
VI 8% 
VII 8% 
VIII 2% 
IX 8% 
X 8% 
XI 2% 
XII 2% 
XIII 2% 
XIV 2% 
XV 2% 
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Discussion 
 
The diffusely infiltrative growth of human gliomas and the predominantly intact blood 
brain barrier in these areas contribute to the poor response of human gliomas to 
conventional tumor therapies
81,82,118
 and at the same time allow escape from anti-
angiogenic therapy.
76,78,95,96,118-121,123
 Although gliomas are certainly at the extreme end of 
a spectrum with respect to infiltrative growth, it was recently shown that targeting of the 
angiogenic pathway also in subcutaneous xenografts leads to enhanced invasive growth 
and metastases.
266,267
 Such adverse effects are not expected to occur when directing  
therapy against the existing tumor vasculature. So far, tumor vascular targeting has 
focused on markers which are specifically expressed on newly formed vessels, among 
others the ED-B domain of fibronectin, VCAM-1 and αvβ3 integrin. Targeting of newly 
Figure 2. Immunohistochemical analysis of the reactivity of selected nanobodies in glioma xenografts.  
Clones obtained from group A (a) and D (b) are representative for nanobodies which specifically recognized 
subsets of glioma vessels in immunostainings on paraffin-embedded sections of E98 xenografts. Nanobodies 
produced by clones from group IX (c) and VIII (d) demonstrate representative immunoreactivity on E434 
vasculature. Note the absence of immunoreactivity on vessels in unaffected brain areas (insets).  
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formed vessels with agents directed against such molecules has already been shown to 
result in potent anti-tumor effects in preclinical models of subcutaneous xenografts.
126-129
 
However, these results can not be translated directly to clinically relevant situations: in 
subcutaneous xenografts the vasculature is more or less synchronized and will be 
homogeneously susceptible to targeting of angiogenic vessels. In contrast, the vasculature 
of clinical tumors is composed of a heterogeneous population of vessels
223
 which requires 
that clinically relevant anti-vascular therapies combine targeting of newly formed vessels 
with targeting of more mature or co-opted vessels.  
The E434 orthotopic glioma model is an extreme example of an angiogenesis-independent 
tumor which grows exclusively via incorporation of pre-existent brain vessels, as 
evidenced by their positivity for glucose transporter-1, which is expressed on brain 
endothelium with a functional blood-brain barrier.
121
 Despite a lack of sprouting 
angiogenesis in these tumors, the vasculature is activated as exemplified by more 
prominent staining for the vessel marker CD34.
121
 In addition, our data show that these 
vessels display specific proteins which are distinct from those expressed on normal 
vessels, and that these differences in proteome can be used for targeting purposes. The 
concept of therapeutic targeting of incorporated pre-existent tumor vasculature is 
probably applicable to all tumors which grow in vessel dense tissues and which may 
progress via co-option. Obviously, especially in brain tumors, therapy directed against 
incorporated pre-existent vessels carries a particular risk of toxicity due to micro-
infarctions which may have effects beyond the tumor. So, this requires thorough 
examination in relevant tumor models. In other tissues this issue may be less relevant as 
some anoxic tissue necrosis may be tolerable, as long as a proper inflammation response 
can be induced that cleans up the necrotic debris. 
In accordance with previous in vivo biopanning experiments in mice carrying cerebral E98 
xenografts in our lab in which we used an immune-naive nanobody phage display library 
(submitted) we ended up with nanobodies that specifically reacted with tumor vessels of 
corresponding cerebral glioma xenografts after only one round of biopanning. We propose 
that using this in vivo biopanning protocol, phages against common endothelial surface 
proteins are depleted from the circulation by the excess of normal mouse endothelium. 
Importantly, following the same in vivo biopanning procedure we rescued six times more 
interacting phages from E98 xenografts using our immune Llama phage library compared 
to the immune-naive Llama phage library. This suggests that, as expected, nanobodies 
against tumor vessel epitopes are more represented in our immune library than in the 
immune-naive library. In addition, although in vivo biopanning in mouse glioma models 
resulted in the isolation of nanobodies against mouse endothelium, it is reasonable to 
assume that they also recognize their human counterparts since they are derived from a 
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Llama after immunization with clinical GBM tissues. Preliminary immunostainings on 
clinical GBM indeed suggests that this is the case. 
The aim of the present work was to select nanobodies which can be further developed 
into tumor vessel targeting agents. Identification of the ligands which are recognized by 
our nanobodies is ongoing in our lab.   
In conclusion, we showed that triggering the immune system of a Llama with a 
homogenate of clinical GBM tissues provoked an immune response against all 
components present in these tissues. Our phage library displaying nanobodies which were 
cloned from lymphocytes of this Llama is a potential source of targeting agents against 
different glioma components. Importantly, in vivo biopanning using this phage library in 
well characterized mouse glioma models led to selection of various tumor vessel 
recognizing nanobodies, among them ones which discriminated incorporated pre-existent 
vessels from normal brain vessels. Overall, construction of nanobody-displaying immune 
phage libraries and subsequent in vivo biopanning in appropriate animal models is a very 
promising approach for future identification of novel molecular tools for targeting vascular 
beds. 
  127 
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In recent years targeted tumor therapies which aim at the interaction with tumor cell-
specific molecular targets have made a firm entry in oncology practice. Unfortunately, 
such therapies appear beneficial for only subsets of cancer patients and the ultimate goal 
of these therapies, which obviously is cure, is very seldomly, if  ever, achieved. Targeting 
the genetically stable tumor endothelium, which is well accessible after intravenous 
injection of agents is an attractive alternative approach to accomplish tumor regression 
via disruption of the tumor’s blood supply. Targeting tumor blood vessels may be 
accomplished by anti-angiogenesis, which prevents formation of new vasculature, or anti-
vascular therapies, which aim at acute regression of existent tumor vasculature. Despite 
promising results in preclinical studies in which anti-angiogenic therapy translates into 
potent anti-tumor effects, implementation of these therapies in clinical settings has 
learned that beneficial effects in the patient are less pronounced. Therefore, adjuvant 
anti-vascular therapy, targeting the existing vascular bed with the aim to induce tumor-
specific coagulation, seems to be an attractive approach to deprive a tumor from blood 
supply. 
This thesis focused on the identification of novel vascular targeting agents directed against 
tumor endothelium, in particular brain tumor vasculature, and the expression patterns of 
their targets in (clinical) tumor samples. In addition, a powerful platform for the 
identification of novel targetable tumor vessel associated markers is presented.  
 
Vascular heterogeneity  
As described in chapter 2 various primary and metastatic clinical brain tumors present 
with different vascular phenotypes. These differences can be explained by a model which 
incorporates both isoform specific vascular effects and the trigger for VEGF-A expression. 
The VEGF-A165 and 189 isoforms are capable of inducing a true angiogenic response.
77,78
 
However, due to their strong cell surface and extracellular matrix binding they only exert 
effect on vessels in the direct neighborhood of the VEGF-A secreting cells. Therefore, in 
tumors with constitutive VEGF-A expression all isoforms are able to exert their effects on 
nearby vessels, resulting in a classical angiogenic phenotype. In contrast, in tumors where 
only central parts express hypoxia-induced VEGF-A, the larger isoforms are retained by 
extracellular matrix, leaving only freely diffusible VEGF-A121 which is not able to induce a 
neovascular bed but rather modulates and dilates pre-existent vessels.
77,78
 This results in a 
phenotypically different vasculature, despite the expression of truely angiogenic VEGF-A 
isoforms. We previously demonstrated in a mouse brain metastasis model of human 
melanoma that tumor cells are able to thrive in the presence of pre-existing brain 
vasculature without becoming hypoxic by infiltrating the brain parenchyma in the 
perivascular space.
76
 Similarly, clinical low grade gliomas are able to grow by means of 
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infiltration and incorporation of pre-existing blood vessels without the need for 
angiogenesis (chapter 2).  
 
Vascular targeting 
Thus, tumors obtain their blood supply by the formation of new vasculature and/or by the 
incorporation, and possibly subsequent modulation, of pre-existent vessels. As a 
consequence, tumor vasculature is generally highly heterogeneous, not only between 
tumor types but even within individual tumors.
225,230,268
 This vascular heterogeneity has 
clinical implications for anti-tumor therapies which aim at interference with a tumor’s 
blood supply. Since VEGF-A-targeting results in inhibition of only the early stages of 
angiogenesis, vessels in more matured stages are not affected
73
 and this may in part 
explain the limited clinical effects of such therapies. With this in mind, additional vascular 
targeting therapy in which the existing tumor vascular bed is attacked with the aim to 
induce acute coagulation seems to be an attractive approach to effectively deprive tumors 
from blood supply. Clearly, this approach requires the availability of specific tumor 
vascular targeting agents that recognize the entire heterogeneous tumor vasculature. 
However, currently available tumor vessel targeting agents are directed against molecules 
of which expression is restricted to vessels in early stages of angiogenesis, leaving 
incorporated or more matured tumor vasculature unaffected. In addition, since we can 
rule out the possibility that one single marker will behave as a targetable pan-tumor-
endothelial antigen there is a need for appropriate mixtures of different tumor vessel 
targeting agents that, in combination,  specifically target a tumor’s vascular bed.  
 
Tumor vessel targeting agents (TVTAs) 
As demonstrated in chapter 3 we identified Plexin D1 as a tumor vascular target. Plexin D1 
is a member of the Plexin-family consisting of large transmembrane proteins that are 
receptors for Neuropilins and Semaphorins
170,197
 and as such are involved in regulation of 
axonal patterning during embryonic development.
171,173,184,198
 Apart from its expression by 
neuronal cells, Plexin D1 is also expressed by vascular endothelial cells during 
embryogenesis
174
 and is of pivotal importance for vascular patterning, as illustrated by the 
fact that  Plexin D1 knock-down in mice and zebrafish results in maldevelopment of the 
cardiovascular system.
175,176,227
 Via panning of an immune naive Llama phage display 
library against a Plexin D1-specific peptide we isolated nanobodies against Plexin D1 and 
showed that expression of Plexin D1 is also prominent during tumor-associated 
angiogenesis. Furthermore we demonstrated that these nanobodies were able to 
specifically target tumor blood vessels in mice carrying brain lesions of angiogenic 
melanoma. Although Plexin D1 is expressed during developmental and tumor-associated 
angiogenesis, in malignant tissues its expression is not restricted to vessels in early 
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maturation stages. This membrane protein is also abundantly expressed on a subset of 
established activated tumor vessels and tumor cells of both primary and metastatic clinical 
brain tumors (chapter 3). Whereas a role of Plexin D1 in vessel patterning during 
development is well established, the functional consequences of Plexin D1 expression on 
tumor cells and vessels are less clear. As described in chapter 4 we demonstrated that 
Plexin D1 expression by tumor cells is correlated with tumor invasion and metastasis in a 
human melanoma progression series. Nevertheless, the Neuropilin-independent ligands of 
Plexin D1, Semaphorin 3E and 4A inhibit, rather than promote, (tumor) angiogenesis 
(chapter 4).
202
 Moreover, Semaphorin 3E even exhibits anti-tumor and anti-metastatic 
properties,
229
 whereas overexpression of Semaphorin 3C, which binds with high affinity to 
a Neuropilin-1/Plexin D1 complex, does not affect tumor angiogenesis and metastasis 
(chapter 4). However, the presence of consensus motifs for Rac-Rho signaling in the 
intracellular domain of Plexin D1
174
 is consistent with a possible regulatory role in cellular 
migration and invasion. These processes are fundamental in both angiogenesis and tumor 
metastasis, indeed suggesting that Plexin D1 may be functionally involved in tumor 
development in multiple ways. Irrespective of a potential function in tumor biology, we 
show in chapter 5 that Plexin D1 is a pan-tumor target due to its abundant expression on 
both angiogenic and activated co-opted tumor vasculature, as well as on tumor cells in a 
wide range of clinical solid tumors of different origin. This expression profile suggests that 
Plexin D1 may be a valuable tumor target for established solid tumors in which vessel 
activation has occurred, allowing simultaneous targeting of different tumor 
compartments, i.e. vessels and tumor cells. Importantly, non-tumor related tissues lack 
Plexin D1 expression, except for some expression by subsets of fibroblasts and 
macrophages (chapter 4 and 5). The effects of targeting of these stromal cells are 
currently not known and should be thoroughly investigated. It should also be realized that 
Plexin D1 expression is absent in a subset of matured tumor vessels and quiescent tumor-
associated endothelium (chapter 4 and 5) and will therefore probably not suffice for 
effective therapy as single agent.  
Therefore, in order to identify additional TVTAs we performed in vivo biopanning 
experiments using phage display libraries in orthotopic mouse xenograft models of glioma 
which display vessel heterogeneity, similar to human tumors.
121
 As described in chapter 6 
we identified nanobody C-C7 as a specific TVTA by in vivo biopanning of an immune naive 
Llama phage display library in mice carrying E98 glioma xenografts.
121
 Nanobody C-C7 
specifically recognizes a target on a subpopulation of activated tumor vessels and also in 
clinical glioma specimens. Unfortunately, expression of the C-C7 target is less prominent in 
quiescent tumor vessels. To identify the target of C-C7, this nanobody was introduced in a 
yeast-two-hybrid system as a GAL4-DNA binding domain-fused bait and screened against a 
GAL4-activation domain-bovine retina expression prey library. From this screen the C-C7 
Ch a p t e r  8   
 
134 Summarizing discussion and future perspectives 
 
target was identified as the p150
glued 
subunit of dynactin, a dynein-microtubule-associated 
protein complex which is involved in intracellular membrane trafficking.
255
  
As stated above the heterogeneity of vasculature in brain tumors requires the 
identification of additional antibodies which, as mixture, target the entire tumor 
vasculature. Since immune-specific phage display libraries exhibit the advantage of 
displaying antibodies with higher affinity and specificity the use of such libraries seems to 
be a promising approach to select for high affinity antibodies. In chapter 7 we describe the 
construction of nanobody-displaying phage libraries cloned from lymphocytes of a Llama 
after immunization with a mixture of three homogenates from surgically obtained clinical 
high grade gliomas. Subsequent in vivo biopanning of  these phage display libraries in 
orthotopic mouse models of glioma E98 and E434
121
 resulted in the isolation of various 
glioma vessel recognizing nanobodies, also against non-angiogenic blood vessels in diffuse 
infiltrative tumor areas. 
 
Nanobodies 
In the biopanning experiments described in this thesis we used nanobody-displaying 
phage libraries since recombinant nanobodies (the antigen binding parts of cameloid 
heavy-chain antibodies (figure 1)), have distinct advantages over the, more regularly used, 
single chain antibodies (Fig. 1B).
254,269
 The latter are composed of a variable heavy (VH) and 
light (VL) chain, connected via a flexible linker. This generally affects affinity and makes 
them more susceptible to proteolytic cleavage. Also the chance that corresponding VH and 
VL chains are ligated during library preparation is infinitely small. We previously 
constructed a phage library expressing these single chain antibodies cloned from a chicken 
after successful immunization with a homogenate of clinical glioblastoma multiforme 
tissues (unpublished results). However, isolated single chain antibodies obtained via in 
vivo biopanning in the E98 mouse model of glioma were predominantly negative in 
immunostainings. Nanobody libraries constitute a greater chance on success because 
these antibody fragments consist of a single polypeptide chain, which can be cloned in 
phagemid vectors in one step. In a phage-context, conformation and binding properties of 
nanobodies are therefore optimally resembling the characteristics of the original single 
domain antibody. Furthermore, we experienced that yields of nanodies expressed in E. coli 
are 10 to 100 times higher than single chain antibodies.  
Although the studies described in this thesis mainly focused on tumor endothelial cell-
specific nanobodies, our Llama nanobody-phage display libraries are also a potential 
source of nanobodies against tumor cells. Importantly, the immune nanobody-phage 
display libraries described in chapter 7 contain antigen-binding fragments raised against 
all tumor components, allowing isolation of tumor cell recognizing nanobodies which have 
several advantages over conventional antibodies with respect to in vivo targeting of tumor 
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cells. Due to their low molecular weight nanobodies more rapidly diffuse into the tumor 
tissue after extravasation from leaky tumor vessels and rapidly clear from the circulation 
and non-target tissues.
270
 In addition, their small size may allow access to epitopes which 
are inaccessible or barely antigenic to conventional antibodies.
271
 Although our anti-Plexin 
D1 nanobodies exhibit relatively good affinities (Kd = 2-4 x 10
-8
 M), binding properties of 
conventional antibodies are generally in the low nanomolar range. However, targeting of 
the tumor cells may be more efficient with lower affinity antibodies due to higher tumor 
penetrance compared to high affinity antibodies.
185
  
 
 
  
Figure 1. Schematic overview of conventional (A) and heavy-chain (C) antibodies and their corresponding 
antigen binding fragments in B and D respectively. Note the absence of the light chain and CH1 domain in 
heavy-chain antibodies.  
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In general, nanobodies exhibit a higher conformational stability compared to conventional 
antibody fragments
272-274
 and can, due to their monomeric nature, be easily genetically 
manipulated facilitating their development into therapeutic or diagnostic compounds. 
From this point of view simultaneous targeting of different tumor compartments via a 
mixture of nanobodies targeting existing tumor vasculature and ones enabling a second 
wave of action against tumor cells is an attractive approach. Importantly, the nanobody 
framework shares high homology with the human VH III region,
275
 reducing 
immunogenicity when applied in humans. Interestingly, nanobodies have already 
effectively been used for in vivo diagnosis and therapy.
242,243
 
 
Nanobody conjugations 
As described in this thesis anti-Plexin D1 nanobody A12, nanobody C-C7 and various 
nanobodies described in chapter 7 recognize their respective targets in clinical tumor 
specimens suggesting that these nanobodies can be further developed for future clinical 
application once their therapeutic and/or diagnostic value is determined in preclinical 
studies. Of interest, pre-therapy immunohistochemical analyses on tumor biopsies with 
the targeting nanobodies may allow for proper selection of patients which are amenable 
to therapy with the respective nanobodies, and this concept may be extended to staining 
with other tumor-cell targeting nanobodies, resulting in a tailor-made therapeutic 
approach for individual cancer patients. Conjugation of nanobodies to diagnostic or 
therapeutic compounds is facilitated by the single domain nature of these antibodies. 
Introduction of conjugatable tags allows directional conjugation of e.g. N-hydroxy-
succimidyl to free ε-NH2 groups in lysines or maleimide to free SH groups in cysteines. This 
provides a platform in which nanobodies can be turned into therapeutic or diagnostic 
compounds, e.g. via conjugation to cytotoxic agents or radioisotopes. In case of vessel 
targeting, cytotoxic therapy is expected to result in endothelial cell death, followed by 
coagulation and an avalanche of tumor cell death in the tumor area supplied by these 
vessels. Alternatively, nanobodies fused to truncated tissue factor can be used to target 
this initiator of the coagulation cascade to the tumor vasculature in order to introduce 
tumor embolization.
129
 
Besides these therapeutic applications, nanobodies can also be used to deposit  imaging 
agents to tumor vasculature, which has high diagnostic relevance in gliomas. Whereas the 
disrupted blood brain barrier in regions of prominent angiogenesis allows MRI-based 
detection of high grade gliomas by extravasation and accumulation of contrast agents in 
the interstitial spaces,
120
 diffuse infiltrative tumor growth, in which the blood brain barrier 
is intact, is often missed in conventional magnetic resonance imaging leading to a 
significant underestimation of the actual glioma load. Noteworthy, anti-angiogenic 
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therapy further deteriorates contrast agent extravasation in these tumors by inducing 
vessel normalization and closure of the blood brain barrier.
96
  
 
Conclusions 
Anti-angiogenic therapies have not fulfilled the initial expectations of turning cancer into 
chronic disease, and patients may benefit from additional anti-vascular therapies. To 
target the heterogeneous tumor vasculature there is a need for appropriate mixtures of 
different TVTAs that, in combination, recognize the majority of tumor vessels. Since 
endothelial cells in different tissues and tumors display specific antigens,
224,225,239,268
 it is 
assumable that also quiescent tumor endothelial cells will be subject to tumor-derived 
factors and hence have alterations in their proteomes which can be targeted. In this thesis 
we have shown that the use of immune nanobody phage libraries, in combination with 
appropriate animal models of disease, and yeast-two-hybrid screens with appropriate 
prey libraries, is a very powerful platform for the identification of novel tumor vessel 
targeting agents and their ligands. 
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Hoewel in de afgelopen decennia veel vooruitgang is geboekt in de behandeling van 
kankerpatiënten is deze ziekte voor een aanzienlijk deel van hen nog steeds dodelijk. 
Doordat er steeds meer duidelijk wordt welke eiwitten betrokken zijn bij het ontstaan en 
de groei van kanker zijn er therapieën ontwikkeld die zulke eiwitten remmen. In 
hoofdstuk 1 wordt een overzicht gegeven van dergelijke targeted therapieën die 
momenteel gebruikt worden bij de behandeling van kankerpatiënten. Naast het remmen 
van de werking van eiwitten die betrokken zijn bij de ontwikkeling van kanker heeft een 
deel van de targeted therapieën (tevens) anti-tumor effecten door middel van een 
antilichaam-gemedieerde immuunrespons tegen de tumorcellen. Hoewel targeted 
therapieën die gericht zijn tegen tumorcel specifieke eiwitten kunnen bijdragen aan een 
verbeterde progressievrije overleving zijn dergelijke therapieën slechts gunstig voor 
subgroepen kankerpatiënten. Hiernaast hebben targeted therapieën die zich richten tegen 
tumorcellen in solide tumoren een verminderde werking doordat intraveneus 
toegediende antilichamen tumorcellen lastig kunnen bereiken. Het aanvallen van het 
vaatbed van tumoren ten einde hun bloedvoorziening te verstoren is een goede oplossing 
om dergelijke beperkende factoren van targeted tumortherapieën te omzeilen. Immers, 
de endotheelcellen die de vaatwand aan de binnenkant bekleden zijn genetisch stabiel en 
goed te bereiken zijn na intraveneuze injectie. Tumoren worden van bloed voorzien door 
vaten die nieuw aangelegd worden onder invloed van een tumor (angiogenese) en/of 
door het reeds bestaande vaatbed (vaatcoöptie), welke al dan niet onder invloed van de 
tumor gemoduleerd wordt. Hierdoor zijn er in verschillende tumoren, maar zelfs ook 
binnen één tumor, diverse soorten vaten aanwezig. Deze vaatheterogeniteit heeft 
implicaties voor het gebruik van kankertherapieën die er op gericht zijn te interfereren 
met de bloedvoorziening van een tumor. Aangezien het tegengaan van de nieuwvorming 
van vaten (anti-angiogene therapie) enkel leidt tot remming van de vroege stadia van 
angiogenese worden meer volwassen vaten niet getroffen, waardoor de effectiviteit van 
anti-angiogene therapieën aanzienlijk beperkt is. Derhalve lijkt het tevens aanvallen van 
het bestaande vaatbed (vasculaire targeting) een aantrekkelijke toevoeging om tumoren 
effectief af te snijden van bloed.  
 
Hoofdstuk 2 beschrijft de verschillen in kenmerken van het vaatbed (vasculaire fenotype) 
en expressieprofielen van de belangrijkste factor die angiogenese teweegbrengt, Vascular 
Endothelial Growth Factor A (VEGF-A), in verscheidene primaire hersentumoren en 
hersenmetastasen. De verschillen in vasculaire fenotypes kunnen verklaard worden aan 
de hand van een model welke de specifieke effecten van verschillende VEGF-A varianten 
(isovormen) combineert met de impuls die leidt tot VEGF-A expressie. Hoewel de VEGF-
A165 en 189 isovormen in staat zijn om een echte angiogene respons teweeg te brengen, 
hebben deze isovormen een sterke binding aan celoppervlakken en structuren in het 
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omliggende weefsel (extracellulaire matrix) waardoor ze enkel effect hebben op vaten in 
de directe omgeving van de tumorcellen die VEGF-A maken en uitscheiden. Zodoende 
kunnen in tumoren die vanaf hun ontstaan VEGF-A maken (constitutieve expressie) alle 
isovormen effect hebben op nabij gelegen vaten wat resulteert in een echt angiogeen 
fenotype. Daarentegen worden in tumoren waar VEGF-A wegens een tekort aan zuurstof 
(hypoxie) slechts in centrale gebieden wordt gemaakt de grotere isovormen vastgehouden 
door extracellulaire matrix. Hierdoor kan alleen de vrij verspreidbare VEGF-A121 isovorm 
welke niet in staat is angiogenese op te roepen maar slechts verwijding van reeds 
bestaande (pre-existente) vaten, effect op het verder gelegen vaatbed uitoefenen. Dit 
resulteert in een fenotypisch ander vaatbed, ondanks de gelijktijdige expressie van de 
VEGF-A isovormen 165 en 189. Tevens kunnen tumorcellen in goed doorbloede weefsels 
zoals de hersenen doorgroeien zonder een tekort aan zuurstof door middel van infiltratie 
in het hersenweefsel en gebruik te maken van de reeds bestaande hersenvaten 
(vaatcoöptie), zoals waargenomen wordt in gliomen. Aangezien endotheelcellen in 
verschillende weefsels en tumoren specifieke eiwitten presenteren, is het aannemelijk dat 
ook endotheelcellen in gecoöpteerde vaten onderhevig zijn aan invloeden van de tumor 
en zodoende veranderingen in hun eiwitprofiel laten zien die specifiek aangevallen 
kunnen worden.  
 
Om tumoren effectief af te snijden van bloedvoorziening zijn stoffen nodig die specifieke 
merkers (tumorvat targets) op het volledige heterogene tumorvaatbed herkennen. In 
hoofdstuk 3 wordt Plexine D1 gepresenteerd als een nieuwe tumorvat target. Plexine D1 
behoort tot een familie van transmembraan eiwitten die functioneren als receptoren voor 
Neuropilines en Semaphorines en als zodaning betrokken zijn bij de vorming van het 
zenuwstelsel en vaatbed tijdens de embryonale ontwikkeling. Zoals beschreven in dit 
hoofdstuk komt Plexine D1 eveneens tot expressie op nieuwe vaten in tumoren. Tevens is 
dit eiwit uitgebreid aanwezig op een deel van de bestaande geactiveerde tumorvaten en 
op tumorcellen in verscheidene primaire hersentumoren en hersenmetastasen. Met 
behulp van de faagdisplay technologie zijn er antilichaamfragmenten (nanobodies) 
geselecteerd tegen Plexine D1. Na injectie van deze nanobodies in de bloedbaan van 
muizen met hersenmetastasen van melanoom binden deze nanobodies specifiek aan het 
nieuwe gevormde vaatbed in deze uitzaaiingen.  
 
Hoewel bekend is dat Plexine D1 een centrale rol speelt in de ontwikkeling van het 
vaatbed, is de functie van Plexine D1 expressie op tumorcellen een stuk minder duidelijk. 
Omdat Plexine D1 alle karakteristieken heeft van een eiwit dat betrokken is bij de 
voortbeweging van cellen, lijkt het aannemelijk dat Plexine D1 betrokken is bij de uitgroei 
van tumoren in het omliggende weefsel (invasie) en het uitzaaien naar verderop gelegen 
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plekken in het lichaam (metastaseren). In hoofdstuk 4 wordt inderdaad aangetoond dat 
Plexine D1 expressie gecorreleerd is met tumorinvasie en metastasering in verschillende 
ontwikkelingsstadia van melanoom. Plexine D1 is afwezig in de pigmentvormende 
(melanocytaire) cellen in moedervlekken (naevi) en in lesies waarbij de tumorcellen enkel 
nog gelegen zijn in de opperhuid (in situ melanomen), terwijl in primaire melanomen 
tumorcelexpressie toeneemt met de mate van invasie en bijna alle melanoom metastasen 
tumorcelexpressie van Plexin D1 tonen. Semaphorine 3E, een eiwit dat aan Plexine D1 
bindt en als zodanig betrokken is bij het functioneren van Plexine D1,  laat echter een 
omgekeerde correlatie met tumorprogressie zien, met zo goed als geen  waarneembaar 
Semaphorine 3E in melanoommetastases. Functionele analyse van Semaphorine 3E 
overexpressie in een muis model voor metastaserend melanoom toont aan dat 
Semaphorine 3E de nieuwvorming van tumorvaten tegengaat en het vermogen van 
tumorcellen om uit te zaaien aanzienlijk doet afnemen. Gebaseerd op de resultaten 
beschreven in dit hoofdstuk kan Semaphorine 3E uitgesloten worden als activerend ligand 
voor Plexine D1.  
 
Hoofdstuk 5 beschrijft Plexine D1 expressie in solide tumoren van verschillende oorsprong 
en niet-tumor gerelateerde weefsels. Plexine D1 is uitgebreid aanwezig op zowel nieuw 
gevormde en geactiveerde gecoöpteerde tumorvaten als op tumorcellen. In niet-tumor 
gerelateerde weefsels is Plexine D1 slecht aanwezig op een kleine groep cellen, 
vermoedelijk geactiveerde fibroblasten en macrofagen. Dit expressieprofiel suggereert dat 
Plexine D1 een belangrijk tumor target kan zijn voor solide tumoren waarin vaat-activatie 
heeft plaatsgevonden, aangezien het de mogelijkheid biedt om tegelijkertijd tumorcellen 
en tumorvaten aan te pakken.  
 
Teneinde de bloedtoevoer naar tumoren die (tevens) gebruik maken van reeds bestaande 
vaten te blokkeren is het noodzakelijk extra stoffen te identificeren die samen het gehele 
heterogene vaatbed van een tumor kunnen aanvallen. Dergelijke stoffen kunnen 
geïsoleerd worden met behulp van de biopanning techniek, waarvan een in vivo 
toepassing wordt beschreven in hoofdstuk 6. Door middel van biopanning van een naïeve 
Llama faagbank in een muis model voor hoog gradig glioom (E98) is nanobody C-C7, welke 
specifiek tumorvaten herkent in E98 tumoren, verkregen. Het ligand van C-C7 is met 
behulp van de gist-2-hybride techniek geïdentificeerd als dynactin-1-p150
glued
, een eiwit 
dat betrokken is bij het membraan verkeer binnenin cellen. Dynactin-1-p150
glued
 is 
specifiek aanwezig op een deel van de geactiveerde tumorvaten in verscheidene muis 
tumormodellen, echter, in enkele tumormodellen is dit eiwit afwezig op het vaatbed. 
Aangezien nanobody C-C7 eveneens de menselijke tegenhanger van dynactin-1-p150
glued
 
op vaten van gliomen herkent, kan het een geschikte kandidaat zijn om opgenomen te 
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worden in een mengsel van stoffen die gezamenlijk het hele tumorvaatbed kunnen 
aanvallen. 
 
In hoofdstuk 7 is de procedure om nieuwe stoffen (nanobodies) te isoleren die 
tumorvaten herkennen verder uitgewerkt. Dit hoofdstuk beschrijft de constructie van een 
nanobody-faagbank, gecloneerd uit lymfocyten van een Llama na immunisatie met 
weefsel van hoog gradige gliomen. Deze bank bevat fagen met op hun oppervlak 
nanobodies die gericht zijn tegen alle weefselcomponenten in hoog gradige gliomen, 
inclusief bloedvaten. Door middel van in vivo biopanning van deze faagbank in 
glioommodellen met verschillende vasculaire fenotypes zijn verscheidene nanobodies 
geïsoleerd die tumorvaten herkennen in de corresponderende glioommodellen, 
waaronder ook nanobodies die geïncorporeerde reeds bestaande vaten in infiltratieve 
tumorgebieden kunnen onderscheiden van normale hersenvaten.  
 
Teneinde tumoren effectief af te snijden van bloedvoorziening zijn er geschikte mengsels 
van stoffen nodig die gezamenlijk het gehele heterogene vaatbed herkennen. In dit 
proefschrift is aangetoond dat de combinatie van in vivo biopanning van immuun 
nanobody-faagbanken in geschikte tumormodellen en gist-2-hybride analyses met juiste 
prooibanken een krachtig platform vormt voor de identificatie van nieuwe nanobodies die 
gericht zijn tegen het tumorvaatbed en hun bijbehorende targets. 
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Curriculum Vitae 
 
De auteur van dit proefschrift werd geboren op 3 februari 1980 te Ede en groeide op in 
Ellecom. Na het behalen van haar VWO diploma aan ’t Rhedens te Rozendaal is ze in 1998 
begonnen met de studie Biomedische Gezondheidswetenschappen aan de Katholieke 
Universiteit Nijmegen. Als onderdeel van haar hoofdvak Toxicologie heeft ze 
reproductietoxicologisch onderzoek uitgevoerd bij het Rijksinstituut voor Volksgezondheid 
en Milieu, Laboratorium voor Effectenonderzoek. Onder begeleiding van Dr. A. Piersma is 
gedurende zes maanden de invloed van antioxidanten op reactieve zuurstof species- 
geïnduceerde teratogeniteit in ratten bestudeerd. In het kader van het hoofdvak 
Pathobiologie heeft ze gedurende vijf maanden onderzoek verricht bij de afdeling 
Pathologie van het Universitair Medisch Centrum Nijmegen, waar ze onder begeleiding 
van Dr. W. Leenders de expressie van verschillende VEGF-A isovormen en hun relatie tot 
vasculaire fenotypes in humane hersentumoren in kaart heeft gebracht. In september 
2002 heeft ze het doctoraal examen Biomedische Gezondheidswetenschappen met de 
ontvangst van het diploma afgesloten. 
 
Van februari 2003 tot augustus 2008 heeft ze als junior onderzoeker op de afdeling 
Pathologie van het Universitair Medisch Centrum Nijmegen onder begeleiding van Dr. W. 
Leenders het in dit proefschrift beschreven onderzoek verricht. Ze presenteerde haar 
resultaten op verschillende nationale en internationale bijeenkomsten. Tevens was ze 
tijdens haar promotieonderzoek betrokken bij de begeleiding van verscheidene stagiaires.  
Sinds november 2008 is ze werkzaam als onderzoeker op de afdeling Pathologie van het 
Universitair Medisch Centrum Nijmegen onder begeleiding van Dr. W. Leenders, waar ze 
het werk beschreven in dit proefschrift voortzet.  
 
Gedurende haar studententijd en promotieonderzoek is Ilse actief geweest in 
verenigingsbesturen. Van 1998 tot 2002 is ze secretaris geweest van 
Paardensportvereniging De Loenermarkruiters te Loenen, waar ze sinds 2002 voorzitter 
van is. Tevens is ze van 2002 tot 2006 voorzitter geweest van de Vereniging van Eigenaren 
van Vinkenlaan 1-23 te Dieren.  
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Dankwoord 
 
Daar is ie dan, HET boekje waar een groot deel van mijn werk van de afgelopen jaren in 
beschreven staat. Uiteraard zou dit proefschrift niet tot stand zijn gekomen zonder de 
inzet en betrokkenheid van verschillende mensen, die ik hierbij graag wil bedanken. 
 
Uiteraard wil ik als eerste mijn copromotor Dr. William Leenders bedanken. Via Rob de 
Waal ben ik in 2002 bij jou stage komen lopen, wat een erg leerzame periode is geweest. 
Ook voor jou, want je was ineens van mening dat het begeleiden van studenten toch niet 
zo’n kwelling was (ook al ben je inmiddels weer meermaals van gedachten veranderd). 
Daaropvolgend heb ik dankzij Rob en jou de mogelijkheid gekregen om op de afdeling 
Pathologie aan de slag te gaan als junior onderzoeker. Hoewel er in eerste instantie 
onvoldoende financiering was voor een volledig promotietraject heb jij je erg ingespannen 
om dit toch rond te krijgen en zoals iedereen nu kan lezen met succes door o.a. een 
samenwerking met N.V. Organon. Daarnaast heb je met je creatieve ideeën, 
wetenschappelijk denken en enorme enthousiasme een essentieel aandeel gehad in dit 
proefschrift. William, ik heb ontzettend veel van je geleerd de afgelopen jaren! Toen je de 
subsidie van Stichting Vanderes toegekend kreeg, ben je me komen polsen of ik op dat 
project wilde gaan werken want je vond “dat we wel goed konden samenwerken”, nou 
William, ik ben het (een keer) geheel met je eens. 
 
Professor van Krieken, beste Han, bedankt dat ik op de afdeling Pathologie mijn 
promotieonderzoek heb mogen verrichten en voor het aanvaarden van het 
promotorschap.  
 
Kiek, zoals je jezelf al had omschreven in het concept dankwoord wat jij en Fieke voor dit 
proefschrift hadden geschreven, je bent een super collega. Je hebt me vele technieken 
geleerd, we hebben veel gepraat en gelachen en gelukkig weinig (ik bedoel eigenlijk nooit, 
maar dan zijn we weer van die koele kikkers) gehuild. Samen met Fieke en An hebben we 
als “de vier musketiers” ook buiten het werk de nodige gezelligheid gehad tijdens feestjes 
in Nijmegen, Kranenburg en Loenen (of Klarenbeek als je na een avondje feesten op de 
fiets stapt). Kiek, ik ben erg blij dat jij mijn paranimf wilt zijn.  
Fieke, je bent toch een beetje mijn lab-soulmate geweest. We houden beiden van werken 
met een muziekje erbij, gezelligheid en goede grappen uithalen (met als hoogtepunt onze 
“lepeltje-lepeltje” act). Met name met dit laatste hebben we onze naaste collega’s toch 
wel regelmatig het bloed onder de nagels vandaan gehaald (of niet Kiek?). Thnx voor de 
gezelligheid de afgelopen jaren zowel op het werk als daarbuiten. Ik vind het fijn dat je 
mijn getuige bent.  
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Ja An, de volgende van de vier musketiers, ook jou wil ik bedanken voor de gezelligheid en 
leuke gesprekken. Hoewel mijn Belgisch nog steeds te wensen overlaat, doe ik hierbij toch 
een poging. Ik heb het altijd erg plezant gevonden om met jou een werkkamer te delen, 
hoewel ik ook wel eens onnozel van jou werd. An-viseerdag was altijd toppie! Ik wens je 
heel veel succes met je studie Geneeskunde. 
 
Cathy, ik wil je bedanken voor de goede gesprekken. Je kijk op dingen, openheid, interesse 
in je medemens en spraakzaamheid hebben me altijd erg aangesproken. Verder wil ik van 
de Agiogenese-groep Rob, Benno, Gürsah en natuurlijk alle stagiares (Leonie, Anjo, Ton, 
Tom, Jouk, Roel, Geert, Iris, Meritha, Eric, Gaby, Maarten, Corine, Anke, Jori, Melvin en 
Martijn) bedanken voor de vruchtbare werkbesprekingen en goede samenwerking. 
 
Beste Léon, je deur stond altijd open als ik weer eens wat te vragen had, bedankt!  
(Ex-)Kamergenoten Anke, Lieke en Yvonne, allen bedankt voor de hulpvaardigheid en 
gezelligheid. Gelukkig vonden jullie de radio geen probleem! (Voormalige) Promovendi 
Jack, Bart, Margit, Corine, Miriam, Jolien, Martijn en Anneke bedankt voor de leuke tijd en 
nodige adviezen. Allen veel succes met jullie verdere carrière.   
Verder wil ik alle andere medewerkers van de afdeling Pathologie bedanken voor de 
goede werksfeer, nuttige werkoverleggen en gezellige labuitjes.  
 
Ook wil ik een aantal mensen bedanken van de afdeling Biomoleculaire Chemie en 
Modiquest B.V. waar ik een deel van mijn onderzoek heb ik verricht.  
Jos, dankzij jou kennis heb ik veel ervaring op mogen doen met faagdisplay. Het eerste 
jaar heb je mij samen met Daniëlle wegwijs gemaakt in deze veel omvattende techniek, 
beiden dank hiervoor. Jos, ik ben blij dat jij met je bedrijf Modiquest nog steeds betrokken 
bent bij ons onderzoek. Tevens wil ik Tom, Kalok, Reinout, Angelique en Carla bedanken 
voor de samenwerking, gastvrijheid en gezelligheid de afgelopen jaren. 
 
Beste Hans, de (financiële) ondersteuning van N.V. Organon heeft een groot aandeel 
gehad in de totstandkoming van dit proefschrift. Ik wil je bedanken voor de nuttige 
besprekingen in het kader van onze samenwerking en hoop dat we deze in de toekomst 
kunnen voortzetten.  
 
Tenslotte wil ik mijn (schoon)familie en vrienden bedanken die door de nodige 
gezelligheid, ontspanning, vriendschap en steun indirect hebben bijgedragen aan dit 
proefschrift. In het bijzonder wil ik mijn ouders bedanken. Pap, je hebt erg uitgekeken 
naar het verschijnen van dit proefschrift en hebt min of meer gesolliciteerd naar het 
“baantje” paranimf. Ik ben erg blij dat ik je heb aangenomen voor deze taak. Moeders, 
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toen ik naar de middelbare school ging heb je je meermaals afgevraagd hoe mijn rapportje 
er uit zou zien, want ik zat toch alleen maar “op m’n peerd te hobbelen”. Hoewel er wat 
dat betreft nog weinig veranderd is ligt er nu toch een mooi boekje, iets waar jij en pap 
ook trots op mogen zijn. Dat Maarten en ik toch nog gaan trouwen heeft je aangenaam 
verrast en ik hoop dat jij net zo verheugd bent als ik dat je mijn getuige bent. 
 
Lieve Maarten, je was er toen ik mijn VWO-diploma in ontvangst mocht nemen en 
gelukkig ben je er nu nog steeds. Ik ben je dankbaar voor alle steun en liefde in de 
afgelopen jaren. Ik hoop dat we er straks als getrouwd stel ook een hele mooie tijd van 
maken!  
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Chapter2, Figure 1. Representative examples of spatial distribution of VEGF-A expression (A,D,G), hypoxia 
(B,E,H) and blood vessels (C,F,I) in brain metastases of sarcoma (A-C) and  renal cell carcinoma (D-F) and in 
glioblastoma multiforme (G-I). VEGF-A transcripts were highlighted by in situ hybridization with an antisense 
VEGF-A RNA probe, hypoxia was  demonstrated by immunohistochemistry using an anti-Glut-1 antibody, 
vessels were stained with an antibody against CD31. Note in B, E and H that no Glut-1 positive tumor cells 
are present. The positivity in these sections is due to erythrocytes in dilated vessels. In the GBM some blood 
vessels also stain positive, indicating that these are in fact pre-existent capillaries with a functional blood 
brain barrier. The arrow in I points at a glomeruloid proliferation. These stainings show that in this group of 
tumors there is no correlation between hypoxia and VEGF-expression. 
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Chapter 2, Figure 2. Spatial distribution of VEGF-A expression as determined by VEGF-A ISH (A,D,G), hypoxia 
(Glut-1 immunostaining, B,E,H) and blood vessels (CD31 immunostaining, C,F,I) in brain metastases of 
melanoma (A-C), adenocarcinoma (D-F), and in low grade glioma. In melanoma and adenocarcinoma 
metastases, there is a clear co-localization of Glut-1 expression and VEGF-A expression, suggesting that in 
these tumor types VEGF-A is expressed as a response to hypoxia. In melanoma the hypoxic areas are 
confined to concentric regions at regular distances from dilated blood vessels, in the adenocarcinoma 
metastases the hypoxia and VEGF-A expression occurred primarily in epithelial cells distant from the 
fibrovascular regions (arrows). The blood vessels in the low grade astrocytoma are positive for Glut-1, 
indicating that these are pre-existent brain capillaries with a functional blood brain barrier. Note that the 
sections shown are obtained from the same tumor regions. Due to technical reasons, however, these are 
not exact serial sections.  
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Chapter 2, Figure 5. Proliferation indices of tumors as revealed by MIB-1 staining. Shown are brain 
metastases of sarcoma (A), renal cell carcinoma (B), adenocarcinoma (C), melanoma (D,E) and a GBM (F). 
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Chapter 3, Figure 1. A) ISH analysis of a cerebral Mel57-VEGF lesion using a mouse-specific plxnd1 RNA 
probe. Note the strong positivity of tumor vessels (arrows) whereas brain capillaries, distant from the 
lesions, are negative (compare the ISH profile with the CD34 staining in the inset). B-D) Human PLXND1-
specific ISH analyses of a brain metastasis of sarcoma (B), melanoma (C) and normal brain (D). Insets show  
CD31 stainings of serial sections. Control ISH using sense probes were negative (not shown). Note in B and C 
that PLXND1 expression is not confined to the blood vessels: also in tumor cells high levels of the PLXND1 
transcript are found. t=tumor, V=vessel 
In normal human brain, no vessel-associated expression of PLXND1 was detected (Figure 1D). ISH revealed 
that tumor cells themselves also were often strongly positive for PLXND1 (compare ISH profiles with the 
CD31 stainings in the insets in Figure 1B and 1C). Also primary brain tumors were found to be positive for 
PLXND1 both on blood vessels and tumor cells (not shown).  
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Chapter 3, Figure 3. Immunohistochemistry using sdab A12 and F8. A) Growth plate of a trabecular bone in 
a mouse embryo (E16.5), stained with sdab A12. Note the immunoreactivity in the blood vessels which is 
consistent with ISH for plxnd1 (inset). B) Immunostaining with sdab F8 of a Mel57-VEGF-A165 lesion in mouse 
brain. A similar expression profile is seen as in the ISH depicted in figure 1A. Vessels stain positive (arrows) 
while tumor cells are moderately positive. C) and D) show immunostainings with sdab A12 of the sarcoma 
(C) and melanoma (D) brain metastases, of which PLXND1 ISHs are shown in Figure 1. The insets in C and D 
show control stainings with anti-VSV antibody only. V=vessel.  
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Chapter 3, Figure 4. In vivo targeting: homing of phage A12, F8 or an irrelevant phage to Mel57-VEGF165 
brain lesions. Tumor-bearing mice were injected with 1012 phages in the tail vein as described in the text. 
Mice were sacrificed, brains removed and frozen sections were analyzed for phage content and distribution. 
A) M13 staining of a frozen section of brain Mel57-VEGF165  lesions. Phages are clearly vessel-associated, as 
evidenced by the anti-CD31 immunostaining on a serial section, shown in B). The arrows point at a CD34-
positive vessel, distant from the lesion, which is not highlighted by anti-M13 staining. The inset in (A) shows 
a control experiment where an irrelevant phage was injected. C) Distribution of sdab F8 after intravenous 
injection in tumor bearing mice. Sdabs are visualized by immunohistochemistry using an anti-VSV antibody. 
Note that the sdab is detected in tumor vessels but not in normal brain capillaries. The inset shows the 
control experiment where an irrelevant sdab was injected. An interstitial localization was observed, 
consistent with the leaky nature of the vessels in these tumors. D) Quantification of phage homing. Tumor 
tissue was dissected from 10 µm frozen sections using laser capture dissection microscopy. Number of 
colony-forming phages (cfp) were counted after infection of TG1 cells. Twenty-fold more F8 phages were 
eluted from tumors than from comparable areas of unaffected brain tissue.  
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Chapter 4, Figure 1. Immunohistochemical analysis of PLXND1 and Sema3E expression in naevi. PLXND1 is 
not detected in melanocytes in naevocellular (A) and dysplastic (B) naevi. Note the PLXND1-positivity of 
macrophage- (arrow in A) and fibroblast-like (arrowhead in A) cells. Melanocytes in naevocellular (C) and 
dysplastic (D) naevi abundantly express Sema3E. Note that vessels in a dysplastic naevus express Sema3E 
(arrows in D).  
Chapter 4, Figure 2. PLXND1 expression in primary melanomas and a melanoma metastasis as revealed by 
immunostaining with single domain antibody A12. Shown are PLXND1 positive tumor cells in a Clark II 
melanoma (A), Clark IV melanomas (B and C) and a lymph node metastasis (D). Note in B that tumor vessels 
in a melanoma with a Breslow thickness of 3.2 mm express PLXND1 (arrows), while PLXND1 is absent in the 
vasculature of a Clark IV melanoma with a Breslow thickness of 0.65 mm (arrow in C). The insets in B, C and 
D show Sema3E staining in a Clark IV melanoma (B), a Clark II melanoma (C) and a lymph node metastasis 
(D).  
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Chapter 4, Figure 3. Analysis of subcutaneous Mel57-VEGF-A xenografts co-expressing Sema3E or Sema3C. 
A) shows PLXND1 expression in subcutaneous Mel57-VEGF-A xenografts as revealed by 
immunohistochemistry using single domain antibody A12. Both Mel57-VEGF-A cells and endothelium 
express PLXND1 (the inset shows a negative control staining with anti-VSV-G antibody). B) Tumor growth 
curves of Sema3E () and Sema3C(▲)-expressing Mel57-VEGF-A xenografts and control Mel57-VEGF-
A/EGFP lesions (). Tumor volumes are calculated as height x depth x width. Note that the xenografts co-
expressing Sema3(C/E) show comparable growth rates. Histological analysis of subcutaneous Mel57-VEGF-
A/Sema3E and -/Sema3C tumors by H&E staining (C and E) and anti-CD34 staining (D and F). Note the 
absence of micronodular transformation in Sema3E-expressing tumors (C and D), while Mel57-VEGF-
A/Sema3C xenografts show the typically VEGF-A induced micronodular growth pattern (E and F). In contrast 
to Mel57-VEGF-A/Sema3C xenografts, Sema3E-expressing tumors only show a  well vascularized tumor rim. 
The insets in C and E show Sema3E and Sema3C immunostainings on Mel57-VEGF-A/Sema3E (C) and -
/Sema3C (E) xenografts respectively.  
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Chapter 4, Figure 4. Analysis of  metastatic burden, localization and composition. A) Metastasis count of 
mice carrying different subcutaneous Mel57-VEGF-A xenografts. Lung lesions were counted after H&E 
staining. Note that in mice carrying subcutaneous Mel57-VEGF-A/Sema3E xenografts metastatic burden is 
significantly reduced compared to Mel57-VEGF-A/EGFP (p=0.022) and -/Sema3C tumors (p=0.006). In 
contrast, metastatic load in mice carrying Sema3C expressing tumors is not significantly different from 
Mel57-VEGF-A/EGFP xenografts (p=0.289). Histochemical analysis of lung metastases by H&E staining (B and 
C) and anti-CD34 staining (insets) show that lung metastases derived from Mel57-VEGF-A/Sema3C 
xenografts (B) are predominantly located in the larger branches of the pulmonary vessels. Note in C that the 
small lesion in the tip of the lung derived from a Mel57-VEGF-A/Sema3E tumor is not surrounded by 
endothelial cells (inset in C). EGFP immunostainings on lung metastases derived from Mel57-VEGF-
A/Sema3C (D) and -/Sema3E (E) xenografts tagged with EGFP-expressing tumor cells. Note that most lung 
metatases derived from Mel57-VEGF-A/Sema3C xenografts are of multicellular origin with both Mel57-
VEGF-A/Sema3C and Mel57-EGFP cells (D), while the EGFP-negative lung lesion in a mice carrying a 
subcutaneous Mel57-VEGF-A/Sema3E xenograft likely originates from clonal expansion of a single tumor cell 
(E).  
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Chapter 4, Figure 5. Fold-changes in mRNA expression of extracellular matrix and adhesion molecules in 
Sema3E overexpressing tumors relative to the control subcutaneous Mel57-VEGF-A lesions as revealed by 
RT-PCR array analysis (A). Columns represent fold changes in expression in Sema3E-expressing tumors 
relative to subcutaneous Mel57-VEGF-A lesions. Upper columns (>1.00) represent molecules whose mRNA 
expression is up-regulated, lower columns (<1.00) molecules whose expression is down-regulated. 
Immunohistochemical analysis of THBS expression in subcutaneous Mel57-VEGF-A (B) and Mel57-VEGF-
A/Sema3E xenografts (C). In contrast to Mel57-VEGF-A/Sema3E lesions THBS is abundantly expressed in 
Mel57-VEGF-A tumors (the insets show negative control stainings with anti-mouse antibody). Note in B that 
THBS expression is clearly associated with the network of vessel wall elements and tumor cells.  
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Chapter 5, Figure 1. Immunohistochemical analysis of PLXND1 expression in representative clinical tumor 
samples. PLXND1 is abundantly expressed in adenocarcinoma brain metastases (A), glioblastomas 
multiforme (B), neuro-endocrine lung tumors (C), an ovarian adenocarcinoma (D), and prostatic urothelial 
cell carcinomas (E). The arrows point at PLXND1-positive vasculature. PLXND1 is absent in both tumor 
vasculature (arrowheads) and tumor cells in vulvar squamous cell carcinomas (F). The insets in A and B show 
corresponding PLXND1 mRNA in situ hybridization analyses.  
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Chapter 5, Figure 2. Immunohistochemical analysis of PLXND1 expression in representative clinical tumor 
samples. PLXND1 is expressed at high levels in primary ductal breast carcinomas (A) and corresponding 
lymph node metastases (B), colon adenocarcinomas (C) and corresponding liver metastases (D) and a renal 
cell carcinoma (E) and corresponding brain metastasis (F). The arrows point at PLXND1-expressing tumor 
vessels. PLXND1 is not detected in normal human cerebral cortex (G) and heart (H) tissue samples. The 
insets in F, G and H show corresponding PLXND1 mRNA in situ hybridization analyses. 
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Chapter 6, Figure 1. Phage distribution in orthotopic glioma xenografts after in vivo biopanning. Procedures 
are described in Materials and Methods. After sacrifice, brains were removed and serial frozen sections of 
E98 glioma xenografts were analyzed for phage distribution by anti-M13 (A) or anti-CD31 (B) 
immunostaining. Note that phages are clearly more associated with tumor vasculature than normal vessels. 
N=normal, T=tumor 
Chapter 6, Figure 2. Immunohistochemical analysis of nanobody C-C7 reactivity in cerebral E98 xenografts 
(A), unaffected mouse brain parenchyma (B), a brain metastasis of Mel57-VEGF165 melanoma (C) and a 
cerebral U87 xenograft (D).  C-C7 recognizes subsets of tumor vessels in both diffuse infiltrative E98 tumor, 
while normal mouse brain vessels and the vasculature of intracerebral U87 glioma are negative. Insets in A, 
B and D show CD34 immunostainings of serial sections. N=normal, T=tumor, V=vessel. 
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Chapter 6, Figure 3.  C-C7 also recognizes human tumor blood vessels. Shown are immunostaining with 
nanobody C-C7 of human GBM (A), low grade glioma (B,C) and normal brain (D). Subsets of vessels are 
strongly positive for C-C7 (A-B), while C-C7 reactivity is absent in the vasculature of a low grade glioma (C) 
and normal brain endothelium (D).  
Chapter 6, Figure 4. In vivo targeting of phages displaying C-C7 to cerebral E98 xenografts. Monoclonal C-C7 
phages were injected in mice with orthotopic E98 xenografts and phage distribution analyzed by M13 
staining after cardiac perfusion. (A) Frozen brain sections stained for M13 phages. Phages displaying C-C7 
home to a subset of tumor vessels in E98 xenografts, but not to normal brain vessels, as evidenced by the 
anti-CD31 immunostaining on a serial section (B).  
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Chapter 6, Figure 5. Identification of dynactin-1 p150glued as the C-C7 ligand. A) Western blot analysis of GP8 
cell extract with C-C7. Nanobody C-C7 (lane 3) but not two irrelevant single domain antibodies (lanes 1 and 
2)  recognizes an endothelial protein of approximately 150 kDa (arrow). B) Structural domains in p150glued 
and recognized domains of C-C7. The aminoterminal domains contain a CAP-Gly domain and and a coiled-
coil domain which are responsible for microtubule (MT) binding and dynein binding (DIC=dynein 
intermediate chain). A second coiled-coil domain, encompassing a binding site for Arp1, is present in the 
carboxyterminal part of the protein and mediates binding to membrane components. 
Chapter 6, Figure 6. Comparative immunohistochemistry with a commercial anti-dynactin-1-p150glued 
antibody (A) and C-C7 (B) on serial sections of a high grade glioma. Note that both antibodies react similarly 
in these tissues. Control stainings were negative (not shown). 
Chapter 6, Figure 7. Immunolocalization of  the carboxyterminal domain of dynactin-1-p150glued in 
transfected COS-1 cells, as illustrated by costaining with C-C7 (green) and  commercial anti-dynactin (red). 
Cells were transiently transfected with p3xflg-CMV-dyn-2532-3837 and analysed two days later with a 
confocal microscope. Both antibodies colocalize as shown in the merged figure. 
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Chapter 7, Figure 2. Immunohistochemical analysis of the reactivity of selected nanobodies in glioma 
xenografts.  Clones obtained from group A (a) and D (b) are representative for nanobodies which specifically 
recognized subsets of glioma vessels in immunostainings on paraffin-embedded sections of E98 xenografts. 
Nanobodies produced by clones from group IX (c) and VIII (d) demonstrate representative immunoreactivity 
on E434 vasculature. Note the absence of immunoreactivity on vessels in unaffected brain areas (insets).  
Chapter 7, Figure 1. Phage distribution in cerebral glioma xenografts after in vivo biopanning of an immune 
Llama phage  library. Paraffin-embedded sections of E98 (a) and E434 (b) xenografts were analyzed for 
phage localization by M13 immunostainings. As evidenced by anti-CD34 immunostainings on serial sections 
of E98 (c) and E434 (d) xenografts phages are clearly associated with the tumor vasculature (arrowheads in 
figure 1a and 1b), whereas vessels in unaffected brain parenchyma are not highlighted by anti-M13 staining 
(arrows in figure 1c and 1d). Note the CD34 up-regulation on tumor-associated endothelial cells compared 
to normal brain capillaries (c and d).  
 
